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STS	 sulfatase	
SULT	 sulfotransferase	
TMD	 transmembrane	domain	
TTC	 trials	to	criterion	
WCST	 Wisconsin	Card	Sorting	Task	
WT	 wildtype	
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Abstract	
Dysfunction	of	the	N-methyl-D-aspartate	(NMDA)	receptor	is	thought	to	
contribute	to	the	cognitive	deficits	of	many	neurodegenerative	diseases	and	
psychiatric	disorders.	Cognitive	symptoms	of	Alzheimer’s	disease	can	be	
treated	with	NMDA	receptor	antagonists	or	drugs	targeting	the	cholinergic	
system;	however,	there	are	no	effective	treatments	for	cognitive	deficits	of	
schizophrenia	or	Huntington’s	disease.	With	the	discovery	of	a	potent	and	
selective	allosteric	modulator	of	the	NMDA	receptor,	there	is	the	possibility	of	
new	treatments	based	on	NMDA	receptor	functional-enhancement	through	
neuroactive	steroids,	closely	related	in	structure	to	the	endogenous	
neurosteroid,	cerebrosterol.	The	aim	of	this	thesis	was	to	examine	steroidal	
modulation	of	the	NMDA	receptor	both	in	vitro	and	in	vivo.	In	chapter	2,	
NMDA	receptor	enhancement	of	both	the	synthetic	and	endogenous	
neuroactive	steroids	was	assessed	in	neurons	maintained	in	cell	culture	using	
calcium	imaging	techniques.	Sulphation	of	the	steroids	greatly	increased	the	
efficacy	of	NMDA	receptor	enhancement	compared	to	the	unsulphated	
steroids.	Chapters	3	and	4	investigate	the	potential	for	neuroactive	steroids	to	
treat	cognitive	impairments	of	Huntington’s	disease.	Using	a	mouse	model,	
tests	were	selected	that	were	analogous	to	those	in	which	patients	are	
impaired;	however,	no	impairments	were	found	in	the	mouse	model.	Chapter	
5,	therefore,	used	a	different	model	of	cognitive	impairment	–	namely,	rats	
with	a	set-shifting	impairment,	as	is	seen	in	many	psychiatric	and	neurological	
disorders,	including	Huntington’s	disease	–	to	assess	the	effect	of	the	synthetic	
steroid	administration.	Unfortunately,	the	rats	did	not	show	the	expected	
impairment.	The	lack	of	reliable	animal	models	compromised	testing	the	
efficacy	of	these	promising	NMDA	receptor	positive	allosteric	modulators.	
Nevertheless,	the	promising	in	vitro	results	suggest	that	there	could	still	be	
therapeutic	potential.	In	addition,	the	compound	is	a	useful	research	tool	for	
exploring	NMDA	receptor	function	in	health	and	disease.	
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Chapter	1	
	
General	Introduction	
	
	
“No	one	really	starts	anything	new,	Mrs.	Nemur.	Everyone	builds	on	other	
men's	failures.	There	is	nothing	really	original	in	science.	What	each	man	
contributes	to	the	sum	of	knowledge	is	what	counts.”	–	Daniel	Keyes,	Flowers	
for	Algernon	
	
	
Illustration	by	C.	Brazaitis	
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The	discovery	of	a	safe	and	effective	cognitive-enhancing	drug	has	been	the	
focus	of	decades	of	neuroscience	and	pharmacology	research	to	treat	the	
cognitive	deficits	associated	with	a	multitude	of	neurodegenerative	diseases	
and	psychiatric	disorders.	One	treatment	approach	targets	the	glutamate	
system,	where	receptors	and	transporters	of	glutamate	of	been	the	focus	of	
drug	targets.	This	introduction	will	provide	an	overview	of	the	glutamatergic	
system	in	health	and	disease,	and	describe	why	the	N-methyl-D-aspartate	
(NMDA)	receptor	is	a	particularly	good	target,	but	will	also	explain	the	pitfalls	
that	may	occur	with	this	approach.	Then,	an	overview	will	be	given	of	the	
tasks	used	to	measure	cognition,	using	the	deficits	seen	in	Huntington’s	
disease	(HD)	as	a	focus	disease	model.	Previous	attempts	to	develop	drugs	
targeting	the	NMDA	receptor	will	be	discussed,	and	finally,	the	background	
will	be	given	to	the	molecules	that	are	the	focus	of	this	thesis.	As	these	
molecules	are	also	found	endogenously,	in	addition	to	being	used	as	possible	
treatments,	their	effects	could	help	elucidate	NMDA	receptor	modulation	in	
health	and	disease	states.	
1.1 NMDA	Receptors:	History,	Form	and	Function	
1.1.1	Glutamate	System	
Glutamate	is	an	excitatory	amino	acid	(EAA)	and	is	the	major	excitatory	
neurotransmitter	in	the	mammalian	central	nervous	system	(Watkins	and	
Jane,	2006).	Glutamate	is	the	most	abundant	amino	acid	in	the	brain	(Zhou	
and	Danbolt,	2014).	The	first	clues	that	glutamate	acts	as	a	neurotransmitter	
were	discovered	in	the	1940s	in	Japan	by	Hayashi	(1954)	(as	cited	by	Takagaki	
(1996)	and	Watkins	and	Jane	(2006)),	who	found	that	directly	injecting	
glutamate	into	the	motor	cortex	of	dogs	resulted	in	convulsions.	Later,	
Watkins	published	a	series	of	papers	showing	further	support	for	the	
excitatory	action	of	glutamate	on	neuronal	activity	using	recordings	from	in	
vivo	cat	spinal	cord	neurons	and	isolated	toad	spinal	cord	preparations	(Curtis	
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et	al.,	1961,	Curtis	et	al.,	1960,	Curtis	and	Watkins,	1960).	N-methyl-D-
aspartate	(NMDA)	was	the	first	synthetic	ligand	found,	and	it	was	proposed	
that	it	caused	membrane	depolarisation	by	binding	to	the	receptor,	causing	a	
conformational	change	which	opens	a	central	ion	pore,	allowing	for	the	influx	
of	sodium	ions	(Curtis	and	Watkins,	1960,	Curtis	and	Watkins,	1965).	Later,	
other	synthetic	agonists	were	discovered	such	as	kainate	(Shinozaki	and	
Ishida,	1981)	and	a-amino-3-	hydroxy-5-methyl-4-isoxazolepropionic	acid	
(AMPA)	(Honore	et	al.,	1982,	Krogsgaard-Larsen	et	al.,	1982).	However,	it	
wasn’t	until	the	availability	of	selective	glutamate	receptor	antagonists	that	
the	existence	of	multiple	receptors	could	be	confirmed,	where	magnesium	
(Mg2+)	was	the	first	antagonist	to	separate	NMDA	receptors	from	the	others,	
as	addition	of	Mg2+	to	the	isolated	frog	spinal	cord	caused	a	dramatic	decrease	
in	NMDA-induced,	but	not	kainate-	or	AMPA-induced	responses	(for	review	
see:	Watkins	and	Jane,	2006).	Later	the	NMDA	receptor	specific	antagonist	D-
2-amino-5-phosphonopentanoate	(APV)	was	discovered,	as	well	as	the	AMPA	
receptor	selective	and	potent	quinoxalinediones	(Honore	et	al.,	1988).	Biscoe	
et	al.	(1977)	crucially	showed	that	the	selective	NMDA	antagonist	D-a-
aminoadipate	(DaAA)	could	block	non-cholinergic,	but	not	cholinergic,	
excitation	in	cat	spinal	cord	Renshaw	cells	in	vivo	showing	that	glutamate	is	a	
neurotransmitter	of	synaptic	NMDA	receptors.	At	the	time	aspartate,	another	
EAA,	was	hypothesised	as	the	endogenous	neurotransmitter.	However,	
Olverman	et	al.	(1984)	showed	that	glutamate	had	a	10-fold	higher	affinity	for	
the	NMDA	receptor	than	aspartate,	promoting	it	to	the	position	of	the	major	
excitatory	neurotransmitter	in	the	brain.	
Glutamate	binds	to	two	different	classes	of	receptors	in	the	CNS:	
metabotropic	and	ionotropic	glutamate	receptors.	Metabotropic	glutamate	
receptors	(mGluRs)	are	G-protein	coupled	receptors,	which	activate	second	
messenger	systems	in	the	post	synaptic	neuron	and	couple	to	specific	ion	
channels	(Conn	and	Pin,	1997,	Niswender	and	Conn,	2010).	Depending	on	the	
mGluR	subtype,	distinct	second	messenger	pathways	are	activated:	group	I	
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activate	the	phospholipase	C	and	phosphoinositide	pathways,	or	the	adenylyl	
cyclase	(AC)	pathway;	group	II	and	III	inhibit	AC	(Conn	and	Pin,	1997,	
Niswender	and	Conn,	2010).	These	different	pathways	lead	to	a	variety	of	
cellular	processes	being	activated	or	inhibited.		
As	suggested	above,	ionotropic	receptors	can	also	be	further	divided	into	
three	categories:	AMPA,	kainate,	and	NMDA	receptors.	Each	receptor	is	an	
integral	membrane	protein	made	up	of	four	large	subunits	encoded	by	
different	gene	families	(Alexander	et	al.,	2008,	Dingledine	et	al.,	1999,	
Traynelis	et	al.,	2010).	Distinct	from	the	metabotropic	receptors,	binding	of	a	
ligand	to	the	receptor	directly	gates	an	associated	cation-conducting	ion	
channel,	which	allows	permeation	of	specific	ions	in	and	out	of	the	cell.	
Ionotropic	receptors	consist	of	an	ion	channel	(transmembrane	domain,	TMD),	
a	ligand	binding	(or	agonist	binding)	domain	(LBD),	and	an	amino	terminal	(or	
modulatory)	domain	(ATD)	(Figure	1.1).	The	ligand	or	agonist	(e.g.	glutamate)	
binds	to	the	LBD,	causing	a	conformational	change	that	opens	the	ion	channel	
allowing	passage	of	ions.	All	three	receptor	subtypes	allow	influx	of	sodium	
ions	(Na+)	and	efflux	of	potassium	ions	(K+)	upon	activation	by	an	agonist,	
resulting	in	depolarisation	of	the	neuron,	which	can	be	detected	as	an	
excitatory	post	synaptic	potential	(EPSP).	Note	certain	receptor	isoforms	are	
additionally	permeable	to	calcium	ions	(Ca2+)	(see	next	section	1.1.2).	AMPA	
receptors,	in	particular,	mediate	the	fast	depolarisation	component	of	the	
EPSP	(Lester	et	al.,	1990).	In	addition	to	gating	ion	channels,	ionotropic	
receptors	can	also	activate	intracellular	pathways,	as	shown	by	the	activation	
of	the	Mitogen-activated	protein	kinase	(MAPK)	pathway	by	the	AMPA	
receptor	(Hayashi	et	al.,	1999).	All	three	receptor	subtypes	share	a	similar	
protein	sequence,	suggesting	that	they	share	a	similar	structure	(Traynelis	et	
al.,	2010).	
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Figure	1.1:	A	schematic	of	the	structure	of	one	of	the	four	subunits	of	an	ionotropic	
glutamate	receptor.	Depicted	are	the	extracellular	amino	terminal	domain	(ATD,	green)	and	
ligand-binding	domain	(LBD,	blue),	the	transmembrane	domain	(TMD)	consisting	of	
membrane-spanning	helices	(M1,	M3,	and	M4,	orange)	and	the	membrane	re-entrant	loop	
(M2).	The	intracellular	C-terminal	domain	(CTD)	is	also	shown.	Adapted	from	Traynelis	et	al.	
(2010).	
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Glutamate	is	released	from	nerve	terminals	via	exocytosis	of	synaptic	vesicles	
(Danbolt,	2001)	into	the	extracellular	space,	and	binds	to	specific	glutamate	
receptors	expressed	on	neuronal	and	glial	cell	membranes.	Glutamate	can	also	
be	released	via	non-vesicular	mechanisms,	such	as	the	reversal	of	the	
glutamate	reuptake	system,	as	occurs	during	cerebral	ischaemia	(Rossi	et	al.,	
2000)	or	via	anion	channels	(Wang	et	al.,	2013).	It	is	also	possible,	though	
debated,	that	astrocytes	are	able	to	release	glutamate	via	exocytosis	(Bezzi	et	
al.,	2004,	Zhou	and	Danbolt,	2014).	The	concentrations	of	extracellular	
glutamate	are	tightly	regulated	to	enhance	the	transmission	of	the	signal	
(Danbolt,	2001).	
Following	release	of	glutamate	into	the	synaptic	cleft,	controlled	regulation	of	
glutamate	levels	is	achieved	by	the	efficient	reuptake	of	glutamate	from	the	
synaptic	cleft	by	specific	glutamate	transporters	(see	Figure	1.2).	This	
controlled	regulation	also	prevents	excitotoxicity	caused	by	an	excess	of	
extracellular	glutamate	(Danbolt,	2001).	If	glutamate	uptake	is	inhibited,	the	
constant	release	of	glutamate	into	the	extracellular	fluid	causes	glutamate	
build	up	in	a	matter	of	seconds	(Jabaudon	et	al.,	1999).	On	the	other	hand,	too	
little	glutamate	is	also	deleterious	as	it	is	required	for	healthy	synaptic	
transmission;	therefore,	a	delicate	balance	is	required.	The	transporters	that	
are	responsible	for	efficient	glutamate	reuptake	are	called	excitatory	amino	
acid	transporters	and	there	are	5	subtypes	(EAAT	1-5),	each	expressed	in	
specific	brain	regions	and	cells	(Kim	et	al.,	2011).	The	most	common	
transporter	is	EAAT2,	which	is	largely	expressed	in	astrocytes	and	is	
responsible	for	the	majority	of	glutamate	reuptake	from	glutamatergic	
synapses	(Kim	et	al.,	2011).	Low	EAAT2	expression	in	the	hippocampus,	
temporal	lobe	(Shan	et	al.,	2013),	and	prefrontal	cortex	(Spangaro	et	al.,	2012)	
has	been	associated	with	schizophrenia.	Despite	the	EAATs,	low	ambient	
levels	of	glutamate	are	still	present	extracellularly,	and	Le	Meur	et	al.	(2007)	
showed	that	these	ambient	extrasynaptic	glutamate	levels	were	able	to	
activate	specific	extrasynaptic	glutamate	receptors	in	the	rat	hippocampus.	
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Glutamate	receptors	are	expressed	both	in	the	synapse	and	outwith	the	
synapse;	whereby,	the	extrasynaptic	receptors	may	be	activated	by	synaptic	
spill-over	or	glutamate	released	outside	of	the	synapse	(Petralia,	2012).	
Before	the	glutamate	is	cleared	from	the	cleft,	it	is	able	to	bind	to	receptors	on	
the	post	synaptic	neuron.	These	are	the	metabotropic	and	ionotropic	
receptors	introduced	above.	The	metabotropic	receptors	transmit	signals	
slower,	as	second	messenger	systems	result	in	modulation	of	synaptic	
transmission	and	excitability	(Niswender	and	Conn,	2010).	In	contrast,	when	
glutamate	binds	to	the	ionotropic	receptors,	depolarisation	of	the	
postsynaptic	neuron	causes	rapid	signal	transmission.	The	AMPA	and	kainate	
receptors	are	activated	first,	followed	by	the	NMDA	receptors.	NMDA	receptor	
function	will	be	discussed	in	detail	in	the	next	section.	
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Figure	1.2:	A	summary	of	the	glutamatergic	synapse.	The	transmission	of	the	signal	moves	
from	the	presynaptic	to	the	postsynaptic	neuron.	Glia	and	astrocytes	act	as	support	cells	to	
remove	glutamate	from	the	cleft	via	excitatory	amino	acid	transporters	(EAAT).	GABAergic	
neurons	serve	a	modulatory	purpose.	After	glutamate	is	released	from	the	presynaptic	
neuron,	molecules	activate	AMPA	and	kainate	receptors,	the	resulting	depolarisation	allows	
the	activation	of	the	NMDA	receptor	which	is	additionally	permeable	to	calcium	ions.	The	
ionotropic	receptors	mediate	the	fast	transmission	of	signal.	Metabotropic	glutamate	
receptors	(mGluR)	mediates	the	slow	transmission	of	signal	causing	downstream	changes	due	
to	excitation.	Reproduced	with	permission	(Swanson	et	al.,	2005).	
	
1.1.2	NMDA	Receptor	
The	NMDA	receptor	is	a	tetrameric	protein	with	two	binding	sites	for	the	
endogenous	agonist	glutamate	(or	aspartate)	and	the	co-agonist	glycine	on	
the	LBD	(Paoletti	et	al.,	2013,	Laube	et	al.,	1998).	The	LBD	of	the	subunit	is	
often	described	as	a	clamshell	(also	illustrated	in	Figure	1.1)	where	the	agonist	
binds	and	causes	the	clamshells	to	close	(conformational	change)	which	is	
tightly	linked	to	channel	opening	(Traynelis	et	al.,	2010).	There	are	seven	types	
of	subunits	which	make	up	the	receptor:	NR1,	NR2	(A,	B,	C,	D),	and	NR3	(A,	B).	
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These	receptors	assemble	in	a	heteromeric	fashion,	where	a	receptor	always	
contains	two	NR1	subunits	and	two	regulatory	subunits	of	either	NR2,	or	NR2	
and	NR3	subunits	combined	(Yashiro	and	Philpot,	2008).	NMDA	receptor	
function	varies	depending	on	the	subunit	composition.	Glycine,	the	co-agonist,	
binds	to	NR1	subunits,	while	glutamate,	the	agonist,	binds	to	NR2;	the	kinetics	
and	pharmacology	also	differ	depending	on	subunit	composition	(Cull-Candy	
et	al.,	2001).	Receptors	consisting	of	NR1/NR2A	and	B	subunits	have	a	high	
single	channel	conductance	and	high	Mg2+	sensitivity,	while	NR1/NR2C	and	B	
subunit	assemblies	have	a	reduced	conductance	and	Mg2+	sensitivity	(Siegler	
Retchless	et	al.,	2012).	Incorporation	of	the	NR3	subunit	causes	a	marked	
decrease	in	single	channel	conductance,	Ca2+	permeability,	and	Mg2+	
sensitivity	(Sasaki	et	al.,	2002,	Paoletti	and	Neyton,	2007).	Due	to	differences	
in	pharmacology,	agonists	and	antagonists	specific	to	certain	subunits	can	be	
used	to	identify	receptor	assembly.	For	example,	ifenprodil	is	a	selective	NR2B	
antagonist	(Williams,	1993),	and	zinc	is	a	selective	NR2A	antagonist	at	
nanomolar	concentrations	(Paoletti	et	al.,	1997).	This	can	be	used	to	examine	
NMDA	receptor	properties	during	development,	differences	in	synaptic	and	
extrasynaptic	receptors	(see	also	section	1.2.4),	and	to	assess	NMDA	subtypes	
during	specific	functions	such	as	synaptic	plasticity	(Cull-Candy	et	al.,	2001).	
A	key	difference	between	the	activation	of	the	NMDA	receptor	and	other	
ionotropic	receptors	is	its	ability	to	act	as	a	co-incidence	detector,	and	in	that	
it	is	permeable	to	Ca2+.	The	NMDA	receptor	is	able	to	act	as	a	co-incidence	
detector	because	ion	conduction	is	both	voltage	sensitive	(Nowak	et	al.,	1984,	
Mayer	et	al.,	1984)	and	requires	both	glutamate	and	glycine	binding	for	the	
channel	to	open	(Laube	et	al.,	1998).	When	the	ion	channel	does	open,	it	is	
permeable	to	Ca2+	(in	addition	to	Na+	and	K+),	which	flows	into	the	cell	
activating	many	downstream	pathways	(Mayer	et	al.,	1987,	Kawamoto	et	al.,	
2012,	Wang	and	Zhang,	2012).	The	voltage	sensitivity	is	caused	by	a	
magnesium	ion,	which	directly	blocks	the	ion	channel	when	the	cell	is	in	a	
resting	state	(Nowak	et	al.,	1984,	Mayer	et	al.,	1984).	Upon	sufficient	
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membrane	depolarisation	by	AMPA	receptor	activation,	the	Mg2+	is	dislodged	
from	the	ion	channel,	and	as	long	as	sufficient	agonist	(i.e.	glutamate)	and	co-	
agonist	(i.e.	glycine)	are	present,	the	ion	channel	is	active.	Therefore,	the	
NMDA	receptor	requires	both	presynaptic	glutamate	release	and	post	synaptic	
depolarisation	to	become	active.	This	is	why	AMPA	receptors	and	kainite	
receptors	are	activated	first	by	glutamate	in	the	synaptic	cleft,	which	then	
provide	the	conditions	necessary	to	additionally	activate	NDMA	receptors.	
Not	only	is	the	NMDA	receptor	distinct	from	the	AMPA	receptor	with	regard	
to	its	Mg2+	sensitivity,	it	also	differs	in	its	kinetics.	The	NMDA	receptor	has	a	
much	slower	onset	of	excitatory	post	synaptic	current	(EPSC,	which	is	
responsible	for	the	EPSP	and	is	measured	in	voltage-clamp	conditions,	which	is	
a	recording	of	the	current	shift	required	to	hold	the	voltage)	and	also	a	longer	
lasting	EPSC	(hundreds	of	milliseconds)	due	to	the	high	affinity	and	prolonged	
binding	of	glutamate	to	the	receptor	(Lester	et	al.,	1990,	Paoletti	et	al.,	2013,	
Hestrin	et	al.,	1990).	
1.1.3	Long	Term	Potentiation:	A	Neural	Correlate	of	Learning	and	
Memory?	
NMDA	receptors	are	involved	in	a	multitude	of	functions,	including	pain	
sensitisation	(Petrenko	et	al.,	2003),	locomotion	(Dale	and	Roberts,	1985),	
neuronal	development	(Van	Horn	et	al.,	2013),	and	cell	death	and	survival	
(Kaufman	et	al.,	2012).	Of	particular	interest	is	the	mediation	of	synaptic	
plasticity	by	NMDA	receptors,	particularly	during	long	term	potentiation	(LTP),	
which	is	a	putative	neural	correlate	of	learning	(Bliss	and	Collingridge,	1993).	
LTP	can	be	induced	using	many	different	mechanisms,	but	here	only	NMDA-
dependent	LTP	in	the	CA1	of	the	hippocampus	will	be	discussed.	LTP	can	also	
be	observed	in	other	brain	regions	such	as	the	cerebral	cortex	(Feldman,	
2009),	amygdala	(Dityatev	and	Bolshakov,	2005),	and	cerebellum	(Grasselli	
and	Hansel,	2014).	The	proposed	mechanism	of	LTP	in	the	CA1	of	the	
hippocampus	is	the	pre-synaptic	glutamate	induced	activation	of	postsynaptic	
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ionotropic	receptors.	This	activation	causes	the	influx	of	sodium	ions,	
depolarizing	the	cell.	This	depolarisation	relieves	the	magnesium	ion	block	of	
the	NMDA	receptor;	the	resulting	influx	of	calcium	ions	through	the	NMDA	
receptor	activates	downstream	pathways	strengthening	the	transmission	
between	the	pre-	and	postsynaptic	neurons	(Bliss	and	Collingridge,	1993).	LTP	
may	cause	synaptic	strengthening	via	many	different	mechanisms	both	
presynaptic	and	postsynaptic.	A	likely	presynaptic	mechanism	is	increased	
glutamate	release	probability;	while	postsynaptic	mechanisms	involve	AMPA	
receptor	changes,	including	increased	channel	conductance,	and	insertion	of	
additional	AMPA	receptors	in	the	postsynaptic	synapse	(for	review	see	Bliss	
and	Collingridge	(2013)).	
Early	in	vivo	experiments	that	demonstrated	an	involvement	of	NMDA	
receptors	in	learning	were	performed	in	rats,	which	had	to	remember	where	a	
platform	was	located	in	a	water	maze,	testing	hippocampal	dependent,	
episodic	like,	spatial	memory	(Morris,	1989).	The	NMDA	receptor	is	an	
especially	good	candidate	for	facilitating	episodic	like	memory	due	to	its	co-
incidence	detecting	properties	that	allow	association	of	distributed	
information.	This	means	that	associations	can	be	formed	between	two	stimuli,	
where	one	can	predict	the	other,	but	the	predictor	does	not	need	inherent	
value	or	relevance	(Morris,	2013).	Morris	(1989)	showed	that	a	rat	with	
chronic	intraventricular	infusion	with	the	selective	NMDA	receptor	antagonist,	
APV,	took	much	longer	to	find	the	platform	than	controls	with	vehicle	
infusions.	However,	if	APV	was	given	after	the	location	of	the	platform	had	
already	been	learned,	performance	was	equivalent	to	controls,	indicating	that	
NMDA	receptors	are	involved	in	acquisition	of	spatial	memory,	but	not	in	
retrieval.	These	experiments	were	based	on	in	vitro	findings	that	APV	
prevented	the	induction	of	LTP	in	CA1	of	rat	hippocampal	slices,	suggesting	
that	NMDA	receptors	are	involved	in	LTP	induction	(Collingridge	et	al.,	1983).	
The	slower	kinetics	of	the	NMDA	receptor	response,	compared	to	other	
ionotropic	receptors,	allows	for	summation	of	responses	and	is	crucial	to	LTP	
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induction,	and	it	depends	on	specific	frequencies	of	stimulation	(Bliss	and	
Collingridge,	1993).		
From	the	explanation	above,	it	is	clear	that	NMDA	receptors	are	crucial	for	
synaptic	plasticity	and	healthy	cell	signalling;	however,	NMDA	receptor	
activation	can	also	be	the	cause	of	cell	death.	At	first	this	was	thought	to	be	
due	to	the	degree	of	calcium	influx	through	NMDA	receptor	activation,	
according	to	an	inverted	U-shaped	relationship,	where	a	moderate	calcium	
influx	is	beneficial,	and	excessive	calcium	becomes	toxic	(Hardingham	and	
Bading,	2003).	This	model	has	more	recently	been	replaced	with	the	NMDA	
receptor	location	hypothesis;	more	specifically,	synaptic	NMDA	receptor	
activation	is	pro-survival	and	even	neuroprotective	(Hardingham	et	al.,	2002),	
while	extrasynaptic	NMDA	receptor	activation	is	pro-cell	death	(Hardingham	
and	Bading,	2010).	This	difference	in	cell	signalling	simply	due	to	calcium	influx	
at	different	locations	could	be	due	to	three	factors:	first,	the	receptor	
signalling	complex	could	be	different	in	the	two	locations;	second,	the	
receptor	subunit	composition	could	be	different,	particularly	the	NR2B	and	
NR2A	subunits	are	thought	to	promote	cell	death	and	survival,	respectively	
(Liu	et	al.,	2007b);	and	finally,	synaptic	and	extrasynaptic	receptors	are	usually	
differentially	activated	by	transient	trans-synaptic	glutamate	and	chronic	
ambient	glutamate,	respectively,	which	could	result	in	a	possible	mechanism	
for	a	difference	in	cell	survival	signalling	(Hardingham	and	Bading,	2010).	The	
central	role	that	NMDA	receptors	play	in	such	a	wide	range	of	cellular	
processes,	from	synaptic	plasticity,	to	cell	death	and	survival	make	it	a	well-
studied	receptor	both	in	health	and	disease.	
1.2	NMDA	Receptor	Dysfunction	and	Disorders	
NMDA	receptors	are	involved	in	many	disorders	due	to	glutamate	being	a	
widespread	neurotransmitter.	This	section	will	focus	on	the	cognitive	deficits	
associated	with	NMDA	receptors	in	a	range	of	disorders.	Modulation	of	the	
NMDA	receptor	is	an	avenue	for	the	possible	treatment	of	the	cognitive	
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deficits	associated	with	neurological	and	psychiatric	disorders.	Specifically,	
potentiating	the	NMDA	receptor	could	facilitate	cognition,	potentially	by	the	
modification	of	LTP	mediated	plasticity.	 
1.2.1	Schizophrenia	
Schizophrenia	is	a	psychiatric	disorder	that	can	have	a	wide	range	of	
symptoms,	including	psychosis,	negative	symptoms	(e.g,	anhedonia,	alogia)	
and	cognitive	impairments	(Tsai	and	Coyle,	2002).	There	are	many	theories	of	
disease	aetiology,	including	the	dopamine	hypothesis;	and	indeed	dopamine	
receptor	antagonists	have	been	important	in	treating	psychoses	related	to	
schizophrenia,	but	treatment	of	negative	symptoms	and	cognitive	deficits	
have	proven	to	be	a	more	difficult	task	(Tsai	and	Coyle,	2002).	The	glutamate	
system,	and	in	particular	the	NMDA	receptor,	have	been	implied	in	the	
aetiology	of	the	disease	as	NMDA	receptor	antagonists	such	as	ketamine	have	
produced	symptoms	that	are	similar	to	those	of	schizophrenic	patients	(Krystal	
et	al.,	1999).	Phencyclidine	(PCP)	is	a	dissociative	anaesthetic	and	NMDA	
receptor	antagonist,	which	causes	schizophrenic-like	symptoms	by	blocking	
the	ion	channel	and	preventing	ion	influx	(Javitt	and	Zukin,	1991,	Beraki	et	al.,	
2008).	Rats	treated	with	ketamine	(also	a	NMDA	receptor	ion	channel	blocker,	
like	PCP)	showed	an	increase	in	dopamine	release	in	the	prefrontal	cortex,	
likely	due	to	increased	glutamate	release	and	therefore,	AMPA	receptor	
activation;	additionally,	these	rats	were	impaired	in	memory	tests	requiring	
the	prefrontal	cortex	(Moghaddam	et	al.,	1997).	This	indicated	that	glutamate	
disruption	may	contribute	to	abnormal	dopamine	levels.	Dopamine	and	
glutamate	must	also	be	functionally-coupled,	as	antipsychotic	drugs	that	act	
on	the	D1	receptor	also	enhance	the	function	of	NMDA	receptors	through	
phosphorylation	(Goff	and	Coyle,	2001,	Wittmann	et	al.,	2005).	To	highlight	
the	difference	in	the	roles	played	by	glutamate	and	dopamine	in	
schizophrenia,	volunteers	were	given	both	PCP	and	amphetamine	(which	
increases	dopamine	levels),	resulting	in	amphetamine	producing	positive	
symptoms	(i.e.	psychosis)	of	schizophrenia;	whereas,	PCP	was	capable	of	
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inducing	positive,	negative	and	cognitive	symptoms	(Javitt	and	Zukin,	1991).	
These	results	indicate	that	while	dopamine	dysfunction	can	contribute	to	
positive	symptoms,	PCP	is	capable	of	producing	a	much	broader	spectrum	of	
schizophrenic	symptoms.	Mice	with	the	NR1	subunit	knocked	out	of	excitatory	
neurons	in	the	medial	prefrontal	cortex	(mPFC)	showed	cognitive	deficits	(in	
prepulse	inhibition	of	the	auditory	startle	reflex	and	object	recognition	
memory	tests)	also	seen	in	schizophrenia	(Rompala	et	al.,	2013),	indicating	
that	NMDA	receptor	hypofunction	may	play	a	role	in	cognitive	impairment.	
Chronic	administration	of	antipsychotic	drugs	has	also	been	shown	to	increase	
mRNA	expression	of	NMDA	receptor	subunits	NR1	and	NR2,	which	may	be	
combating	reduced	NMDA	receptor	function	(Goff	and	Coyle,	2001).	
1.2.2	Aging	
The	cognitive	deficits	associated	with	aging	are	primarily	memory	loss	and	loss	
of	executive	function	(Jagust,	2013).	Age	related	changes	include	a	reduction	
in	glutamate	binding	to	the	NMDA	receptor	(Magnusson	and	Cotman,	1993)	
both	in	the	cerebral	cortex	and	hippocampus,	as	well	as	reduced	NR1	subunit	
expression;	these	changes	were	found	in	a	variety	of	species	(Magnusson	et	
al.,	2010).	These	deficits	have	been	correlated	with	reduced	performance	in	
spatial	memory	tasks	using	the	water	maze	(Magnusson,	1998).	Similarly,	aged	
rats	that	were	impaired	in	set-shifting	(a	task	of	executive	function)	exhibited	
reduced	glutamate	binding	to	NMDA	receptors	(Nicolle	and	Baxter,	2003).	
Barnes	et	al.	(1996)	showed	a	reduced	EPSP	in	the	CA1	region	of	the	
hippocampus	in	aged	rats,	that	was	likely	to	be	NMDA	receptor	independent	
and	may	have	been	due	to	loss	of	synapses	due	to	old	age.	Although	the	
NMDA	receptors	may	still	be	functioning	normally,	further	enhancing	their	
function	could	potentially	make	up	for	synaptic	loss	in	aging.		
1.2.3	Epilepsy	
There	are	many	types	of	epilepsy,	however,	in	general,	it	is	described	as	a	
seizure	caused	by	aberrant	excitatory	activity.	This	is	usually	due	to	alterations	
	15	
in	both	inhibitory	circuits	and	excitatory	circuits.	There	is	evidence	to	suggest	
that	increased	NMDA	receptor	expression	plays	a	part	in	the	pathophysiology	
of	seizures	in	temporal	lobe	epilepsy	(Mathern	et	al.,	1999).	Additionally,	
changes	in	NMDA	receptor	subunit	expression	may	be	associated	with	focal	
cortical	dysplasia	where	increased	expression	of	NR2B	subunits	was	found	in	
temporal	lobe	tissue	with	epilepsy	(Liu	et	al.,	2007a).	NMDA	receptor	
antagonists	show	promising	results	in	treating	epilepsy,	and	it	is	possible	that	
current	antiepileptic	drugs	also	target	the	NMDA	receptor,	contributing	to	its	
therapeutic	effect	(Ghasemi	and	Schachter,	2011).	As	NMDA	receptors	and	
glutamatergic	neurotransmission	plays	such	a	crucial	role	in	epilepsy,	drugs	
that	change	these	levels	of	excitation,	particularly	if	this	activity	is	being	
increased,	pose	a	potential	threat	not	only	to	enhance	the	risk	of	excitotoxicity	
(see	section	1.1.3),	but	also	seizures	such	as	those	seen	in	epilepsy.	
1.2.4	Huntington’s	Disease	
NMDA	receptor	loss	of	function	can	be	detrimental	to	cognition	as	described	
above.	However,	excessive	activation	of	the	NMDA	receptor	can	have	
deleterious	consequences.	Many	neurodegenerative	disorders	are	associated	
with	cognitive	deficits,	such	as	Parkinson’s,	Alzheimer’s,	and	Huntington’s	
disease	(HD);	and	NMDA	receptor	dysfunction	is	also	implicated	in	disease	
aetiology	(Xu	et	al.,	2012).	HD	is	a	dominant	autosomal	genetic	disorder	
caused	by	a	polyglutamine	repeat	in	the	ubiquitous	huntingtin	protein	(htt),	
coded	by	an	expanded	CAG	repeat	in	exon	1	of	the	gene	that	encodes	the	
protein	(Abada	and	Ellenbroek,	2016).	HD	is	unusual	as	the	genetic	link	to	
disease	development	is	very	strong;	the	onset	of	the	disease	is	inversely	
proportional	to	the	number	of	CAG	repeats.	An	individual	with	37	repeats	and	
upwards	is	likely	to	develop	the	disease	during	their	lifetime	(Abada	and	
Ellenbroek,	2016).	HD	causes	cognitive	deficits,	mood	changes	and	motor	
impairments	(Fernandes	and	Raymond,	2009).	It	is	primarily	known	for	the	
motor	symptoms	of	chorea	(involuntary	movement)	followed	by	akinesia	
during	disease	progression.	The	motor	symptoms	are	often	considered	for	
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diagnosis	but	are	not	required;	however,	up	to	15	years	prior	to	motor	
symptom	onset,	cognitive	deficits	may	be	apparent	(Paulsen,	2011).	
The	role	of	wildtype	(WT)	htt	remains	to	be	elucidated;	however,	mice	with	
the	gene	deleted	are	not	viable	past	embryonic	day	8	and	the	viable	
heterozygotes	have	motor	and	cognitive	dysfunctions	(Nasir	et	al.,	1995).	
These	findings	indicate	that	the	gene	plays	a	crucial	role	in	development	and	
health.	Mutant	huntingtin	(mhtt)	impairs	vesicular	transport	of	brain-derived	
neurotrophic	factor	(BDNF)	which	is	needed	for	neurotrophic	support	
(Gauthier	et	al.,	2004).	mhtt	also	impacts	upon	calcium	regulation	and	
mitochondrial	function,	and	is	implicated	in	transcriptional	dysregulation.	
These	factors	all	contribute	to	the	cell	death	strongly	seen	in	the	striatum	of	
Huntington’s	patients	(Abada	and	Ellenbroek,	2016).	
As	the	genetic	origin	of	HD	is	straightforward,	a	number	of	genetic	mouse	
models	have	been	developed	to	study	the	disease.	These	can	be	grouped	into	
three	categories:	fragment	models,	which	have	expanded	CAG	repeats	only	in	
exon	1	of	the	huntingtin	gene;	knock-in	models,	where	healthy	CAG	repeats	
are	replaced	with	the	expanded	pathological	repeats	in	the	endogenous	
mouse	gene;	and	full-length	models,	where	mice	express	the	full	human	
mutated	human	huntingtin	gene	(Abada	and	Ellenbroek,	2016).	The	R6/2	
model	is	an	example	of	a	fragment	model,	and	shows	an	aggressive	disease	
onset:	motor	deficits	at	4.5	weeks,	neurodegeneration	at	12	weeks,	and	onset	
of	cognitive	impairments	between	3.5	and	8	weeks	(Lione	et	al.,	1999,	Carter	
et	al.,	1999).	Knock-in	models	include	the	HDHQ111	and	HDH(CAG)150	mice,	which	
show	mhtt	nuclear	inclusions	in	striatal	neurons,	late	onset	motor	
dysfunctions,	and	cognitive	impairments	(Wheeler	et	al.,	2002,	Wheeler	et	al.,	
2000)	(also	see	section	1.3.6).	Full	length	models	include	the	128	YAC	mice	
which	also	display	cognitive	impairments	(Brooks	et	al.,	2012c,	Brooks	et	al.,	
2012b)	and	motor	impairments	starting	at	4	months	(Brooks	et	al.,	2012a).	
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HD	is	characterised	by	the	loss	of	striatal	neurons,	where	medium	spiny	
neurons	(MSNs)	of	the	indirect	pathway	are	particularly	vulnerable,	due	to	
excitotoxicity.	Neuronal	death	caused	by	excitotoxicity	has	been	related	to	
NMDA	receptor	function.	Zeron	et	al.	(2001)	have	shown	that	expression	of	
mutant	huntingtin	protein	with	NMDA	(NR1A/NR2B)	receptors	in	HEK293	cells	
increased	apoptotic	cell	death	after	NMDA	application.	Zeron	et	al.	(2002)	
then	showed	that	MSNs	were	vulnerable	to	NMDA	application	in	a	YAC	mouse	
model,	expressing	the	full-length	mutant	huntingtin	protein,	which	was	
reversible	with	the	NR2B	subunit	specific	antagonist,	ifenprodil.	Quinolinic	
acid	is	a	NMDA	receptor	agonist,	and	striatal	lesions	using	this	drug	have	
produced	characteristics,	both	in	behaviour	and	physiology,	that	are	similar	to	
HD	(Beal	et	al.,	1986).	Therefore,	potentiating	the	NMDA	receptor	to	enhance	
cognitive	deficits	must	take	into	account	that	NMDA	receptor	potentiation	
may	mediate	some	of	the	disease	progression.	As	mentioned	above	(section	
1.1.3),	extrasynaptic	NMDA	receptors	are	thought	to	be	involved	in	cell	death,	
and	these	extrasynaptic	receptors	may	also	play	a	role	in	the	cell	death	
associated	with	HD	(Parsons	and	Raymond,	2014,	Milnerwood	et	al.,	2010)	
due	to	mitochondrial	dysfunction	and	intracellular	calcium	release	(Raymond,	
2016).	As	it	is	particularly	the	MSNs	of	the	striatum	that	are	targeted	by	
degeneration	in	HD,	it	is	interesting	to	note	that	the	YAC72,	YAC128,	and	R6/2	
models	showed	increased	NMDA	receptor	currents	in	the	striatum	in	response	
to	stimulation	of	glutamatergic	afferents,	and	that	mature	MSNs	have	
increased	expression	of	NR2B	subunits,	which	are	linked	to	cell	death	
signalling	(Raymond	et	al.,	2011).	Finally,	Okamoto	et	al.	(2009)	found	a	direct	
relationship	between	NMDA	receptor	location	and	mhtt:	synaptic	NMDA	
receptor	activation	increased	mhtt	inclusions,	resulting	in	neuroprotection	as	
damaging	proteins	are	sequestered;	while	extrasynaptic	NMDA	receptor	
activation	caused	a	decrease	in	inclusions	and	increased	cell	death	in	cortical	
neurons.	
	18	
As	NMDA	receptor	signalling	plays	a	critical	role	in	synaptic	plasticity,	it	is	vital	
for	the	functioning	of	cognition.	In	HD,	as	well	as	other	neurodegenerative	
diseases	(and	also	schizophrenia	and	aging	mentioned	above),	loss	of	cognitive	
functions	is	one	of	the	early	and	most	detrimental	symptoms	of	the	disease.	
HD	patients	have	a	wide	range	of	cognitive	deficits	including	in	emotion	
recognition,	attention,	working	memory,	spatial	memory,	pattern	recognition,	
episodic	memory,	and	verbal	fluency	(Johnson	et	al.,	2007,	Kirkwood	et	al.,	
2000,	Lawrence	et	al.,	1998,	Lawrence	et	al.,	1996).	Paulsen	(2011)	describes	a	
general	decrease	in	the	speed	of	cognitive	processing	in	prodromal	HD,	where	
an	ordinary	mental	task	becomes	“more	tiring	and	takes	more	time	to	achieve	
the	same	outcome”.	Paulsen	suggests	this	is	due	to	relying	on	alternative	
processing	routes	and	lack	of	automation.	
HD	is	an	ideal	model	system	to	study	the	effects	of	NMDA	receptor	
modulation	on	cognition,	as	NMDA	receptor	dysfunction	is	a	prominent	
component	of	disease	progression	and	cognitive	deficits	are	likely	associated	
with	this	NMDA	receptor	dysfunction.	This	thesis	uses	Huntington’s	as	a	focus	
for	the	study	of	the	NMDA	receptor’s	involvement	in	cognition	by	
investigating	a	range	of	behaviours	in	rodent	models,	which	were	developed	
to	measure	different	areas	of	cognition,	from	spatial	memory	to	executive	
functions.	These	are	described	in	detail	below,	along	with	the	role	NMDA	
receptors	in	particular,	play	in	these	processes.	
1.3	Behavioural	Tasks:	Memory	
1.3.1	Novel	Object	Recognition	and	Novel	Place	Recognition	
Novel	object	recognition	(NOR)	is	widely	used	for	assessing	memory	in	
rodents.	It	is	very	popular	as	it	requires	no	specialist	equipment,	does	not	
require	any	training,	and	capitalises	on	the	innate	behaviours	of	the	rodent	to	
spontaneously	explore	novelty.	More	specifically,	NOR	is	often	used	to	test	
episodic	memory,	where	a	battery	of	task	variations	assess	the	what-where-
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which	aspects	of	this	memory	(Mumby	et	al.,	2002).	In	the	basic	NOR	test,	the	
subject	is	presented	with	two	identical	objects,	after	a	short	interval,	one	of	
the	objects	is	replaced	with	a	new	object.	If	the	subject	preferentially	explores	
the	new	object,	we	can	infer	that	an	implicit	memory	for	the	familiar	object	
has	been	formed.	In	a	similar	fashion,	spatial	memory	can	be	tested	with	the	
novel	place	recognition	(NPR)	task.	Here	the	subject	is	again	presented	with	
two	identical	objects,	however	instead	of	changing	the	object	identity,	one	of	
the	objects	changes	location.	If	the	object	in	the	new	location	is	preferentially	
explored,	we	can	conclude	that	a	memory	for	the	familiar	location	has	been	
formed.	
1.3.2	The	Role	of	the	Hippocampus	and	NMDA	Receptors	in	NPR	
	The	hippocampus	has	been	placed	in	centre	stage	for	spatial	memory,	with	
NMDA	receptors	playing	a	critical	role	in	synaptic	plasticity	through	LTP	(see	
section	1.1.3).	Therefore,	it	is	not	surprising	that	it	has	also	been	shown	to	
play	a	role	in	NPR	tasks.	For	example,	rats	with	lesions	to	the	hippocampus	
were	still	able	to	perform	the	NOR	task;	however,	rats	no	longer	preferred	
novelty	in	the	NPR	task	and	a	contextual	task	(Mumby	et	al.,	2002,	Barker	and	
Warburton,	2011).	In	contrast,	perirhinal	cortex	lesions	were	shown	to	
decrease	preference	for	the	novel	object	in	the	NOR	task	(Aggleton	et	al.,	
2010),	but	place	recognition	remained	intact	(Glenn	and	Mumby,	1998,	Barker	
and	Warburton,	2011).	Collectively,	these	studies	indicate	a	dissociated	role	
for	the	perirhinal	cortex	and	hippocampus	for	object	and	place	recognition,	
respectively.	Further,	only	tests	which	require	allocentric	(rather	than	
egocentric)	spatial	memory	seem	dependent	on	the	hippocampus	(Langston	
and	Wood,	2010).	This	supports	the	role	of	the	hippocampus	as	creating	a	
“cognitive	map”	of	the	environment	(O'Keefe	and	Nadel,	1978),	where	place	
and	grid	cells	provide	the	mechanism	to	create	these	spatial	“place	fields”	
(Burgess	and	O'Keefe,	2011).	Shapiro	(2001)	describes	a	key	role	of	NMDA	
receptors	in	creating	place	fields,	which	are	spatial	locations	where	place	cells	
fire	when	the	animal	is	that	location.	This	is	supported	by	a	number	of	studies	
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which	show	that	NMDA	receptors	are	involved	in	NPR	tasks.	For	example,	
NMDA	receptor	antagonists	that	were	given	intraperitoneally	before	the	
sample	phase,	but	not	before	the	test	phase,	of	the	NPR	task,	reduced	
preference	for	the	novel	place	(Larkin	et	al.,	2008).	APV	infusions	directly	to	
the	hippocampus	before	the	sample	phases	also	impaired	rats	in	the	NPR	task,	
but	not	the	NOR	task	(Barker	and	Warburton,	2015).	Additionally,	APV	infusion	
via	various	paths	(dentate	gyrus,	CA3,	and	CA1)	to	the	hippocampus	also	
impaired	preference	of	the	novel	place	(Hunsaker	et	al.,	2007).	This	was	also	
found	in	juvenile	rats	(Jablonski	et	al.,	2013).	
1.3.3	Morris	Water	Maze	
The	Morris	water	maze	(hereafter	referred	to	as	“water	maze”)	was	
developed	by	Morris	(1984)	in	St	Andrews	for	rats.	In	this	classic	test,	rats	are	
required	to	swim	in	a	pool	of	water	to	locate	a	submerged	and	invisible	
platform,	which	is	the	only	means	of	escape	from	the	water.	The	rat	is	placed	
into	the	pool	from	different	release	sites	chosen	randomly	during	each	trial,	
and	required	to	use	extra-maze	cues	to	locate	the	platform.	The	transfer	test,	
also	called	probe	trial,	tests	for	spatial	memory	by	removing	the	platform	
completely	after	training,	and	recording	the	swim	paths	of	the	subjects.	If	
memory	for	the	platform	location	has	been	established,	the	subjects	will	
spend	more	time	swimming	in	the	proximity	of	the	old	platform	location.	
1.3.4	The	Role	of	the	Hippocampus	and	NMDA	Receptors	in	the	
Water	Maze	
The	hippocampus	is	thought	to	be	critical	for	spatial	learning	in	the	water	
maze,	a	concept	supported	by	lesion	studies	both	in	rats	(Pearce	et	al.,	1998,	
Morris	et	al.,	1982,	Morris,	1984)	and	mice	(Cho	et	al.,	1999).	In	particular,	the	
place	cells	of	the	hippocampus	are	implicated	in	spatial	learning,	as	
demonstrated	by	impaired	platform	location	acquisition	in	conditions	where	
place	cell	learning	is	disrupted	(Bures	et	al.,	1997)	and	by	place	cell	firing	
during	exploration	of	enclosed	environments	(Poucet	et	al.,	2000).	Place	cells	
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also	show	place	specific	firing	in	mice	(Silva	et	al.,	1998).	The	hippocampus	is	
thought	to	be	needed	for	acquisition,	retrieval	and	storage	of	spatial	memory	
required	for	water	maze	learning	(D'Hooge	and	De	Deyn,	2001).	Other	brain	
regions,	such	as	the	striatum,	are	also	implicated	in	spatial	learning,	as	well	as	
the	connections	between	these	regions	and	the	hippocampus	(Miyoshi	et	al.,	
2012).	
As	described	above	(section	1.1.3),	NMDA	receptors	are	implicated	in	the	
formation	of	spatial	memory,	possibly	through	the	process	of	LTP.	NMDA	
receptor	involvement	in	water	maze	spatial	learning	was	first	suggested	by	
Morris	(1989),	where	intraventricular	infusions	of	APV	(an	NMDA	antagonist)	
caused	spatial	memory	impairments	in	the	water	maze.	Other	studies	showed	
that	impaired	LTP	in	the	CA1	region,	created	by	a	knockout	of	the	NMDA	
receptor,	caused	spatial	impairments	(Wilson	and	Tonegawa,	1997,	Sakimura	
et	al.,	1995).	Transgenic	disruption	of	LTP	downstream	signalling	also	caused	
impaired	spatial	learning	in	the	water	maze	(Silva	et	al.,	1992,	Bourtchuladze	
et	al.,	1994)	as	did	protein	synthesis	inhibitors	(Meiri	and	Rosenblum,	1998).	
Bannerman’s	group	(2014)	has	challenged	the	established	view	that	
hippocampal	NMDA	receptors	are	needed	for	spatial	learning	in	the	water	
maze.	They	used	transgenic	mice	lacking	NMDA	receptors	in	the	CA1	region	
and	dentate	gyrus	of	the	hippocampus	in	a	water	maze	task,	where	the	mice	
were	required	to	discriminate	between	two	beacons	associated	with	the	
platform	based	on	location	(where	only	one	beacon	signalled	the	platform	
location).	Transgenic	mice	were	unimpaired	compared	to	WT	in	learning	the	
platform	location	when	released	from	sites	equidistant	between	the	beacons.	
However,	transgenic	mice	were	impaired	at	inhibiting	the	urge	to	visit	the	
incorrect	beacon	when	released	near	it	(Taylor	et	al.,	2014).	If	two	visually	
distinct	beacons	were	used,	where	one	predicted	the	platform	location,	and	
the	other	did	not,	the	mice	lacking	NMDA	receptors	were	unimpaired	
(Bannerman	et	al.,	2012).	These	findings	indicate	that	while	NMDA	receptors	
of	the	hippocampus	may	not	be	needed	for	spatial	learning	per	se,	they	are	
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critical	for	inhibiting	inappropriate	responses	when	confronted	with	conflicting	
information.	
1.3.5	Spatial	Memory	Impairments	in	HD	Patients	
HD	patients	also	show	spatial	memory	impairments.	Lawrence	et	al.	(2000)	
found	that	patients	in	early	stages	of	HD	were	impaired	in	spatial	memory	
compared	to	a	control	group.	Subjects	were	required	to	remember	the	
locations	of	five	squares	on	a	touchscreen	and	recall	these	locations	when	
paired	with	a	square	in	a	new	location.	A	later	study	showed	that	HD	patients	
were	impaired	compared	to	control	subjects,	Parkinson’s	disease,	and	AD	
patients,	in	a	task	requiring	the	subjects	to	place	9	stimulus	cards	in	the	same	
locations	as	they	were	previously	shown	(Brandt	et	al.,	2005).	Both	authors	
suggest	the	spatial	impairments	are	due	to	the	two	different	visual	
information	processing	streams:	the	ventral	and	dorsal	streams	within	the	
cerebral	cortex,	which	are	associated	with	object	cognition	and	visuospatial	
cognition,	respectively.	As	HD	is	primarily	considered	a	disease	which	targets	
the	striatum	and	the	cortex,	and	the	connectivity	between	them,	it	is	clear	
why	spatial	memory	impairments	are	explained	in	these	terms.	However,	
many	HD	mouse	models	also	show	hippocampal	deficits	(Gauntlett-Gilbert	et	
al.,	1999,	Gil	et	al.,	2005,	Kolodziejczyk	et	al.,	2014,	Murphy	et	al.,	2000),	
which	may	contribute	to	spatial	memory	dysfunctions.	Specifically,	the	R6/2	
line	showed	a	clear	spatial	impairment	in	the	water	maze	compared	to	WT	
controls,	both	during	platform	acquisition,	and	in	the	probe	trial	(Murphy	et	
al.,	1992,	Lione	et	al.,	1999).	The	HDHQ111+/-	mouse	is	discussed	in	the	next	
section.	Interestingly,	Begeti	et	al.	(2016),	noticing	the	trend	of	spatial	
impairments	in	the	water	maze	in	mouse	models,	set	out	to	replicate	these	
findings	in	HD	patients.	The	authors	used	a	virtual	reality	version	of	the	water	
maze	with	early	HD	patients	and	pre-manifest	patients.	Early	HD	patients	were	
impaired	compared	to	controls,	and	performance	correlated	with	the	
estimated	years	to	diagnosis	for	pre-manifest	patients.	
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1.3.6	Memory	Impairments	in	the	HDHQ111+/-	Mouse	Model	of	
Huntington’s	Disease.		
The	hippocampus	is	connected	to	both	the	frontal	cortex	(Barker	and	
Warburton,	2011)	and	to	the	striatum	(Delcasso	et	al.,	2014),	areas	which	are	
known	to	be	affected	in	HD	(see	section	1.2.4).	NMDA	receptor	dysfunction	
has	also	been	shown	to	play	a	role	in	HD	(see	section	1.2.4).	To	find	a	model	to	
test	possible	therapeutics	for	this	aspect	of	cognitive	dysfunction	in	HD,	the	
Lambert/Langston	laboratory	has	investigated	cognitive	impairments	in	the	
HDHQ111+/-	mouse	model	in	an	attempt	to	identify	a	phenotype	similar	to	that	
observed	in	HD	patients.	Previous	findings	include:	a	LTP	deficit	in	the	CA1	
region	of	the	hippocampus	(Figure	1.3A);	a	deficit	in	the	episodic-like	memory	
(“object-place-context”	task,	Figure	1.3B);	and	long-term	(24	hour)	NOR	task	
(Figure	1.3C)	(Mitchell,	2012).	Finally,	there	is	evidence	that	the	HDHQ111+/-	
mouse	has	a	reduced	preference	for	the	novel	place	in	the	NPR	task,	
compared	to	WT	controls	(Chandler	(2014),	Figure	1.3).	
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Figure	1.3:	The	phenotype	of	the	HDHQ111+/-	mouse	model	of	HD	at	2	months.	(A)	The	
heterozygote	(HDHQ111+/-)	and	homozygote	(HDHQ111+/+)	is	impaired	at	a	4-theta-burst	
stimulation	(TBS)	compared	to	wildtype	(WT)	controls	(p<0.05).	(B)	Both	the	heterozygous	and	
homozygous	mouse	is	impaired	at	the	episodic-like	(“object-place-context”)	memory	task	
(p<0.05).	(C)	Both	the	heterozygous	and	homozygous	mouse	is	impaired	at	the	24-hour	NOR	
task	(p<0.05).	A	positive	discrimination	index	indicates	a	preference	for	the	novel	object.	Data	
from	Mitchell	(2012).	 	
A 
C B 
	25	
	
Figure	1.4:	The	HDHQ111+/-	mouse	(HET)	shows	no	preference	for	the	novel	location	in	the	NPR	
task	compared	to	wildtype	(WT)	controls	(p<0.001)	at	5	months	of	age.	A	positive	
discrimination	index	(DI)	indicates	a	preference	for	the	novel	place.	Data	collected	by	Chandler	
(2014).	
As	the	HDHQ111+/-	mouse	seems	to	show	cognitive	impairments	well	before	
motor	impairment	onset	(which	only	becomes	mildly	apparent	starting	at	9	
months	(Yhnell	et	al.,	2016a)),	it	is	an	ideal	candidate	for	behavioural	testing.	
Not	only	is	there	no	concern	of	motor	impairments	interfering	with	
behavioural	measurements,	but	it	also	more	closely	mimics	the	patient	
disease	progression	(Roos,	2010).	The	HDHQ111+/-	mouse	also	more	closely	
models	the	human	disease	as	cognitive	impairments	are	present	in	the	
heterozygous	(not	just	the	homozygous)	animal;	likewise,	HD	is	an	autosomal	
dominant	genetic	disease,	therefore,	only	one	copy	of	the	gene	is	required	for	
disease	onset.	
1.4	Behavioural	Tasks:	Executive	functions	
1.4.1	Attentional	Set-Shifting	task	
Forming	attentional	set	is	a	cognitive	function	shared	by	humans	and	other	
animals.	Having	an	attentional	set	can	be	regarded	as	a	cognitive	short-cut;	it	
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works	as	a	filter	so	that	limited	processing	resources	can	be	preferentially	
assigned	to	stimuli	that	are	currently	most	relevant.	However,	such	a	filter,	
whilst	highly	efficient	in	many	circumstances,	also	requires	processes	that	will	
over-ride	it	in	certain	circumstances.	For	example,	a	particularly	salient	
stimulus	will	capture	attention,	in	spite	of	an	attentional	set.	Attentional	set	
also	must	not	be	static	and	fixed;	the	attentional	set	must	shift	if	
circumstances	change.	The	ability	to	shift	an	attentional	set	is	impaired	in	
certain	human	illness;	for	example,	in	schizophrenia	(Pantelis	et	al.,	1999,	
Ceaser	et	al.,	2008)	and	following	frontal	lobe	damage	(Owen	et	al.,	1993,	
Pantelis	et	al.,	1999).	Therefore,	tests	of	attentional	set-shifting	have	been	
used	for	many	decades	as	an	archetypal	test	of	behavioural	flexibility.		
The	classic	and	most	well-known	test	of	attentional	set-shifting	is	the	
Wisconsin	Card	Sorting	Task	(WCST).	However,	the	
intradimensional/extradimensional	(ID/ED)	task	(particularly	varieties	that	
have	a	‘total	change	design’	(Slamecka,	1968),	with	novel	stimuli	at	each	
acquisition	stage)	is	a	more	‘pure’	test	of	the	ability	to	form	and	shift	
attentional	set.	Furthermore,	it	has	been	adapted	for	numerous	other	species	
enabling	inter-species	comparisons	to	be	made.	The	Cambridge	
Neuropsychological	Testing	Automated	Battery	(CANTAB)	contains	an	ID/ED	
task	often	used	for	patient	assessment	(Potter	et	al.,	2012).	
In	the	rat	version	of	the	ID/ED	task,	introduced	by	Birrell	and	Brown	(2000),	
rats	are	required	to	dig	in	bowls	to	find	a	food	reward.	The	rat	is	presented	
with	two	bowls	that	differ	in	both	smell	and	the	digging	medium	within	the	
bowl.	The	rat	learns	that	only	one	of	the	stimulus	dimensions	(the	odour	or	
the	medium)	is	relevant	to	finding	the	food	and	consequently,	over	relatively	
few	discriminations,	attention	is	directed	preferentially	to	the	stimuli	in	the	
relevant	dimension;	this	demonstrates	that	an	attentional	set	for	this	
dimension	has	been	formed.	Set-shifting	is	a	test	for	how	easily	this	
attentional	set	can	be	moved	to	another	dimension.	The	number	of	trials	
needed	to	dig	in	the	bowls	to	reach	criterion	to	move	to	the	next	stage	(trials	
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to	criterion;	TTC)	reflects	the	behavioural	flexibility	of	the	subject	to	shift	
attentional	set	to	another	dimension.	
Birrell	and	Brown	(2000)	not	only	introduced	the	ID/ED	task	for	rats,	showing	
that	rats	form	attentional	set,	they	also	showed	that	a	lesion	of	the	medial	
prefrontal	cortex	(mPFC)	impaired	their	ability	to	shift	attentional	set.	This	
coincides	with	marmoset	literature	showing	lateral	lesions	to	the	prefrontal	
cortex	(PFC)	caused	set-shifting	deficits	(Dias	et	al.,	1997),	and	above	
mentioned	human	frontal	lobe	damage	(Owen	et	al.,	1993,	Pantelis	et	al.,	
1999).	
1.4.2	Role	of	the	NMDA	Receptor	in	Attentional	Set-Shifting	
The	NMDA	receptor	is	vital	for	a	wide	range	of	cognitive	abilities	and	
attentional	set-shifting	is	not	an	exception.	Both	pharmacological	
manipulations	of	the	NMDA	receptor	and	genetic	mutations	have	been	
studied	in	rodents	to	assess	the	role	of	the	NMDA	receptor	in	set-shifting.	
Kos	et	al.	(2011)	showed	that	ketamine	administration	increased	TTC	at	the	ED	
stage	of	a	set-shifting	task	modified	for	mice.	These	authors	also	found	that	
the	NR2B	antagonist,	Ro	25-6981,	decreased	the	TTC	at	the	ED	stage.	This	
indicates	that	the	NR2B	subunit	may	have	a	specific	role	in	behavioural	
flexibility,	however,	as	there	was	no	reversal	cost	it	is	likely	that	a	set	was	not	
formed	in	the	first	place	and	conculsions	of	behavioural	flexibility	cannot	be	
drawn.	Marquardt	et	al.	(2014)	showed	that	a	GluN2A	knockout	mouse	took	
significantly	more	TTC	at	the	ED	stage	of	the	ID/ED	task	compared	to	WT	and	
heterozygous	littermates,	indicating	a	set-shifting	impairment.	While	
Thompson	et	al.	(2015)	set	out	to	further	explore	the	role	of	the	NR2B	subunit,	
showing	that	mice	lacking	these	subunits	were	unable	to	form	attentional	set	
in	the	first	place.	Although	this	particular	finding	cannot	give	information	
about	set-shifting,	it	does	indicate	the	NR2B	subunit	plays	an	important	role	in	
set	formation	and	learning.	Together	these	studies	suggest	that	the	plasticity	
required	to	allow	the	cortical	regions	to	shift	strategies	could	involve	the	
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NMDA	receptor,	in	a	similar	fashion	to	its	established	role	in	memory	
formation.	
1.4.3	Set-Shifting	in	Huntington’s	Disease	
Patients	with	HD	have	a	variety	of	executive	function	deficits.	HD	patients	
were	shown	to	be	impaired	in	the	WCST	due	to	increased	perseverative	
responding	(Josiassen	et	al.,	1983).	Patients	in	the	early	phases	of	HD	also	
showed	a	deficit	at	the	ED	stage	of	the	CANTAB	set-shifting	task	(Lawrence	et	
al.,	1996).	The	cortex	has	many	feedback	loops	to	the	basal	ganglia	in	order	to	
allow	for	appropriate	action	selection.	Although	HD	is	classically	known	as	a	
disorder	that	primarily	causes	degeneration	in	the	striatum,	it	can	be	
postulated	that	disruption	to	the	corticostriatal	loops	from	striatal	damage	can	
cause	set-shifting	impairments.	Monkey	anatomy	suggests	that	the	
dorsolateral	prefrontal	cortex	(analogous	to	the	mPFC	in	rats)	projects	to	the	
dorsal	striatum	(Alexander	et	al.,	1986).	Additionally,	there	is	good	evidence	
that	dysfunction	of	cortical	pyramidal	neurons,	which	project	to	the	striatum,	
are	impaired	in	HD	as	seen	in	patients	as	well	as	mouse	models	(Estrada-
Sanchez	and	Rebec,	2013).	NMDA	receptors	may	be	involved	in	cortical	
dysfunction	as	Dallerac	et	al.	(2011)	found	LTP	impairments	in	the	prefrontal	
cortex	of	the	R6/1	mouse.	
Behavioural	flexibility	has	also	been	measured	in	mouse	models	for	HD,	such	
as	in	the	Barnes	maze,	where	the	R6/1	mouse	was	unable	to	change	search	
strategies	(Nithianantharajah	et	al.,	2008).	Brooks	et	al.	(2006)	attempted	an	
ID/ED	task	in	the	HdhCAG(150)	mouse,	claiming	to	have	found	an	ED	deficit;	
however,	as	there	was	no	ID/ED	difference	for	the	experimental	or	WT	control	
group,	this	cannot	be	concluded	as	no	set	was	formed	in	the	first	place.	
1.4.4	Reversal	Learning	
Reversal	learning,	as	well	as	attentional	set	formation	and	set-shifting,	come	
under	the	umbrella	term	of	“executive	function”.	This	term	includes	any	
behaviour	that	requires	complex	cognitive	functioning	to	select	actions	such	
	29	
as	planning	and	rule	learning	and	changing	in	response	to	stimuli	(Talpos	and	
Shoaib,	2015).	Reversal	learning	is	the	reversal	of	an	established	stimulus-
outcome	(or	stimulus-reward)	contingency.	Usually	the	subject	first	learns	a	
discrimination	task,	and	discrimination	is	then	reversed	so	that	the	previously	
rewarded	stimulus	is	no	longer	rewarded,	and	the	previously	unrewarded	
stimulus	becomes	rewarded.	Reversal	learning	consists	of	4	stages:	(1)	
detection	of	the	learned	action	no	longer	resulting	in	reward	(2)	inhibition	of	
the	now	unrewarded	action	(3)	changed	behaviour	to	discover	new	stimulus-
reward	contingency	(4)	learning	of	the	new	contingency	(Talpos	and	Shoaib,	
2015).	
Lesion	studies	have	shown	that	the	PFC	is	required	for	reversal	learning	in	
rodents	and	non-human	primates;	specifically,	lesions	of	the	orbitofrontal	
cortex	(OFC)	selectively	cause	reversal	learning	impairments	(Dias	et	al.,	1996,	
Dias	et	al.,	1997,	McAlonan	and	Brown,	2003).	Human	studies	also	show	
increased	OFC	activation	during	reversal	learning	(Hampshire	and	Owen,	2006,	
Cools	et	al.,	2002)	and	lesions	of	the	striatum	impair	reversal	learning	(Cools	et	
al.,	2006).	The	frontal	cortex	does	not	work	in	isolation,	and	corticostriatal	
circuits	have	also	been	implicated	in	reversal	learning.	The	OFC	also	has	strong	
glutamatergic	projections	to	the	basal	ganglia,	particularly	the	nucleus	
accumbens	and	dorsomedial	striatum	(DMS)	(Haber	et	al.,	1995).	The	basal	
ganglia	serve	as	a	feedback	system	for	action	selection;	it	receives	
glutamatergic	inputs	not	only	from	the	cortex,	but	also	the	thalamus,	
amygdala	and	hippocampus,	which	it	integrates	with	dopaminergic	inputs	
from	the	ventral	midbrain	(Voorn	et	al.,	2004).	Striatal	contribution	is	further	
supported	by	lesions	to	the	DMS	impairing		reversal	learning	in	rats	(Castane	
et	al.,	2010,	Ragozzino,	2007,	Graybeal	et	al.,	2011).	DMS	lesions	also	caused	
reversal	impairments	in	mice	in	a	cue-based	water	maze	task	(Lee	et	al.,	2014).	
Clarke	et	al.	(2008)	found	that	medial	striatum	lesions	in	marmosets	caused	
similar	reversal	learning	impairments	as	OFC	lesions.	DMS	lesions	in	rats	also	
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impaired	attentional	set-formation	(Lindgren	et	al.,	2013),	which	also	occurs	
with	OFC	lesions	(Chase	et	al.,	2012).	
1.4.5	NMDA	Receptors	and	Reversal	Learning	
As	the	NMDA	receptor	is	required	for	some	forms	of	synaptic	plasticity,	it	
seems	likely	to	be	involved	in	behavioural	flexibility	tasks	such	as	reversal	
learning	that	require	adaptive	behaviours.	An	acute	block	of	NMDA	receptors	
in	the	dorsal	striatum	impaired	reversal	learning	in	rats	(Palencia	and	
Ragozzino,	2004).	However,	the	involvement	of	NMDA	receptors	in	reversal	
learning	is	not	clear	cut	as	some	laboratories	found	deficits	with	NMDA	
receptor	antagonist	administration	(Abdul-Monim	et	al.,	2007),	while	others	
found	no	difference	(Janhunen	et	al.,	2015).	Reduced	NMDA	receptor	
expression	in	the	dorsal	striatum	due	to	gene	(Grin1)	inactivation	caused	a	
deficit	in	rule	shifting	but	not	reversal	learning	in	mice	(Darvas	and	Palmiter,	
2015).	The	NR2B	subunit	may	be	particularly	important	for	reversal	learning,	
as	systemic	administration	of	the	selective	antagonist,	Ro25-6981,	impaired	
reversal	learning,	but	not	initial	discrimination	learning	in	rats	(Dalton	et	al.,	
2011).	Others	found	that	localised	antagonist	administration	or	genetic	
deletion	of	the	NR2B	subunit	in	the	OFC	caused	reversal	deficits	due	to	
perseveration	in	mice	(Brigman	et	al.,	2013,	Thompson	et	al.,	2015).	
1.4.6	Reversal	Learning	in	Huntington’s	Disease	
Executive	function	deficits	are	some	of	the	early	symptoms	of	HD	(Paulsen,	
2011),	and	as	the	as	the	striatum	and	cortex	are	the	main	targets	for	
neurodegeneration	and	dysfunction,	it	is	not	surprising	that	HD	patents	in	the	
early	stages	(Lawrence	et	al.,	1999)	and	preclinical	(Lawrence	et	al.,	1998)	
stages	of	the	disease	were	shown	to	have	a	probabilistic	reversal	learning	
deficit	compared	to	age	matched	controls.	In	contrast,	in	late	HD	progression,	
simple	reversal	learning	is	impaired	due	to	perseverative	responding	
(Lawrence	et	al.,	1996).	Habits	and	automated	processes	increase	processing	
speed;	therefore,	if	more	cortical	control	is	required,	due	to	a	less	efficient	
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striatum,	actions	may	become	slower.	Similarly,	if	the	striatum	is	no	longer	
able	to	respond	efficiently	to	the	glutamatergic	signals	to	change	behaviour	
and	induce	plasticity,	perseverative	behaviour	can	occur.	This	would	also	slow	
behaviour,	as	inappropriate	responses	would	be	preferentially	executed.		
There	have	been	a	few	reports	of	mouse	models	of	HD	showing	reversal	
learning	impairments.	For	example,	the	R6/2	mouse	model	has	been	reported	
to	show	an	age	dependent	reversal	learning	deficit	at	6.5	weeks	of	age	in	a	
water	maze	environment	discriminating	between	a	bright	and	a	dimmed	light,	
but	without	an	acquisition	impairment	(Lione	et	al.,	1999).	Impaired	switching	
between	delayed	match	to	position	and	delayed	non-match	to	position	tasks	
in	the	HDHQ111+/-	mouse	was	interpreted	as	a	‘reversal	learning’	impairment,	
although	this	task	is	clearly	more	complex	than	simply	reversal	learning	(Yhnell	
et	al.,	2015).	Furthermore,	the	HD	and	WT	mice	were	not	performing	at	the	
same	level	before	‘rules’	were	switched.	Therefore,	there	is	clearly	a	need	for	
additional	study	of	the	putative	reversal	impairments	in	HD	mouse	models	
before	concluding	that	they	have	similar	deficits	to	those	seen	HD	patients.	
1.5	NMDA	Receptor	Pharmacology	for	Cognitive	
Enhancement	
As	NMDA	receptor	dysfunction	is	implicated	in	the	aetiology	of	many	
disorders	associated	with	cognitive	impairments,	it	seems	able	to	be	an	ideal	
target	for	treatments	of	cognitive	dysfunction.	However,	care	must	be	taken	
with	any	drug	development	to	minimise	side	effects;	especially	NMDA	
receptor	modulation	must	be	approached	with	caution,	as	it	is	so	central	to	
very	basic	and	important	neuronal	properties	and	networks.	As	mentioned	in	
section	1.1.3	and	1.2.4,	both	too	little	and	too	much	excitatory	signalling	can	
have	detrimental	effects	to	neuronal	functioning	and	care	must	be	taken	to	
prevent	epileptic	activity.	Previous	drugs	have	focused	on	NMDA	receptor	
antagonism	such	as	memantine,	which	is	the	first	drug	used	to	treat	AD	that	is	
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not	focused	on	the	cholinergic	system.	Memantine	preferentially	blocks	
extrasynaptic	NMDA	receptors,	implicated	in	excitotoxicity,	largely	leaving	
synaptic	receptors	to	carry	out	their	normal	physiological	functions	(Xia	et	al.,	
2010).	Alternatively,	treatments	can	focus	on	NMDA	receptor	enhancement,	
such	as	with	NMDA	receptor	co-agonists,	or	positive	allosteric	modulators	
(PAMs),	which	will	be	the	focus	for	this	thesis.	
1.5.1	NMDAR	Co-Agonists	
The	D-serine	site	and	glycine	binding	site	are	the	same	site,	and	it	is	situated	
on	the	LBD	of	the	NMDA	receptor	(see	Figure	1.5),	and	allows	binding	of	both	
glycine	(Ascher	and	Nowak,	2009)	and	D-serine	(Nagai	et	al.,	2012).	This	site	
must	be	occupied	in	addition	to	the	glutamate	binding	site	to	allow	NMDA	
receptor	activation	(Curras	and	Pallotta,	1996).	Papouin	et	al.	(2012)	have	
shown	that	synaptic	NMDA	receptors	are	gated	by	D-serine;	whereas,	
extrasynaptic	receptors	use	glycine	as	the	co-agonist.	As	this	site	is	essential	to	
NMDA	activation,	increasing	the	concentration	of	available	endogenous	
ligands	may	increase	channel	opening	and,	therefore,	potentiation	of	NMDA	
receptor	function.	Glycine	has	been	shown	to	increase	EPSPs	in	the	neocortex	
(Thomson	et	al.,	1989)	as	well	as	reduce	negative	symptoms	in	schizophrenic	
patients	(Coyle	and	Tsai,	2004).	Unfortunately,	glycine	has	poor	blood	brain	
barrier	permeability	(Hashimoto	et	al.,	2013).	
D-serine	was	able	to	reverse	polyriboinosinic-polyribocytidilic	acid	induced	
cognitive	deficits	in	mice,	and	this	reversal	was	inhibited	with	an	NMDA	
antagonist,	suggesting	that	D-serine	is	modulating	the	NMDA	receptor	to	
enhance	cognition	(Nagai	et	al.,	2012).	D-cycloserine	is	also	a	ligand	of	the	D-
serine	site	and	has	been	shown	to	enhance	cognition	(Thompson	et	al.,	1992).	
D-cycloserine	was	also	able	to	decrease	negative	symptoms	of	schizophrenia	
in	patients	as	measured	by	an	improvement	of	reaction	time	needed	on	tests	
requiring	the	PFC	(Goff	et	al.,	1995).	However,	it	is	only	a	parital	agonist,	and	
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therefore,	less	effective	at	increasing	NMDA	receptor	activitiy	than	full	
agonists	like	D-serine	(Heresco-Levy	and	Javitt,	2004).	
Alternatively,	the	concentration	of	available	co-agonist	can	also	be	increased	
by	preventing	the	reuptake	by	glycine	transporters.	This	approach	has	led	to	
the	development	of	glycine	transporter	inhibitors,	that	prevent	the	uptake	of	
glycine	from	the	synaptic	cleft.	One	such	drug,	Bitopertin,	showed	
improvements	in	the	negative	symptoms	of	schizophrenia	(Umbricht	et	al.,	
2014)	but	infortunately	these	results	did	not	replicate	in	phase	III	clinical	trials	
(Lencz	and	Malhotra,	2015).	
Currently,	a	promising	modulator	(partial	agonist	of	an	allosteric	site)	of	the	
glycine	site,	is	under	development	for	treatment-resistant	major	depressive	
disorder	(Moskal	et	al.,	2016).	There	is	also	data	indicating	that	Rapastinel,	
developed	by	Allergan,	has	a	cognitive	enhancing	effect	(Moskal	et	al.,	2016).	
The	approach	of	targeting	the	co-agonist	site	of	the	NDMA	receptor	may	
present	a	godo	alternative	to	direct	activation	of	the	NDMA	receptor	to	
enhance	cognition.	
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Figure	1.5:	The	structure	and	pharmacology	of	the	NMDA	receptor.	The	glycine	binding	site	is	
located	on	the	NR1	subunit,	while	the	glutamate	binding	site	is	located	on	the	NR2	subunit.	
Modulatory	sites	are	present	on	the	N-terminal	domains,	where	zinc	or	ifenprodil	bind,	for	
example.	The	transmembrane	domain	is	the	binding	site	of	channel	blockers,	where	
magnesium	binds	at	resting	membrane	potentials.	It	is	also	the	binding	sites	of	synthetic	drugs	
such	as	MK801,	PCP,	and	ketamine.		Reproduced	with	permission	(Paoletti	and	Neyton,	2007).	
	
1.5.2	Indirect	Modulation	of	the	NMDA	Receptor	
As	described	in	section	1.1.2,	NMDA	receptor	activation	is	dependent	on	
preceding	AMPA	receptor	mediated	depolarisation	of	the	postsynaptic	
neuron.	Therefore,	positive	modulation	of	the	AMPA	receptor	has	the	
potential	to	result	in	downstream	enhanced	NDMA	receptor	activity.	PAMs	of	
the	AMPA	receptor	(known	as	ampakines)	have	been	shown	to	enhance	
memory	encoding	in	preclinical	studies,	however,	conclusive	translation	into	
humans	has	not	yet	been	reached	but	development	of	ampakines	is	ongoing	
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(Lynch	et	al.,	2011).	As	with	NDMA	receptors,	AMPA	receptor	modulation	
must	also	be	approached	with	care	as	too	much	excitatory	activity	could	lead	
to	epileptiform	activity	(see	section	1.2.3).	
1.6	Neuroactive	Steroids	as	Positive	Allosteric	Modulators	
of	the	NMDA	Receptor	
Another	method	to	enhance	NMDA	receptor	function	is	by	positive	allosteric	
modulation.	The	advantage	of	allosteric	modulation	is	that	it	only	has	an	
enhancing	effect	on	receptor	function	in	the	presence	of	a	receptor	agonist.	
PAMs	usually	work	by	prolonging	the	time	the	agonist	binds	to	the	receptor	or	
by	increasing	the	probability	that	the	agonist	will	bind	to	the	receptor.	
Therefore,	the	PAM	should	only	enhance	a	signal	that	is	already	present.	This	
may	have	the	advantage	of	reducing	excitotoxicity	that	is	related	to	NMDA	
agonists,	or	other	methods	such	as	AMPA	enhancement	described	in	the	
section	above,	and	prevent	epileptic	activity	(see	section	1.1.3).		
Section	1.2	has	highlighted	NMDA	receptor	malfunction	in	a	variety	of	
psychiatric	and	neurological	conditions.	In	other	areas	of	receptor	research,	
PAMs	have	provided	useful	avenues	for	treatments	(e.g.	benzodiazepines	on	
the	gamma-aminobutyric	acid	(GABA)A	receptor).	However,	to	date	no	
selective	NMDA	receptor	PAMs	have	progressed	to	clinical	use.	Here	I	will	
review	the	current	literature	regarding	NMDA	PAMs	and	then	discuss	
unpublished	findings	that	identify	highly	selective	PAMs.	Importantly,	these	
studies	have	identified	a	potent	PAM,	which	is	made	within	the	brain	and	may	
act	as	an	endogenous	modulator	of	the	NMDA	receptor	to	fine	tune	neural	
excitation.	
1.6.1	Pregnenolone	and	Pregnenolone	Sulphate	
Pregnenolone	is	a	precursor	to	all	other	steroids	in	the	brain;	however,	it	also	
has	many	other	functions	as	its	molecular	targets	include	the	sigma	1	
receptor,	microtubules,	and	the	type-1	cannabinoid	receptor	(Vallee,	2015).	
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Pregnenolone	sulphate	is	an	endogenous	neurosteroid,	it	is	a	metabolite	of	
cholesterol,	which	binds	to	the	NMDA	receptor	extracellularly	and	increases	
receptor	function	as	a	PAM	(Wu	et	al.,	1991,	Weaver	et	al.,	1998,	Malayev	et	
al.,	2002).	The	term	neurosteroid	was	coined	by	Baulieu	(1997)	to	describe	
cholesterol	metabolites	that	are	synthesised	in	the	CNS.	Pregnenolone	and	
pregnenolone	sulphate	have	been	shown	to	increase	memory	function	in	
rodents	using	a	variety	of	behavioural	tests	(Marx	et	al.,	2011).	Pregnenolone	
was	also	able	to	improve	the	functional	capacity	(ability	to	perform	everyday	
tasks)	of	schizophrenic	patients	(Marx	et	al.,	2014).	Other	preliminary	clinical	
trials	with	small	sample	sizes	have	shown	that	administration	of	pregnenolone	
sulphate	has	no	side	effects,	and	can	improve	attentional	and	learning	deficits	
in	patients	with	schizophrenia,	although	larger	trials	will	be	necessary	to	
confirm	these	results	(Marx	et	al.,	2011).	Pregnenolone	in	its	unsulphated	
form	is	not	active	on	the	NMDA	receptor;	however,	pregnenolone	can	be	
sulphated	in	the	brain	via	the	hydroxysteroid	sulfotransferase	(SULT)	enzyme,	
where	the	SULT2B1	enzyme	is	specific	for	3"-hydroxysteroids	including	
pregnenolone	(Meloche	and	Falany,	2001).	Marx	et	al.	(2014)	suggested	that	a	
possible	mechanism	for	the	symptomatic	improvement	of	schizophrenic	
patients	is	due	to	the	increase	in	pregnenolone	sulphate	from	higher	available	
levels	of	pregnenolone	to	undergo	sulphation.	
1.6.2	Synthetic	Neuroactive	Steroids	
The	demonstration	that	the	steroid	pregnenolone	sulphate	enhances	NMDA	
receptor	function	encouraged	the	search	for	more	potent	and	selective	
steroidal	PAMs	of	the	NMDAR.	Organon	screened	a	large	library	of	steroid	
compounds	in	a	medium	throughput	assay	for	NMDA	receptor	activity.	This	
led	to	the	identification	of	a	potent	and	selective	NMDA	receptor	PAM	named	
Org49209	((3β)-26,27-dinorergost-5-ene-3,24-diol).	Intriguingly,	the	structure	
of	this	steroid	was	closely	related	to	that	of	a	naturally	occurring	brain	steroid,	
cerebrosterol	(Figure	1.7),	raising	the	exciting	prospect	that	brain	NMDA	
receptors	may	be	influenced	by	this	neurosteroid.	
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1.6.3	Cerebrosterol:	History,	Synthesis,	and	Functions	
Cerebrosterol	was	given	this	name	due	to	its	abundance	in	the	horse	and	
human	brain,	where	it	was	first	discovered	by	Ercoli	et	al.	(1953)	(as	cited	by	
Bjorkhem	(2007)).	Cerebrosterol	(also	known	as	24-S	hydroxycholesterol)	is	an	
endogenous	neurosteroid,	and	is	the	major	metabolite	of	cholesterol	in	the	
brain,	among	other	oxysterols	(oxidised	derivatives	of	cholesterol)	such	as	25-	
and	27-	hydroxycholesterol	(Bjorkhem	et	al.,	1998).	Cerebrosterol	is	involved	
in	the	balance	of	cholesterol	in	neurons,	as	cholesterol	concentrations	are	
usually	quite	low	compared	to	glial	cells,	and	cerebrosterol	has	the	ability	to	
activate	neuronal	cholesterol	transporters	(Björkhem,	2007).	Cholesterol	is	
synthesised	de	novo	in	the	brain,	both	neurons	(via	the	Kandutsch-Russel	
pathway)	and	astrocytes	(via	the	Bloch	pathway)	are	able	to	synthesise	
cholesterol	(Figure	1.6);	however,	in	the	adult	synthesis	is	mainly	left	to	the	
endoplasmic	reticulum	of	astrocytes	(Zhang	and	Liu,	2015).	
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Figure	1.6:	Pathways	of	cholesterol	biosynthesis.	Both	the	Bloch	pathway	of	astrocytes	and	
Kandutsch-Russel	pathway	of	neurons	is	shown,	which	form	different	cholesterol	precursors.	
	
Movement	of	free	cholesterol	across	the	blood	brain	barrier	is	very	slow,	
which	means	that	cholesterol	synthesis	and	metabolism	is	separate	from	the	
rest	of	the	body	(Zhang	and	Liu,	2015).	Cholesterol	is	metabolised	to	
cerebrosterol	by	the	P450	enzyme	cholesterol	24-hydroxylase	(Bjorkhem	
(2007),Figure	1.7).	This	is	a	P450	enzyme	coded	by	the	CYP46A1	gene.	24-
hydroxylase	expression	is	very	low	in	glial	cells,	but	expressed	in	the	ER	of	the	
cell	bodies	and	dendrites	of	selective	neuronal	types:	pyramidal	neurons	of	
the	hippocampus	and	cortex,	Purkinje	cells	of	the	cerebellum,	and	
hippocampal	and	cerebellar	interneurons	(Ramirez	et	al.,	2008).	Cerebrosterol	
can	cross	cell	membranes	and	thus	reach	the	blood	circulation,	where	it	is	
catabolised	by	the	liver	(Zhang	and	Liu,	2015).		
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Figure	1.7:	The	metabolism	of	cholesterol	to	cerebrosterol.	The	enzyme	cholesterol	24-
hydroxylase	converts	cholesterol	to	cerebrosterol.	
 
Cholesterol	levels	are	held	constant	in	the	brain	by	producing	new	cholesterol	
as	the	old	cholesterol	is	metabolised	(Zhang	and	Liu,	2015).	Even	when	plasma	
cholesterol	levels	fluctuate	or	are	very	high,	brain	cholesterol	levels	remain	
constant	as	cholesterol	does	not	cross	the	blood	brain	barrier	(Bjorkhem	and	
Meaney,	2004).	Cerebrosterol	is	thought	to	be	one	of	the	messengers	that	is	
able	to	signal	between	astrocytes	and	neurons	to	maintain	cholesterol	
homeostasis.	In	vitro,	cerebrosterol	is	able	to	activate	the	liver	X	receptor	
(LXR)	(Lehmann	et	al.,	1997)	and	is	a	more	effective	ligand	than	all	other	
common	oxysterols	in	the	brain	(Janowski	et	al.,	1999).	The	LXRs	are	nuclear	
receptors	which	are	crucial	in	the	regulation	and	feedback	mechanisms	of	
cholesterol	metabolism	(Zhao	and	Dahlman-Wright,	2010).	Pfrieger	(2003)	
suggest	that	cerebrosterol	is	involved	in	the	regulation	of	cholesterol	moving	
from	glia	(the	production	site)	to	neurons	via	apolipoprotein	E	(ApoE),	which	is	
regulated	by	a	cholesterol	transporter	under	the	control	of	the	LXR	(Figure	
1.8).	As	cerebrosterol	is	an	efficient	agonist	of	the	LXR,	increased	levels	of	the	
cholesterol	metabolite	would	increase	the	flux	of	cholesterol	from	glia	to	
neurons.	In	support	of	this	model,	cerebrosterol	was	shown	to	induce	ApoE	
transcription,	synthesis,	and	secretion	from	astrocytes	via	the	LXR	(Abildayeva	
et	al.,	2006).	However,	the	role	of	cerebrosterol	in	cholesterol	homeostasis	is	
not	clear-cut,	as	Shafaati	et	al.	(2011)	have	shown	that	the	overexpression	of	
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cerebrosterol	in	transgenic	mice	did	not	result	in	the	expected	activation	of	
LXR	signalling	genes.	
	
Figure	1.8:	An	illustration	of	the	proposed	role	of	cerebrosterol	in	cholesterol	homeostasis	in	
the	brain.	Cerebrosterol	is	produced	in	neurons	from	cholesterol,	and	bind	to	the	liver	X	
receptor	(LXR)	in	astrocytes.	This	increases	cholesterol	biosynthesis	in	astrocytes	and	release	
via	bound	apolipoprotein	E	(ApoE)	to	the	neuron.	Adapted	from	Bjorkhem	(2007).	
1.6.4	Cerebrosterol	Sulphate	 	
It	is	of	relevance	to	note	that	cerebrosterol	sulphate	is	also	found	
endogenously	in	the	brain	(Cook	et	al.,	2009).	Cerebrosterol	is	known	to	be	
sulphated	(or	glucuronidated)	in	the	liver	on	its	journey	to	bile	acids	prior	to	
excretion	(Bjorkhem	et	al.,	2001).	Human	cytosolic	sulfotransferase	(SULT)	is	
able	to	sulphate	cerebrosterol	(Javitt	et	al.,	2001,	Fuda	et	al.,	2007).		
	Three	isoforms	of	SULT	are	active	on	cerebrosterol:	SULT2A1,	SULT1E1,	and	
SULT2B1b	(Cook	et	al.,	2009).	SULT2B1b	and	SULT1E1	only	sulphate	
cerebrosterol	on	the	3-position	of	the	steroid	ring	(to	form	24-
hydroxycholesterol-3-sulphate),	while	SULT2A1	is	able	to	sulphate	both	at	the	
3-	and	24-	position,	creating	a	disulphate	(Cook	et	al.,	2009).	Of	these	
isoforms,	only	SULT2B1b	is	present	in	the	brain	(Geese	and	Raftogianis,	2001).	
Sulphation	can	be	a	reversible	reaction,	where	hydrolysis	by	the	steroid	
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sulfatase	(STS)	enzyme	is	able	to	de-sulphate	most	steroids,	primarily	
oestrogen	sulphates	and	hydroxysteroid	sulphates	(Iwamori,	2005).	STS	is	also	
present	in	the	brain	(Kriz	et	al.,	2005).	With	respect	to	cerebrosterol,	the	3-
sulphate	is	readily	hydrolysed	by	STS,	while	the	24-sulphate	is	resistant,	and	
the	disulphate	can	only	be	hydrolysed	at	the	3-position	(Cook	et	al.,	2009).	
Interestingly,	Cook	et	al.	(2009)	found	that	while	oxysterols	act	as	LXR	
agonists,	the	sulphated	oxysterols	are	significantly	better	antagonists	of	the	
LXR.	This	suggests	that	sulphation	and	de-sulphation	of	cerebrosterol	may	play	
a	role	in	regulating	cholesterol	homeostasis	through	LXR	modulation.	
1.6.5	Cerebrosterol	and	the	NMDA	Receptor	
Unpublished	data	from	the	Lambert	laboratory	showed	that	cerebrosterol	is	
also	capable	of	modulating	the	NMDA	receptor	(Table	1.1).	In	these	
experiments	recombinant	NMDA	receptors	were	expressed	in	Xenopus	leavis	
oocytes.	The	current	induced	by	activation	of	the	receptors	by	a	submaximal	
concentration	of	NMDA	(EC10)	was	enhanced	by	pregnenolone	sulphate	in	a	
concentration	dependent	manner.	Org49209	also	enhanced	such	currents,	but	
was	active	at	far	lower	concentrations	and	exhibited	a	reduced	maximal	effect	
of	pregnenolone	sulphate	(Figure	1.9	A	and	B).	Oocytes	expressing	GABAA	
receptors	exhibited	a	concentration	dependent	decrease	in	GABA-mediated	
current	with	pregnenolone	sulphate,	but	Org49209	was	inactive	(Figure	1.9	C).	
These	findings	indicate	that	Org49209	is	a	selective	NMDA	receptor	PAM.	The	
sulphated	Org49209	(3-sulfate	of	(3β)-26,27-dinorergost-5-ene-3,24-diol,	
Org49230)	was	also	tested	and	was	shown	to	be	just	as	potent	as	
cerebrosterol	and	Org49209,	but	had	a	much	greater	efficacy	(Table	1.1).	
Therefore,	it	is	of	interest	that	cerebrosterol	sulphate	is	also	found	in	the	brain	
(see	section	1.6.4).	As	the	synthetic	Org49209	is	similar	in	structure	to	
cerebrosterol	and	shows	similar	enhancement	of	the	NMDA	receptor	
cerebrosterol	(Table	1.1),	Org49209	studies	can	be	putatively	extrapolated	to	
suggest	the	effects	cerebrosterol	would	have	on	the	NMDA	receptor.	The	
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difference	in	the	range	of	the	maximum	response	values	of	sulphated	and	
unsulphated	steroid	steroids	introduces	an	important	point	on	striking	a	
blance	between	physiological	stimulation	and	stimulation	that	could	be	
excitotoxic.	Although	Org49230	may	have	a	large	effect,	this	may	be	less	use	
in	the	clinic	compared	to	a	potent,	but	moderately	efficacious	steroid	such	as	
Org49209.	
	
Table	1.1:	The	maximum	responses	and	EC50	values	for	NMDA	receptor-active	steroids	in	
oocytes.	Note	the	high	efficacy	of	sulphated	steroids	(pregnenolone	sulphate,	cerebrosterol	
sulphate,	and	Org49230)	compared	to	unsulphated	steroids	(cerebrosterol	and	Org49209).	
Data	from	Etherington	(Lambert	laboratory),	unpublished.
	
	
	43	
	
Figure	1.9:	Org49209	is	a	potent	and	selective	PAM	of	the	NMDA	receptor	in	oocytes.	(A)	The	
raw	trace	of	the	NMDA-induced	current	with	applications	of	increasing	concentrations	of	
Org49209.	(B)	Comparison	of	pregnenolone	sulphate	(PS)	and	Org49209	on	the	NMDA-
induced	current.	(C)	Comparison	of	PS	and	Org49209	on	the	GABA-induced	current.	Figure	
from	Etherington	(Lambert	laboratory),	unpublished.	
	
Paul	et	al.	(2013)	showed	that	Org49209	is	not	selective	for	any	particular	
NMDA	receptor	subunit,	and	that	it	could	reverse	ketamine	induced	
suppression	of	LTP	in	slices.	They	also	showed	that	both	Org49209	and	
cerebrosterol	increase	NMDA-evoked	currents	in	cultured	hippocampal	
neurons.	Additionally,	the	potency	of	cerebrosterol	at	NMDA	receptors	is	
much	higher	than	at	LXR	receptors,	further	suggesting	an	endogenous	role	for	
cerebrosterol	in	modulating	NMDA	receptor	(Paul	et	al.,	2013).	The	Lambert	
laboratory	also	showed	that	Org49209	is	able	to	increase	reduced	LTP	due	to	a	
submaximal	(3-pulse	theta	burst)	stimulation	to	the	level	of	normal	(4-pulse	
theta	burst)	stimulation	in	hippocampal	slices	(Etherington	(2012),	
unpublished	observations,	Figure	1.10).	
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Figure	1.10:	Org49209	is	able	to	increase	low	hippocampal	LTP.	(A)	The	average	field	
excitatory	post	synaptic	potential	(fEPSP)	slopes	with	a	low	(3-pulse	theta	burst	stimulation,	
TBS),	a	normal	4-pulse	TBS,	and	the	low	TBS	with	bath	applied	Org49209	(3	µM).	(B)	Org49209	
significantly	increased	the	3-pulse	TBS	fEPSP	after	60	minutes	(p<0.05).	Figure	from	
Etherington	(Lambert	laboratory),	unpublished.	
	
Cerebrosterol	has	also	been	shown	to	induce	both	cell	death	in	neuronal	
cultures	(Yamanaka	et	al.,	2011),	as	well	as	promote	survival	(Okabe	et	al.,	
2013).	Cell	death	may	be	due	to	esterification	of	cerebrosterol,	which	may	
itself	be	cytotoxic,	or	the	formation	of	lipid	droplets	may	trigger	cell	death;	cell	
survival	is	likely	due	to	LXR	activity	rather	than	NMDA	receptor	activation.	Low	
concentrations	of	Org49209	were	not	toxic	to	neurons	on	their	own,	but	
increased	cell	death	caused	by	mild	hypoxic	stress,	which	is	largely	prevented	
with	an	NMDA	receptor	antagonist	(Sun	et	al.,	2016).	Additionally,	reduced	
cholesterol	levels	due	to	Simvastatin	application,	and	reduced	steroid	levels	
due	to	beta-cyclodextrin	application,	reduced	the	NMDA-induced	toxicity	in	
cortical	neurons	(Zacco	et	al.,	2003).	Although	these	experiments	do	not	
directly	imply	cerebrosterol	activity	on	the	NMDA	receptor,	Simvastatin	and	
beta-cyclodextrin	could	both	also	reduce	cerebrosterol	levels.	Therefore,	the	
ability	for	cerebrosterol	to	act	as	a	PAM	may	play	a	role	in	the	toxicity	of	
NMDA	in	these	cortical	cultures.	However,	it	remains	uncertain	whether	
NMDA	receptor	activation	by	cerebrosterol	can	contribute	to	neuronal	cell	
death.	
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1.7	Cerebrosterol	and	Cognition	
A	growing	body	of	evidence	suggests	that	cerebrosterol	is	responsible	for	
more	than	the	elimination	of	cholesterol	from	the	brain.	It	is	possible	that	
through	the	interaction	with	NMDA	receptors	as	mentioned	above,	
cerebrosterol	has	an	effect	on	synaptic	plasticity	and	cognitive	functioning.	
Some	of	this	evidence	is	outlined	below.	
1.7.1	Biomarkers	for	Neurodegenerative	Diseases	
As	24-hydroxylase,	the	enzyme	responsible	for	the	production	of	
cerebrosterol,	is	predominantly	expressed	in	the	brain,	and	the	ability	for	
cerebrosterol	to	cross	the	blood	brain	barrier	is	the	main	route	of	cholesterol	
leaving	the	brain,	circulating	cerebrosterol	plasma	levels	are	largely	of	cerebral	
origin	(Lutjohann	et	al.,	1996,	Bjorkhem	et	al.,	1998).	Therefore,	it	is	possible	
that	plasma	levels	of	cerebrosterol	are	able	to	give	insight	to	the	state	of	
cholesterol	homeostasis	in	the	brain.	Cerebrosterol	has	been	implicated	as	a	
biomarker	for	AD,	as	increased	levels	are	observed	in	AD	patients	(Zuliani	et	
al.,	2011,	Popp	et	al.,	2012),	and	cerebrosterol	can	increase	AD	associated	
protein	aggregation	in	neurons	(Gamba	et	al.,	2011).	Cerebrosterol,	as	well	as	
27-hydroxycholesterol	have	been	identified	as	possible	candidates	of	
biomarkers	for	AD	as	well	as	mild	cognitive	impairment	(MCI).	Cholesterol	
metabolism	seems	dysfunctional	in	AD,	as	shown	by	Wang	et	al.	(2016)	who	
found	increased	levels	of	both	24S-hydroxycholesterol	and	27-
hydroxycholesterol	in	the	cerebrospinal	fluid	(CSF)	of	MCI	and	AD	patients	
compared	to	age-matched	controls	(also	shown	by	Leoni	et	al.	(2006)).	MCI	is	
often	a	precursor	to	AD	and	early	detection	and	treatment	of	MCI	can	be	
valuable	in	preventing	the	onset	of	AD	(Sperling	et	al.,	2011).	Dysfunctional	
cholesterol	metabolism	is	further	supported	by	abnormal	24-hydroxylase	
activity	in	the	glial	cells	of	patients	with	AD	(Bogdanovic	et	al.,	2001,	Brown	et	
al.,	2004).	Finally,	Heverin	et	al.	(2004)	found	a	decrease	in	cerebrosterol	
levels	in	the	brains	of	patients	with	AD.	Although	there	is	no	consensus	
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regarding	the	levels	of	cerebrosterol	in	plasma	of	AD	patients,	there	is	
agreement	that	levels	are	altered,	and	this	could	be	a	biomarker	for	this	
neurodegenerative	disease.	
1.7.2	“Knockout”	Mice	and	CYP46A1	Mutations	
CYP46A1	is	the	gene	which	encodes	24S-hydroxylase.	CYP46A1	single	
nucleotide	polymorphisms	in	humans	are	associated	with	an	increased	risk	for	
AD	(Garcia	et	al.,	2009,	del	Pozo	et	al.,	2006,	Jia	et	al.,	2016).	These	
polymorphisms	may	also	be	associated	with	cognitive	decline	in	the	elderly	(Fu	
et	al.,	2009).	Mouse	models	have	been	studied	to	a	greater	extent	than	
humans,	which	help	elucidate	the	role	of	24S-hydroxylase	and	cerebrosterol	in	
the	brain.	Djelti	et	al.	(2015)	used	an	adeno-associated	virus	vector	to	
decrease	CYP46A1	gene	expression	in	the	hippocampus	of	mice.	This	knockout	
caused:	increased	cholesterol	accumulation	in	hippocampal	CA3	neurons;	
impaired	spatial	learning	in	the	water	maze;	and	prior	to	cell	death,	increased	
deleterious	amyloid	peptides	associated	with	AD.	Lund	et	al.	(2003)	showed	
that	CYP46A1	knockout	mice	kept	stable	cholesterol	levels,	suggesting	a	
decrease	in	cholesterol	synthesis.	The	knockout	mice	were	severely	impaired	
at	spatial	learning	in	the	water	maze	task	(Kotti	et	al.,	2006),	and	LTP	in	the	
CA1	of	the	hippocampus	was	also	impaired	in	these	animals	(Kotti	et	al.,	2006,	
Kotti	et	al.,	2008).	Collectively,	these	mutation	studies	indicate	that	
cerebrosterol,	the	product	of	24S-hydroxylase,	may	play	a	role	in	the	cognitive	
symptoms	of	neurodegenerative	diseases	and	disease	aetiology.	
1.7.3	Sulphation	Mutations	
As	cerebrosterol	sulphate	has	a	greatly	increased	efficacy	compared	to	
cerebrosterol	in	the	enhancement	of	NMDA	receptor	activity,	it	is	possible	
that	alterations	in	sulphation	could	affect	cognition.	Mutations	of	the	steroid	
STS	gene	have	been	found	in	neurodevelopmental	disorders	such	as	
schizophrenia	(Milunsky	et	al.,	1999)	and	autism	(Shinawi	et	al.,	2009).	
Stergiakouli	et	al.	(2011)	found	that	two	single	nucleotide	polymorphisms	
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(SNPs)	of	the	STS	are	associated	with	attention	deficit	hyperactivity	disorder	
(ADHD).	All	of	these	disorders	are	known	for	their	detrimental	cognitive	
dysfunctions;	however,	it	is	unclear	whether	the	mutation	is	directly	related	to	
these	deficits.		
1.7.4	Huntington’s	Disease	and	Cerebrosterol	
As	seen	in	AD	(see	section	1.7.1),	cerebrosterol	has	also	been	suggested	as	a	
possible	biomarker	in	HD;	increased	plasma	cerebrosterol	has	been	found	in	
early	stages	of	HD	(Leoni	et	al.,	2008).	In	contrast,	a	decrease	in	plasma	
cerebrosterol	was	seen	in	HD	patients	relative	to	disease	progression	(Leoni	
and	Caccia,	2014).	HD	mouse	models	have	also	shown	disrupted	cholesterol	
synthesis	and	metabolism	(Valenza	et	al.,	2007b,	Valenza	et	al.,	2007a,	
Valenza	et	al.,	2010).	In	particular,	the	R6/2	mouse	striatum	and	striatal	cell	
lines	expressing	mhtt	showed	decreased	levels	of	cerebrosterol	(Boussicault	et	
al.,	2016).	
Seeing	the	connection	between	HD	and	cerebrosterol	dysregulation,	
Boussicault	et	al.	(2016)	studied	this	relationship	in	more	detail	by	inhibiting	
CYP46A1	expression	in	the	striatum	in	WT	mice	via	an	adeno-associated	virus.	
This	reproduced	the	HD	phenotype	seen	in	the	R6/2	mouse,	consisting	of	
striatal	neurodegeneration	and	motor	deficits.	Virus-mediated	delivery	of	
CYP46A1	to	R6/2	mice	improved	motor	deficits,	reduced	neuronal	atrophy	and	
decreased	the	size	of	mhtt	aggregates.	The	authors,	therefore,	concluded	that	
24-hydroxylase	activity	has	a	neuroprotective	role	in	HD.	This	may	be	due	to	
increased	levels	of	cerebrosterol;	however,	the	authors	assign	the	
neuroprotective	effects	of	increased	24-hydroxylase	activity	to	an	increase	in	
the	cholesterol	precursors	Lanosterol	and	Desmosterol,	which	were	
neuroprotective	in	mhtt	expressing	striatal	neurons	maintained	in	culture.	
Unfortunately,	cognitive	deficits	were	not	tested	in	the	either	of	the	mouse	
models.	
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1.7.5	Can	Cerebrosterol	Administration	Improve	Cognition?	
Org49209	was	able	to	reverse	spatial	working	memory	deficits	of	mice	tested	
in	the	Y-maze	after	acute	administration	of	MK-801,	a	NMDA	receptor	
antagonist	(Paul	et	al.,	2013).	The	same	authors	used	a	modified	structure	of	
Org49209,	which	has	an	additional	methyl	group	at	the	3-position	of	the	
steroid	ring,	to	reverse	deficits	in	the	NOR	task	and	social	interactions	in	rats	
treated	with	a	subchronic	administration	of	PCP.	Work	from	the	Brown	
laboratory	administered	Org49209	to	middle-aged	rats	with	a	reversal	learning	
impairment,	and	showed	a	reduction	in	trials	to	criterion	(Chase	(2013),	Figure	
1.11).	Collectively,	these	data	suggest	that	cerebrosterol	may	be	an	
endogenous	regulator	of	cognition,	and	Org49209	administration	may	have	
potential	as	a	treatment	for	NMDA	receptor	induced	cognitive	impairments.	
	
Figure	1.11:	Org49209	administration	reduces	reversal	learning	deficits	of	middle-aged	rats.	
Results	from	the	ID/ED	task	(SD,	simple	discrimination;	CD,	compound	discrimination,	REV1,	
reversal	of	CD;	ID,	intradimensional	acquisition;	REV2,	reversal	of	ID;	ED,	extradimensional	
acquisition;	REV3,	reversal	of	ED).	Middle-aged	rats	were	impaired	at	the	reversal	stages	of	
the	task	(grey	bars).	Repeated	acute	administration	(i.p.)	reduced	the	trials	to	criterion	(mean	
±	SEM),	p<0.05.	Data	from	Chase	(2013).	 	
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1.8	Thesis	Aims	
Considering	the	NMDA	receptor	dysfunctions	that	are	associated	with	the	
cognitive	symptoms	of	HD,	an	enhancer	of	NMDA	receptor	function	may	be	
able	to	ameliorate	some	of	these	debilitating	symptoms.	A	synthetic	NMDA	
receptor-active	steroid,	Org49209,	is	a	promising	candidate.	Additionally,	the	
role	of	the	endogenous	steroid,	cerebrosterol,	which	is	also	an	enhancer	of	
NMDA	receptor	function	may	play	a	role	in	cognition	in	both	health	and	
disease.	The	experiments	presented	in	this	thesis	build	on	previous	work	to	
further	investigate	the	potential	of	Org49209	in	treating	the	cognitive	
symptoms	of	HD.	Additionally,	the	effect	of	these	neuroactive	steroids	has	the	
potential	to	give	insight	into	NMDA	receptor	function	in	both	health	and	
disease,	and	the	role	that	the	endogenous	cerebrosterol	may	play	in	the	brain.	
Therefore,	the	aim	of	this	thesis	is	both	preclinical	as	the	effect	of	Org	49209	is	
investigated	as	a	possible	cognitive	enhancer	for	HD,	but	also	basic	science	to	
determine	the	effects	of	NMDA	receptor	modulation.	Specifically,	the	
experiments	presented	set	out	to	answer	the	following	questions:		
1.8.1	Do	cerebrosterol	and	Org49209	potentiate	NMDA	receptor-
evoked	responses	in	neurons?	
Previous	work	both	from	the	Lambert	laboratory	(see	section	1.6.5)	and	
others	(Paul	et	al.,	2013)	have	shown	that	Org49209	is	a	PAM	of	the	NMDA	
receptor.	The	Lambert	laboratory	has	also	demonstrated	that	Org49209	is	
able	to	increase	hippocampal	CA1	LTP,	a	NMDA	receptor	dependent	process.	
Although	(Paul	et	al.,	2013)	also	showed	that	both	Org49209	and	
cerebrosterol	increased	NMDA	receptor	mediated	currents	in	cultured	
hippocampal	neurons,	these	findings	had	not	been	published	when	my	
experiments	had	started.	Therefore,	I	set	out	to	answer	whether	Org49209	
and	cerebrosterol	were	PAMs	of	the	NMDA	receptor	in	cultured	cerebellar	
granule	neurons.	
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1.8.2	What	is	the	effect	of	sulphation	of	Org49209	and	
cerebrosterol	on	NMDA	receptor-evoked	responses	in	neurons?	
As	preliminary	data	from	the	Lambert	laboratory	indicated	that	sulphation	of	
the	3-position	of	the	steroid	ring	of	Org49209	increased	drug	efficacy,	and	
cerebrosterol	is	able	to	be	sulphated	in	the	brain	by	enzymes	present	in	
neurons,	I	wanted	to	show	whether	sulphation	of	both	Org49209	and	
cerebrosterol	produced	an	increase	of	efficacy	in	neuronal	cultures.	This	
would	allow	for	the	exciting	prospect	of	an	additional	mechanism	for	the	fine-
control	of	NMDA	receptor	activity	by	cerebrosterol	and	by	the	synthetic	
steroid	Org49209.	
1.8.3	Can	Org49209	administration	recover	the	behavioural	
phenotype	of	the	HDHQ111+/-	mouse?	
Once	the	action	of	Org49209,	cerebrosterol	and	their	sulphated	analogues	had	
been	investigated	in	vitro,	the	use	of	this	NMDA	receptor	modulator	was	
investigated	in	vivo.	NMDA	receptor	dysfunction	had	been	suggested	to	play	a	
role	in	the	cognitive	deficits	associated	with	HD.	Therefore,	I	used	a	mouse	
model	of	HD	to	investigate	the	possibility	of	using	Org49209	as	a	treatment	for	
cognitive	function.	Previous	work	from	the	Lambert/Langston	laboratory	has	
suggested	that	the	HDHQ111+/-	mouse	has	a	spatial	learning	impairment	(see	
section	1.3.6).	In	addition,	HD	patients	have	reversal	learning	impairments	
(see	section	1.4.6)	and	there	is	some	evidence	for	dysfunctional	reversal	
learning	in	HD	mouse	models	(see	section	1.4.6).	Therefore,	spatial	learning	
was	tested	in	the	HDHQ111+/-	mouse	using	the	NPR	task	and	in	the	water	maze.	
The	water	maze	was	also	used	for	investigating	the	reversal	learning	abilities	
of	the	HDHQ111+/-	mouse,	for	use	as	a	potential	behavioural	test	to	examine	the	
effects	of	Org49209	on	treatment	of	executive	function	disorders.	
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1.8.4	Can	Org49209	administration	recover	the	behavioural	set-
shifting	deficit,	caused	by	inhibition	of	glutamatergic	neurons	in	the	
mPFC,	in	rats?	
As	HD	patients	are	also	impaired	at	set-shifting,	a	perturbation	likely	due	to	
corticostriatal	loop	dysfunctions	(see	section	1.4.3),	and	there	is	some	
evidence	for	set-shifting	impairments	in	HD	mouse	models,	the	effect	of	
Org49209	was	tested	in	rats	with	a	set-shifting	deficit	due	to	chemogenic	
inhibition	of	the	glutamatergic	neurons	in	the	mPFC.	
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Chapter	2	
	
Synthetic	and	Endogenous	Steroids	
Potently	Enhance	the	Function	of	
Neuronal	NMDA	Receptors	
	
	
Illustration	by	C.	Brazaitis	
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2.1	Introduction	
Previous	work	demonstrated	that	both	cerebrosterol	and	a	related	synthetic	
analogue	steroid,	Org49209,	enhance	NMDA	receptor	mediated	cation	
currents.	This	was	demonstrated	both	in	the	Lambert	laboratory	utilising	
Xenopus	laevis	oocytes	expressing	recombinant	NMDA	receptors	and	by	Paul	
et	al.	(2013)	in	rat	hippocampal	neurons	maintained	in	cell	culture	using	
voltage-clamp	techniques.	
Upon	activation,	the	NMDA	receptor	undergoes	a	conformational	change	to	
cause	the	opening	of	an	associated	cation-selective	ion	channel.	As	described	
in	section	1.1.2,	although	the	channel	is	blocked	in	a	use-	and	voltage-
dependent	manner	by	magnesium	ions,	it	is	highly	permeable	to	calcium	ions	
(Vyklicky	et	al.,	2014).	Consequently,	single-cell	calcium	imaging	provides	a	
convenient	method	to	study	NMDA	receptor	function.	
Cerebellar	granule	neurons	(CGNs)	were	used	in	this	assay,	as	the	preparation	
provides	a	high	neuron	to	glial	cell	ratio.	CGNs	are	small	glutamatergic	
neurons	located	in	the	internal	granule	layer	of	the	cerebellum.	There	they	
receive	excitatory	inputs	from	mossy	fibres	and	inhibitory	inputs	from	Golgi	
neurons	and	project	into	the	molecular	layer	of	the	cerebellum	where	they	
synapse	with	Purkinje	cells	(Butts	et	al.,	2014).	The	NMDA	receptor	subunits	
expressed	in	CGNs	include	the	mandatory	NR1	subunit,	and	the	NR2B	subunit,	
which	is	gradually	replaced	with	the	NR2A	subunit	in	the	first	2	postnatal	
weeks	of	maturation	(Llansola	et	al.,	2005,	Farrant	et	al.,	1994).	Between	
postnatal	days	21	and	40	the	incorporation	of	NR2C	subunits	is	also	expected	
(Cathala	et	al.,	2000).		
For	recombinant	NMDARs,	Paul	et	al.	(2013)	have	demonstrated	that	
cerebrosterol	is	active	on	all	four	NR2	subunits	subtypes	when	co-expressed	
with	the	NR1	subunit.	Therefore,	I	expected	to	observe	an	increased	NMDA	
receptor	activation	with	cerebrosterol	and	its	analogues.	Additionally,	24-
hydroxylase	is	highly	expressed	in	Purkinje	cells	of	the	cerebellum	and	in	Golgi	
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neurons	of	the	granule	cell	layer	(Ramirez	et	al.,	2008),	suggesting	that	
cerebrosterol	could	putatively	be	produced	in	the	cerebellum	and	therefore	
potentially	be	able	to	act	as	an	endogenous	modulator	of	NMDA	receptors	to	
influence	cerebellar	function.	
2.2	Methods	
Fura	2-acetoxymethyl	ester	(AM)	is	a	ratiometric	fluorescent	dye	that	is	used	
to	measure	changes	in	intracellular	calcium	levels.	Due	to	the	hydrophobic	
properties	the	AM	group	bestows	on	Fura	2-AM,	it	is	membrane	permeable;	
but	once	Fura	2-AM	is	inside	the	cell,	the	ester	group	is	cleaved	and	the	
molecule	becomes	water	soluble	and	membrane	impermeable	(Figure	2.1).	
This	modification	traps	the	indicator	inside	the	cell,	where	it	is	able	to	bind	
with	intracellular	calcium.	Coupled	with	increased	excitation	intensity,	the	
excitation	peak	of	Fura	2-AM	shifts	from	380	nm	to	340	nm	with	bound	
calcium;	the	light	is	emitted	at	510	nm	(Figure	2.2).	The	ratio	of	bound	calcium	
to	free	calcium	provides	a	measure	of	the	relative	change	in	the	intracellular	
calcium	concentration	(Nicholls,	1994).	The	ratiometric	measurement	of	
bound	calcium	is	advantageous	compared	to	approaches	using	single	
wavelength	dyes	as	is	it	not	affected	by	uneven	dye	uptake,	dye	leakage,	
variable	cell	sizes,	and,	importantly	for	long	term	imaging	experiments,	photo	
bleaching	(Nicholls,	1994).	
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Figure	2.1:	The	structural	formula	of	Fura	2-AM.	Cleaving	of	the	AM	group	occurs	by	an	
esterase	once	Fura	2-AM	has	entered	the	cell.	Intracellular	calcium	can	then	bind	to	Fura	2	to	
form	a	Fura	2-Ca	complex.	
	
Figure	2.2:	The	excitation	spectrum	of	Fura	2	in	response	to	a	range	of	calcium	
concentrations.	Increased	intracellular	calcium	results	in	increased	excitation	intensity	of	Fura	
2,	as	well	as	a	shift	in	the	excitation	peak	from	380	nm	to	340	nm.	Image	taken	from	
http://www.teflabs.com/ion-indicators	
	
2.2.1	Cell	Culture	Preparation	
Cerebellar	granule	cell	preparation	was	modified	from	M.	Cousin’s	protocol	(as	
described	by	Cheung	and	Cousin	(2011)).	CGNs	were	prepared	from	male	and	
female	C57BL6	mouse	pups	of	developmental	ages	ranging	between	postnatal	
days	5-7.	Sterile	coverslips	(13	mm	Ø,	Scientific	Laboratory	Supplies	MIC3276)	
were	coated	in	filter	sterilised	Poly-D-lysine	(PDL,	Sigma	P6407)	and	100	mM	
boric	acid	(BDH	100588W,	at	pH	8.5)	overnight	at	room	temperature	on	a	
roller.	The	following	day	coverslips	were	washed	with	sterile	water	3	times	
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and	left	on	the	roller	for	one	hour.	The	coverslips	were	then	separated	onto	a	
sterile	tissue	in	the	tissue	culture	hood	(Microflow	Biological	Safety	Cabinet	
M51424/2)	to	dry	fully	before	they	were	placed	in	a	24-well	plate	(TPP	92024).	
It	was	vital	to	ensure	that	all	excess	PDL	was	washed	from	the	coverslip	and	
the	coverslip	is	dry	as	free	PDL	is	toxic	to	neuronal	cultures	(Ahmed	et	al.,	
1983).	
Each	cerebellum	was	processed	individually	until	the	final	cell	count	before	
cell	plating.	Pups	were	sacrificed	by	cervical	dislocation	followed	by	
decapitation	in	accordance	with	Schedule	1	of	the	Animals	(Scientific	
Procedures)	Act	1986.	The	cerebellum	was	dissected	and	placed	into	a	dish	
containing	1	ml	HBSS	(Life	Tech	14170088	Ca2+/Mg2+	free;	with	10	mM	HEPES,	
Life	Tech	15630-056).	The	tissue	was	minced	up	in	the	dish	using	fine	forceps.	
The	suspension	was	added	to	a	15	ml	tube	containing	1	ml	of	trypsin	solution	
(0.05%	trypsin	in	HBSS,	as	above).	Trypsin	is	a	proteolytic	enzyme	that	breaks	
down	the	proteins	responsible	for	cell	adhesion	and	allows	for	the	dissociation	
of	cells.	The	tubes	were	left	in	a	water	bath	at	37	ºC	and	were	agitated	every	5	
minutes	by	inverting	the	tube	once.	3	ml	of	serum	containing	neutralisation	
solution	(DMEM	containing	pyruvate,	glutamine	and	high	glucose	(Life	Tech,	
41966029),	supplemented	with	10%	FCS	(Fisher	Scientific	12329772)	and	1%	
penicillin/streptomycin	(pen/strep)	(Life	Tech	15140-122),	and	DNase	
(Invitrogen	18047-019,	at	a	final	concentration	of	30	U/ml)	was	added	to	the	
cells	to	inactivate	the	trypsin.	The	cells	were	spun	down	in	a	centrifuge	
(Eppendorf	5804)	at	1000	RPM	for	one	minute.	The	supernatant	was	
discarded	and	cells	were	re-suspended	in	1	ml	of	neutralisation	solution	using	
a	1	ml	pipette.	Using	the	same	pipette,	the	solution	was	triturated	30-35	times	
to	fully	dissociate	the	tissue.	After	the	cells	were	left	undisrupted	for	2	
minutes,	the	supernatant	was	taken	and	spun	down	at	1500	RPM	for	2	
minutes.	The	supernatant	was	discarded	and	cells	were	re-suspended	in	
neutralisation	solution	(lacking	DNase).	At	this	stage	all	tissue	was	collected	
into	one	tube.	A	10	µl	sample	of	the	cell	suspension	was	diluted	(1:10)	in	
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Trypan	blue.	Trypan	blue	stains	dead	cells.	Alive	(unstained,	bright)	cells	were	
counted	using	a	haemocytometer.	The	cells	were	diluted	in	neurobasal	growth	
media	(Life	Tech	21103-049,	supplemented	with	2%	B27	(Life	Tech	17504-
044),	1X	Glutamax	(Life	Tech	35050-038),	and	1X	pen/strep	solution,	20	mM	
KCl	and	1:5000	AraC	(Sigma	C1768-500mg))	plated	on	coverslips	at	a	density	of	
5x105	and	left	to	adhere	an	incubator	(5%	CO2,	37ºC).	After	one	hour	the	
media	was	exchanged	for	1	ml	fresh	medium	and	every	three	days	a	partial	
medium	change	(0.5	ml)	was	performed.	
Penicillin	was	used	in	the	media	to	prevent	infections.	Acute	application	of	
Penicillin	has	been	shown	to	have	an	effect	on	electrophysiological	properties	
of	neurons,	by	antagonizing	GABAA	receptors,	thereby	causing	cells	to	be	more	
excitable	(Tsuda	et	al.,	1994).	As	it	does	not	have	a	direct	acute	effect	on	
NMDA	receptors,	and	was	not	present	during	recording,	it	was	still	possible	to	
use	penicillin	for	cell	culture	maintenance	although	it	could	be	argued	that	
responses	may	be	slightly	altered	compared	to	non-pen/strep	treated	cultures	
due	to	changes	in	synaptic	plasticity.	
2.2.2	Calcium	Imaging		
2.2.2.1	Fura	2-AM	Loading	
Cerebellar	granule	cells	were	used	from	DIV	6-20	for	single	neuron	calcium	
imaging.	One	coverslip	was	placed	from	the	culture	medium	into	the	
incubation	solution	(in	mM):	120	NaCl,	3.5KCl,	0.4	KH2PO4,	5	NaHCO3,	1.2	
Na2SO4,	10	glucose,	1.2	MgCl2,	1	CaCl2,	and	20	N-2-hydroxyethylpiperazine-N’-
2-ethansulphonic	acid	(HEPES),	pH	adjusted	to	7.4	with	NaOH.	The	coverslip	
was	then	incubated	in	incubation	medium	containing	Fura	2-AM	(3	µM)	for	45	
minutes	at	room	temperature,	followed	by	a	wash	for	15	minutes	in	Fura	2-
AM-	free	medium.	The	wash	removes	the	extracellular	dye,	to	minimise	
background	fluorescence	from	free	Fura	2-AM.	
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2.2.2.2	Imaging	
The	coverslip	was	placed	under	an	inverted	epifluorescence	microscope	with	a	
40X	oil	immersion	objective	(Zeiss	Axiovert	200,	Germany)	and	was	stimulated	
with	excitation	light	from	a	xenon	arc	lamp	(Cairn,	UK),	after	the	wavelengths	
of	340	nm	and	380	nm	were	selected	by	a	monochromator	(Cairn,	UK).	The	
light	was	delivered	via	a	liquid	fibre	optic	cable	to	the	microscope.	The	
resulting	image	from	the	510	nm	emitted	light	was	captured	by	a	camera	
(photometrics	CoolSNAP	HQ,	Roper	Scientific)	and	the	data	was	viewed	and	
recorded	by	MetaFlour	software	(version	7.8.2.0).	All	imaging	was	performed	
in	a	dark	room	to	minimise	photo	bleaching.	Using	the	software,	regions	of	
interest	were	selected	to	measure	the	change	in	fluorescent	intensity	of	the	
cell	bodies	only.	One	region	of	interest	was	placed	outside	of	the	cell	regions	
to	serve	as	a	reference	by	subtracting	the	background	fluorescent	signal	from	
the	signal	obtained	from	the	cell	bodies.	This	design	allowed	for	a	more	
accurate	comparison	of	the	relative	intracellular	calcium	concentration	
changes	between	coverslips.	A	perfusion	system	allowed	for	the	constant	
exchange	of	imaging	solution	(the	incubation	solution	contained	a	low	[0.1	
mM]	MgCl2	concentration,	coupled	with	10	µM	glycine	(G6761	Sigma),	which	
are	conditions	designed	to	facilitate	NMDA	receptor	function).	Images	were	
captured	every	5	seconds	with	a	200	ms	exposure	to	light,	a	protocol	designed	
to	gain	good	temporal	and	spatial	resolution,	without	excessive	photo	
bleaching	over	the	course	of	long-term	(120	mins)	imaging.	The	shutter	
controlling	the	light	intensity	emitted	from	the	xenon	arc	lamp	was	kept	
approximately	90%	open,	again	to	limit	beaching,	without	compromising	on	
image	quality.	A	photodiode	with	narrow	band	pass	filters	for	380	nm	and	340	
nm	was	used	to	check	and	calibrate	the	excitation	wavelengths.	
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2.2.3	Calcium	Imaging	Experimental	Protocols	
2.2.3.1	Characterisation	
The	NMDA	receptor	pharmacology	of	the	cerebellar	granule	cells	was	
characterised	by	obtaining	a	concentration	response	curve	to	NMDA	(M3262,	
Sigma)	with	successive	application	of	NMDA	concentrations	(1	µM-	300	µM)	in	
the	imaging	solution	(see	above,	containing	reduced	Mg2+	and	10	µM	glycine).	
A	curve	was	fitted	to	the	data	using	the	following	equation:	
	
Where:	
Bottom=	The	Y	value	at	the	bottom	of	the	plateau.	This	is	the	minimum	
response.	
Top=	The	Y	value	at	the	top	of	the	plateau.	This	is	the	maximum	response.	
LogEC50=	The	X	value	half	way	between	Bottom	and	Top.	The	EC50	is	the	
effective	concentration	to	reach	half	of	the	maximal	response.	
Hill	Slope=	The	variable	that	describes	the	steepness	of	the	curve.	
	
To	assess	that	the	response	to	NMDA	was	caused	by	NMDA	receptor	
activation,	30	µM	APV	(an	NMDA	receptor	competitive	antagonist)	was	co-
applied	with	NMDA	to	cells	after	submaximal	(30	µM)	application	of	NMDA.	
APV	occupies	the	agonist	binding	site,	therefore	preventing	NMDA	from	
binding	to	the	receptor.	
2.2.3.2	Neurosteroid	Application		
Steroids	were	repeatedly	applied	to	the	same	cells	at	increasing	
concentrations,	in	a	repeated	measures	design.	To	assess	the	effect	of	
repeated	application	of	NMDA	resulting	in	submaximal	receptor	activation,	
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NMDA	(30	µM)	was	applied	to	the	same	coverslip	six	times.	In	between	
applications	the	cells	were	allowed	to	remain	in	wash	for	at	least	5	minutes.	
Various	steroids	were	applied	to	CGNs	maintained	in	cell	culture	to	assess	
their	effect	on	the	NMDA	induced	calcium	response	of	CGNs.	The	steroids	
tested	were	the	known	endogenous	steroids	pregnenolone	(P9129	Sigma),	
pregnenolone	sulphate	(P162	Sigma);	cerebrosterol	and	cerebrosterol	
sulphate	(as	well	as	a	ketone	variation,	all	provided	by	N.	Hamilton);	and	the	
synthetic	Org49209	(kindly	provided	by	Prof.	David	O’Hagan)	and	Org49230	
(provided	by	Niall	Hamilton).	Org49209	and	Org49230	were	originally	
discovered	by	the	pharmaceutical	company	Organon,	using	a	high	throughput	
screen	for	NMDA	receptor	PAMs.	The	imaging	solution	was	perfused	until	a	
stable	baseline	was	obtained	at	which	time	10-30	µM	NMDA	(diluted	from	
10mM	stock)	was	perfused	on	to	the	cells	to	obtain	a	submaximal	NMDA	
response,	followed	by	a	wash	after	the	NMDA	response	had	peaked.	For	most	
experiments,	30	µM	NMDA	was	used;	however,	on	rare	occasions	this	
concentration	produced	an	unusually	large	response,	in	which	case	the	
concentration	was	decreased	to	10	µM	NMDA.	The	cells	were	allowed	to	
remain	in	the	“wash”	control	solution	for	5	minutes	once	the	baseline	was	re-
established	after	agonist	washout.	
Next,	the	steroid	was	applied	in	increasing	concentrations-	first	in	isolation	(to	
assess	any	direct	effects	of	steroid),	followed	by	co-application	with	NMDA	(to	
assess	effects	of	the	steroid	on	the	NMDA-induced	response).	After	each	
steroid/	NMDA	co-application,	a	wash	was	applied	and	the	calcium	levels	were	
allowed	to	reach	baseline	for	5	minutes	before	the	next	steroid	concentration	
was	applied.	Steroid	stock	solutions	were	made	up	in	100%	DMSO,	and	left	in	
a	heated	sonicator	bath	until	fully	dissolved	before	further	dilution	and	use.	At	
the	end	of	the	experiment	40	mM	of	KCl	(activating	voltage-gated	calcium	
channels)	was	perfused	and	again	washed	after	the	response	peaked	(see	
Figure	2.5	for	a	sample	trace).	This	was	to	ensure	that	neurons	responded	with	
an	expected	large	increase	of	intracellular	calcium	to	the	strong	depolarisation	
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of	KCl	via	an	NMDA	receptor	independent	mechanism.	As	astrocytes	also	
express	voltage-gated	calcium	channels,	this	method	unfortunately	could	not	
be	used	to	confirm	recordings	were	only	taken	from	neurons	(Latour	et	al.,	
2003).	
2.2.4	Analysis	
Data	was	saved	as	a	text	file	by	the	Metaflour	data	recording	software.	
Microsoft	Excel	was	used	to	analyse	the	raw	data	and	produce	scatter	graphs,	
the	bar	graphs	and	concentration	responses	curve	were	produced	in	Graph	
Pad.	The	maximum	response	value	(ratio	value)	for	each	experimental	
condition	was	used	for	each	region	of	interest	corresponding	to	one	cell.	Each	
response	was	normalised	to	the	baseline	value	and	the	percent	increase	was	
calculated	as	the	difference	between	the	NMDA-evoked	response	and	the	
NMDA-evoked	response	in	the	presence	of	the	steroid.	Per	treatment	
condition,	a	minimum	of	15	cells	(up	to	50	cells)	were	averaged	to	produce	
one	value.	The	95%	confidence	interval	(CI),	plotted	in	the	bar	graphs,	was	
calculated	from	the	standard	deviation	of	all	cells	in	each	treatment	condition.	
The	95%	CI	is	used	to	show	the	significance	of	the	steroid-induced	change	of	
the	NMDA-induced	calcium	response.	
2.3	Results	
2.3.1	Characterisation	of	CGN	Calcium	Imaging	Responses	
2.3.1.1	The	NMDA	Concentration	Response	Relationship	
Examination	of	the	NMDA	concentration	response	relationship	revealed	that	
10	µM	of	the	agonist	to	be	a	threshold	concentration,	with	100	–	300	µM	
NMDA	producing	a	maximal	effect	(Figure	2.3).	From	further	inspection	of	the	
concentration-response	relationship	the	EC50	for	NMDA	was	found	to	be	29.1	
µM	with	a	confidence	interval	(CI)	ranging	from	23.5	to	36.1	µM	(Figure	2.3,	
n=6).	The	Hill	slope	was	found	to	be	2.7	±	1.1.	
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Figure	2.3:	NMDA	produces	a	concentration-dependent	increase	of	intracellular	calcium	in	
CGNs	(DIV	5	–	19).	(A)	A	representative	trace	of	the	raw	data	showing	the	response	ratio	of	
intracellular	calcium	with	increasing	concentrations	of	NMDA	(black	bars,	showing	in	order:	1,	
3,	10,	30,	100,	300	µM).	(B)	The	concentration	response	relationship	plotting	the	influence	of	
the	NMDA	concentration	(on	a	log	scale)	vs	the	NMDA-induced	change	of	the	intracellular	
calcium	concentration	(a	linear	scale)	expressed	as	a	percentage	of	the	response	(100	%)	to	a	
maximal	concentration	of	NMDA	(300	µM)	determined	for	each	cell	(n=6).	Note	all	ratio	
values	were	normalised	to	the	baseline	response,	maximum	and	minimum	values	were	
normalised	to	100%	and	0%	respectively.	Error	bars	show	SEM.	
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2.3.1.2	NMDA	Response	is	Reduced	by	the	NMDA	Receptor	Antagonist	APV	
At	low	concentrations	of	NMDA	(30	µM)	that	evoke	a	submaximal	response,	
the	application	of	APV	(30	µM)	reduced	this	response	4	fold,	from	47.3	±	2.6%	
to	11.5	±	1.6%	of	the	baseline	calcium	levels	(Figure	2.4).	Not	only	is	NMDA	a	
selective	NMDA	receptor	agonist,	but	the	strong	effect	of	this	selective	
competitive	antagonist	demonstrates	that	NMDA	receptor	activity	was	
measured	using	this	calcium	imaging	technique.	
	
Figure	2.4:	The	calcium	response	to	submaximal	NMDA	(30	µM)	is	decreased	by	4	fold	with	
the	NMDA	receptor	antagonist,	APV	(30	µM).	Application	of	30	µM	NMDA	alone	produced	an	
increase	in	the	baseline	response	by	47.3	±	2.6%,	which	30	µM	APV	reduced	to	11.5	±	1.6%,	
n=4.	Error	bars	show	95%	CI.	
	
2.3.2	Modulation	of	NMDA	Receptors	by	Neuroactive	Steroids	
To	elucidate	the	effect	of	the	various	neuroactive	steroids	on	NMDA	receptor	
function,	the	steroid	was	applied	at	increasing	concentrations	in	conjunction	
with	NMDA.	DMSO	at	a	final	dilution	of	1:1000	(which	was	used	for	steroid	
applications)	was	also	applied	as	a	control	and	had	no	effect	on	intracellular	
calcium	levels	of	CGNs	(data	not	illustrated).	In	each	experiment	a	submaximal	
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concentration	of	NMDA	(10-30	µM)	was	applied	to	the	cells	first,	followed	by	a	
wash.	Each	steroid	was	applied	in	isolation	before	it	was	co-applied	with	the	
same	submaximal	concentration	used	initially.	The	preparation	was	then	
washed	again	and	after	the	cells	recovered	to	baseline,	the	next	concentration	
was	applied.	Figure	2.5	shows	an	example	of	the	trace	from	the	raw	data	of	a	
sample	experiment	recording	from	a	single	neuron.	Importantly,	this	trace	also	
illustrates	the	resistance	for	the	steroid	effect	to	be	reversed	upon	washout.	It	
was	therefore	essential	to	apply	the	steroid	in	increasing	concentrations;	i.e.,	
in	a	cumulative	escalating	concentration	paradigm.	Finally,	the	trace	also	
shows	the	antagonizing	effect	of	APV	(as	shown	in	Figure	2.4).	
	
	
Figure	2.5	A	sample	trace	following	one	cell	through	a	series	of	drug	applications.	The	trace	
shows	the	response	ratio	of	a	single	cell	in	different	drug	conditions:	(A)	30	µM	of	NMDA	
(black	bars)	produced	a	submaximal	response	(B)	Pre-application	of	an	un-named	steroid	(100	
nM,	labelled	(1),	white	bar)	alone	gave	no	response;	however,	the	co-application	of	the	
steroid	with	NMDA	increased	the	calcium	response,	followed	by	a	return	to	baseline	in	the	
wash	(steroid	free)	solution;	(C)	Pre-application	of	300	nM	steroid	again	had	no	effect	
(labelled	(2),	white	bar),	co-application	with	NMDA,	however,	caused	an	even	larger	increase,	
followed	by	return	to	baseline	in	wash	saline.	(D)The	response	remained	elevated	cf	control	
when	NMDA	was	applied	alone.	(E)	This	NMDA	response	was	attenuated	by	the	NMDA	
receptor	antagonist,	APV	(grey	bar).	(F)	KCl	(40	mM,	chequered	bar)	caused	calcium	influx	
through	voltage	gated	calcium	channels,	an	NMDA	receptor	independent	mechanism.	
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2.3.3	Pregnenolone	Sulphate:	A	Known	PAM	of	Neuronal	NMDA	
Receptors.	
Pregnenolone	sulphate	is	a	known	PAM	of	the	NMDA	receptor	and	acts	to	
enhance	cognitive	performance	in	certain	rodent	behavioural	paradigms	(Wu	
et	al.	(1991),	see	also	section	1.6.1).	However,	this	steroid	is	not	selective	for	
NMDA	receptors	as	it	also	inhibits	GABAA	receptors	and	strychnine-sensitive	
glycine	receptors-	actions	that	may	contribute	to	the	cognitive	effects	of	this	
steroid	(Schumacher	et	al.,	2008).	By	contrast,	the	non-sulphated	derivative,	
pregnenolone	was	previously	shown	to	be	inactive	at	the	NMDA	receptor	
(Vallee,	2015,	Wu	et	al.,	1991).	Therefore,	before	investigating	the	actions	of	
novel	steroids	in	the	CGN	assay,	I	first	compared	the	actions	of	pregnenolone	
and	pregnenolone	sulphate	on	NMDA-evoked	increases	of	intracellular	
calcium.	In	agreement	with	published	studies,	here	pregnenolone	(1	–	30	µM)	
had	little	or	no	effect	on	the	NMDA-evoked	response.	However,	at	the	greater	
concentration	of	100	µM	this	steroid	caused	a	modest	enhancement	of	the	
NMDA	(30	µM)-induced	response	(13.3	±	1.5%	(n=4).	By	contrast,	
pregnenolone	sulphate	(3	–	100	µM)	produced	a	clear	concentration-
dependent	increase	of	the	NMDA	(30	µM)-	evoked	response,	with	(30	µM	
pregnenolone	sulphate	causing	a	42.8	±	3.8%	increase	and	100	µM	producing	
an	83.0	±	2.8%	increase	(n=4),	Figure	2.6).	
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Figure	2.6:	Pregnenolone	sulphate,	but	not	pregnenolone	enhances	NMDA	receptor	function	
of	cerebellar	granule	cells.	(A)	The	molecular	structure	of	pregnenolone	and	(B)	pregnenolone	
sulphate.	(C)	Representative	images	of	CGNs	containing	intracellular	Fura	2-AM	showing	
responses	to	(1)	submaximal	(30	µM)	NMDA	and	(2)	the	same	field	of	cells	with	NMDA	+	100	
µM	pregnenolone.	(D)	Images	showing	(1)	submaximal	(30	µM)	NMDA	(2)	the	same	field	of	
cells	with	NMDA	+	100	µM	pregnenolone	sulphate.	The	scale	bars	indicate	the	relative	calcium	
concentration	starting	at	low	concentrations	(blue),	continuing	to	high	concentrations	(red).	
(E)	A	bar	graph	comparing	the	effects	of	pregnenolone	and	pregnenolone	sulphate	on	the	
NMDA	(30	µM)-evoked	response.	Note	that	pregnenolone	(1	-30	µM)	had	little,	or	no	effect	
on	the	NMDA-evoked	response,	although	the	greater	concentration	of	100	µM	produced	a	
modest	enhancement	of	13.3	±	1.5%	(n=4).	By	contrast,	pregnenolone	sulphate	produced	a	
clear	concentration-dependent	(3	–	100	µM)	enhancement	of	the	NMDA	(30	µM)-evoked	
response,	where	30	µM	pregnenolone	sulphate	produced	an	42.8	±	3.8%	increase	and	100	µM	
produced	an	83.0	±	2.8%	increase	(n=4).	The	columns	represent	the	means	with	95%	CI.	 	
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2.3.4	Org49209:	A	Potent	PAM	of	Neuronal	NMDA	Receptors	
Previous	studies	from	the	Lambert	laboratory	utilising	recombinant	receptors	
expressed	in	Xenopus	laevis	oocytes	demonstrated	that	in	contrast	to	
pregnenolone	sulphate,	Org49209	at	concentrations	that	enhanced	NMDA	
receptor	function	had	no	effect	on	GABAA	receptors	(Chapter	1,	Figure	1.9).	
Here	Org49209	(100	nM	–	1	µM)	produced	a	concentration-dependent	
increase	of	the	NMDA	(30	µM)-evoked	increase	of	intracellular	calcium	in	
CGNs.	Specifically,	100	nM	increased	the	response	by	18	±	1.4%	(n=6),	300	nM	
increased	the	response	by	24	±	1.5%	(n=5)	and	1	µM	increased	the	response	
by	38	±	1.5%	(n=9)	(Figure	2.7).	
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Figure	2.7:	Org49209	is	a	potent,	but	relatively	low	efficacy	PAM	of	the	NMDAR.	(A)	The	
molecular	structure	of	Org49209.	(B)	Representative	images	of	CGNs	containing	intracellular	
Fura	2-AM	showing	responses	to	submaximal	(30	µM)	NMDA	and	(C)	the	same	field	of	cells	
now	in	the	presence	of	NMDA	+	1	µM	Org49209.	The	scale	bars	indicate	the	relative	calcium	
concentration	starting	at	low	concentrations	(blue),	continuing	to	high	concentrations	(red).	
(D)	A	sample	trace	of	raw	data	showing	the	response	ratio	of	one	cell	to	a	range	of	drug	
applications:	submaximal	(30	µM)	NMDA	(black	bars)	followed	by	wash	with	agonist	free	
saline	(1)	100	nM	of	Org49209	(white	bars),	followed	by	co-application	with	NMDA	and	wash	
with	drug	free	saline.	(2)	300	nM	Org49209	followed	by	co-application	with	NMDA	and	wash.	
(3)	1	µM	Org49209	followed	by	co-application	with	NMDA	and	wash.	(E)	A	bar	graph	showing	
the	effects	of	Org49209	on	the	NMDA	(30	µM)-evoked	response.	Org49209	increased	the	
NMDA	response	by	17.9±1.4%	at	100nM	(n=6),	increasing	to	24.0±1.5%	at	300nM	(n=5)	and	
37.6±1.5%	at	1	µM	(n=9).	The	columns	indicate	the	mean	with		95%	CI.	 	
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2.3.5	Org49230:	A	Highly	Potent	PAM	of	Neuronal	NMDA	Receptors	
Given	that	pregnenolone	sulphate	is	an	efficacious	PAM	of	the	NMDA	
receptor,	whereas	the	non-sulphated	parent	steroid	pregnenolone	is	relatively	
inert	in	this	respect,	it	was	of	interest	to	investigate	whether	this	chemical	
structural	modification	of	Org49209	would	similarly	enhance	the	efficacy	of	
this	potent	PAM	of	the	NMDA	receptor.	Org49230	is	the	sulphated	derivative	
of	Org49209.	In	common	with	pregnenolone	sulphate,	Org49230	is	sulphated	
at	the	3-position	of	the	A	ring	of	the	steroid	(Figure	2.8A).	
Org49230	(100	nM	-	1µM)	produced	a	concentration-dependent	enhancement	
of	the	NMDA	(30	µM)-induced	response	of	CGNs.	Although	active	at	similarly	
low	concentrations	to	Org49209,	this	sulphated	analogue	was	far	more	
potent,	increasing	the	NMDA-induced	response	by	63.6±2.1%	at	100	nM,	
increasing	to	67.4±2.0%	at	300	nM,	and	76.1±2.1%	at	1	µM	(Figure	2.8E).	The	
response	to	the	sulphated	steroid	compared	to	the	non-sulphated	steroid	
increased	3.5	fold	at	100	nM,	2.8	fold	at	300	nM,	and	2.0	fold	at	1	µM.	As	an	
asymptotic	concentration	for	Org49209	was	not	reached,	it	is	not	possible	to	
deduce	that	Org49230	is	more	efficacious	than	Org49209,	however,	it	is	more	
potent	at	the	same	concentrations.	
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Figure	2.8:	Sulphation	of	Org	49209	to	produce	Org49230	greatly	increased	the	efficacy	of	
the	steroid	to	enhance	NMDA	receptor	function.	(A)	The	molecular	structure	of	Org49230.	(B)	
Representative	images	of	CGNs	containing	intracellular	Fura	2-AM	showing	responses	to	
submaximal	(30	µM)	NMDA	and	(C)	the	same	field	of	cells	now	in	the	presence	of	NMDA	+	1	
µM	Org49230.	The	scale	bars	show	the	relative	calcium	concentration	starting	at	low	
concentrations	(blue),	continuing	to	high	concentrations	(red).	Note	how	the	presence	of	the	
neuroactive	steroid	has	greatly	increased	the	NMDA-induced	response.	(D)	A	sample	trace	of	
raw	data	showing	the	response	ratio	of	one	cell	to	a	range	of	drug	applications:	submaximal	
(30	µM)	NMDA	(black	bars)	followed	by	wash	with	agonist	free	saline	(1)	100	nM	of	Org49230	
(white	bars),	followed	by	co-application	with	NMDA	and	wash	with	drug	free	saline.	(2)	300	
nM	Org49230	followed	by	co-application	with	NMDA	and	wash.	(3)	1	µM	Org49230	followed	
by	co-application	with	NMDA	and	wash.	(E)	A	bar	chart	comparing	the	NMDA-enhancing	
action	of	Org	49209	and	Org	49230.	Here	Org49230	increased	the	NMDA	response	by	
64±2.1%	at	100	nM	(n=8),	67	±2.0%	at	300	nM	(n=6),	and	76	±2.1%	at	1	µM	(n=8).	The	
enhancement	of	the	NMDA-evoked	response	by	Org49230	in	comparison	to	Org49209	was	
3.5	fold	at	100	nM,	2.8	fold	at	300	nM,	and	2.0	fold	at	1	µM.	The	columns	indicate	the	mean	
with	95%	CI.	 	
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2.3.6	Cerebrosterol:	A	Potent	PAM	of	Neuronal	NMDA	Receptors.	
The	endogenous	neurosteroid	cerebrosterol	is	structurally	related	to	the	
synthetic	neuroactive	steroid	Org49209	(compare	Figures	2.9A	and	2.7A).	
Therefore,	cerebrosterol	was	tested	in	the	calcium	imaging	assay	to	determine	
whether	this	steroid,	the	major	metabolite	of	cholesterol	in	mammalian	brain	
(Bjorkhem	et	al.,	1998),	could	enhance	neuronal	NMDA	receptor	function	in	a	
similar	fashion	to	Org49209.	Importantly,	cerebrosterol	(100	nM	–	1	µM)	
increased	the	NMDA-evoked	response	of	CGNs	in	a	concentration-dependent	
manner.	The	threshold	concentration	of	cerebrosterol	was	100	nM	(increasing	
the	NMDA-	evoked	response	by	4.9	±	0.5%,	n=4),	while	300	nM	increased	the	
response	by	13	±	0.8%	(n=4)	and	1µM	increased	the	response	by	23	±	1.0%	
(n=11)	(Figure	2.9).	Given	the	impact	of	sulphation	on	the	NMDA-enhancing	
actions	of	the	endogenous	neurosteroid	pregnenolone,	and	the	synthetic	
neuroactive	steroid	Org49209	described	above	it	is	clearly	of	interest	to	
investigate	whether	the	sulphation	similarly	impacts	upon	the	ability	of	
cerebrosterol	to	enhance	NMDA	receptor	function.	
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Figure	2.9:	Cerebrosterol	is	a	potent	low	efficacy	PAM	of	the	NMDAR.	(A)	The	molecular	
structure	of	cerebrosterol.	(B)	Representative	images	of	CGNs	containing	intracellular	Fura	2-
AM	showing	responses	to	submaximal	(30	µM)	NMDA	and	(C)	the	same	field	of	cells	now	in	
the	presence	of	NMDA	+	1	µM	cerebrosterol.	The	scale	bars	show	the	relative	calcium	
concentration	starting	at	low	concentrations	(blue),	continuing	to	high	concentrations	(red).	
(D)	A	sample	trace	of	raw	data	showing	the	response	ratio	of	one	cell	to	a	range	of	drug	
applications:	submaximal	(30	µM)	NMDA	(black	bars)	followed	by	wash	with	agonist	free	
saline	(1)	100	nM	of	cerebrosterol	(white	bars),	followed	by	co-application	with	NMDA	and	
wash	with	drug	free	saline.	(2)	300	nM	cerebrosterol	followed	by	co-application	with	NMDA	
and	wash.	(3)	1	µM	cerebrosterol	followed	by	co-application	with	NMDA	and	wash.	(E)	A	bar	
graph	showing	the	effects	of	cerebrosterol	on	the	NMDA	(30	µM)-evoked	response.	
Cerebrosterol	increased	the	NMDA	response	by	4.9	±	0.5%	at	100	nM	(n=4),	13	±	0.8%	at	300	
nM	(n=4),	and	23	±	1.0%	at	1	µM	(n=11).	The	columns	indicate	the	mean	with	95%	CI.	 	
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2.3.7	Cerebrosterol	Sulphate:	A	Highly	Potent	PAM	of	Neuronal	
NMDA	Receptors	
Cerebrosterol	sulphated	at	the	3-position	of	the	steroid	A	ring	was	synthesised	
by	Dr.	Niall	Hamilton	and	kindly	provided	by	him	for	experimentation.	As	
described	above,	given	the	impact	of	sulphation	on	the	efficacy	of	these	
steroids	as	NMDA	receptor	PAMs,	it	was	of	interest	to	investigate	whether	
sulphation	similarly	influenced	the	interaction	of	cerebrosterol	with	the	NMDA	
receptor.	Furthermore,	it	is	conceivable	that	cerebrosterol	may	be	sulphated	
in	the	brain	by	the	resident	sulphotransferases	and	desulphated	by	
sulphatases	(Javitt	et	al.,	2001,	Iwamori,	2005).	My	experiments	revealed	
sulphated	cerebrosterol	to	be	a	more	potent	PAM	of	neuronal	NMDA	
receptors	and	cerebrosterol.	Relatively	low	concentrations	of	cerebrosterol	
sulphate	increased	the	NMDA	(30	µM)-evoked	response	in	a	concentration-
dependent	manner	(100	nM	=	32	±	2.7	%	increase,	n	=	6;	300	nM	=	55	±	1.8	%	
increase,	n	=	6;	1	µM	=	77	±	2.0	%	increase,	n	=	3;	Figure	2.10).	In	comparison	
to	the	parent	steroid,	cerebrosterol	sulphate	was	more	potent	at	each	
concentration	tested	with	the	magnitude	of	enhancement	of	the	NMDA-
evoked	response	produced	by	cerebrosterol	sulphate	being	6.5	fold	for	100	
nM;	4.2	fold	for	300	nM	and	3.3	fold	for	1	µM	than	produced	by	equivalent	
concentrations	of	cerebrosterol.	As	with	the	synthetic	steroids,	efficacy	could	
not	be	compared	as	an	asymptotic	concentration	was	not	reached	with	
cerebrosterol.	
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Figure	2.10:	Cerebrosterol	sulphate	is	a	highly	potent	and	efficacious	PAM	of	neuronal	
NMDA	receptors.	(A)	The	molecular	structure	cerebrosterol	sulphate.	(B)	Representative	
images	of	CGNs	containing	intracellular	Fura	2-AM	showing	responses	to	submaximal	(30	µM)	
NMDA	and	(C)	the	same	field	of	cells	now	in	the	presence	of	NMDA	+	1	µM	cerebrosterol	
sulphate.	The	scale	bars	show	the	relative	calcium	concentration	starting	at	low	
concentrations	(blue),	continuing	to	high	concentrations	(red).	Note	how	the	presence	of	the	
neuroactive	steroid	has	greatly	increased	the	NMDA-induced	response.	(D)	A	sample	trace	of	
raw	data	from	a	single	cell	showing	the	response	ratio	of	one	cell	to	a	range	of	drug	
applications:	submaximal	(30	µM)	NMDA	(black	bars)	followed	by	wash	with	agonist	free	
saline	(1)	100	nM	of	cerebrosterol	sulphate	(white	bars),	followed	by	co-application	with	
NMDA	and	wash	with	drug	free	saline.	(2)	300	nM	cerebrosterol	sulphate	followed	by	co-
application	with	NMDA	and	wash.	(3)	1	µM	cerebrosterol	sulphate	followed	by	co-application	
with	NMDA	and	wash.	(E)	A	bar	chart	comparing	the	NMDA-enhancing	action	of	cerebrosterol	
and	cerebrosterol	sulphate.	Here	cerebrosterol	sulphate	increased	the	NMDA	response	by	32	
±	2.7%	at	100	nM	(n=6),	55	±	1.8	%	at	300	nM	(n=6),	and	77	±	2.0	%	at	1	µM	(n=3).	The	
enhancement	of	the	NMDA-evoked	response	by	cerebrosterol	sulphate	in	comparison	to	
cerebrosterol	was	6.5	fold	at	100	nM,	4.2	fold	at	300	nM,	and	3.3	fold	at	1	µM.	The	columns	
indicate	the	mean	with	95%	CI.		
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2.3.8	Summary	of	Neuroactive	Steroids	
To	more	easily	compare	the	effects	of	each	of	the	steroids,	Figure	2.11	
provides	a	summary	of	the	means	of	the	above	presented	steroids,	at	varying	
concentrations.	Particularly	noticeable	is	the	difference	in	potency	between	
pregnenolone	sulphate	and	the	other	neuroactive	steroids,	as	well	as	the	
difference	in	efficacy	of	the	sulphated	steroids	compared	to	the	non-sulphated	
steroids.	
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Figure	2.11:	A	comparison	of	the	NMDA-enhancing	actions	of	neuroactive	steroids.	Both	cerebrosterol	and	its	synthetic	analogue,	Org49209,	are	active	at	relatively	
low	concentrations	(100	nM	–	1	µM).	The	sulphated	steroids	Org49230	and	cerebrosterol	sulphate	are	active	at	the	same	low	concentrations	as	their	non-sulphated	
steroid	counterparts,	but	in	comparison	a	far	more	efficacious.	Pregnenolone	sulphate	is	only	active	at	higher	concentrations	(30	–	100	µM),	while	pregnenolone	is	
mostly	inactive.	The	columns	indicate	the	mean	with	95%	CI.
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2.3.9	Ketone	Group	Properties	
To	assess	the	properties	of	the	steroid	that	are	needed	for	NMDAR	
modulation,	a	compound	was	synthesised	(by	Dr.	Niall	Hamilton)	that	was	
identical	to	cerebrosterol	sulphate,	however,	the	24-alcohol	was	replaced	with	
a	24-ketone.	This	steroid	did	not	increase	the	NMDA	induced	response	at	1	
µM	(n=5,	Figure	2.12).	Cerebrosterol	sulphate	was	tested	post	ketone	
application	as	a	control,	and	showed	the	expected	increase	as	seen	above	
(n=2).	
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Figure	2.12:	Cerebrosterol	sulphate	with	a	24-ketone	replacing	the	24-alcohol	is	inactive	on	
the	NMDAR.	(A)	The	molecular	structure	of	cerebrosterol	sulphate	24-ketone.	(B)	
Representative	images	of	CGNs	containing	intracellular	Fura	2-AM	showing	responses	to	
submaximal	(30	µM)	NMDA	and	(C)	the	same	field	of	cells	now	in	the	presence	of	NMDA	+	1	
µM	cerebrosterol	sulphate	(24-ketone).	The	scale	bars	show	the	relative	calcium	
concentration	starting	at	low	concentrations	(blue),	continuing	to	high	concentrations	(red).	
(D)	A	sample	trace	of	raw	data	showing	the	response	ratio	of	one	cell	to	a	range	of	drug	
applications:	submaximal	(30	µM)	NMDA	(black	bars)	followed	by	wash	with	agonist	free	
saline	(1)	1	µM	cerebrosterol	sulphate	(24-ketone,	white	bars),	followed	by	co-application	
with	NMDA	and	wash	with	drug	free	saline.	(2)	1	µM	cerebrosterol	sulphate	(24-alcohol)	
followed	by	co-application	with	NMDA	and	wash.	(3)	1	µM	cerebrosterol	sulphate	followed	by	
co-application	with	NMD.	(E)	A	bar	chart	comparing	the	NMDA-enhancing	action	of	
cerebrosterol	sulphate	(24-ketone)	and	cerebrosterol	sulphate	(24-alcohol).	Here	
cerebrosterol	sulphate	(24-ketone)	did	not	increase	the	NMDA	mediated	response	(n=5).	
Cerebrosterol	sulphate	(24-alcohol)	was	applied	as	a	control	on	the	same	cells	and	showed	the	
previously	established	enhancement	of	the	NMDA	induced	response	(see	Figure	2.10,	n=2).	
The	columns	indicate	the	mean	with	95%	CI.	 	
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2.4	Discussion	
This	chapter	describes	a	protocol	for	assessing	the	ability	for	certain	steroids	
to	modulate	NMDA	receptors	in	neuronal	cell	cultures.	Here,	calcium	imaging	
was	used	as	an	indirect	measure	of	NMDA	receptor	activity	in	CGNs.	Steroids	
originally	discovered	and	synthesised	by	Organon	as	potential	PAMs	of	the	
NMDA	receptor	were	tested,	as	well	as	structurally-related	endogenously	
occurring	steroids.	
Before	the	activity	of	the	steroids	were	tested,	the	CGNs	were	characterised	
for	their	response	to	NMDA.	In	the	presence	of	glycine,	NMDA	produced	a	
concentration	dependent	increase	of	intracellular	calcium	as	inferred	by	
changes	in	fluorescence	with	an	EC50	comparable	to	responses	observed	by	
others	in	cultured	neurons	(Sinor	et	al.,	2000).	The	Hill	slope	was	higher	than	
predicted	from	others	using	patch	clamp	recordings	(Patneau	and	Mayer,	
1990,	Verdoorn	and	Dingledine,	1988,	Hahn	et	al.,	2015).	This	is	likely	due	to	
the	fact	that	calcium	imaging	is	an	indirect	measure	of	NMDA	receptor	
activity,	and	whole-cell	patch	clamp	preparations	are	needed	to	accurately	
estimate	NMDA	receptor	pharmacology.	However,	APV	(a	competitive	NMDA	
receptor	antagonist)	significantly	reduced	the	response	to	submaximal	NMDA	
application	(Figure	2.4).	Not	only	is	NMDA	a	selective	NMDA	receptor	agonist,	
but	the	clear	effect	of	this	selective	antagonist	gives	a	strong	indication	that	
NMDA	receptor	activity	is	being	measured	using	this	technique.	
Pregnenolone	sulphate	was	tested	first	as	a	well-documented	PAM	of	the	
NMDA	receptor	(Wu	et	al.,	1991).	In	agreement	with	others,	this	steroid	
increased	the	NMDA-evoked	response	in	CGNs	(Figure	2.6).	Pregnenolone	
sulphate	showed	a	clear	and	large	enhancement	of	the	NMDA-evoked	
response	at	30	µM,	consistent	with	the	literature	(Wu	et	al.	(1991),	see	also	
Section	1.6.1).	In	accordance	with	literature	pregnenolone	had	little	or	no	
effect	on	the	NMDA-evoked	response	for	most	concentrations,	surprisingly	a	
slight	response	was	seen	at	the	highest	concentration	tested	(100	µM,	Figure	
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2.6).	This	is	inconsistent	with	the	literature	which	shows	pregnenolone	to	be	
inactive	on	the	NMDA	receptor	(Vallee,	2015).	Although	pregnenolone	
sulphate	is	clearly	very	efficacious,	relatively	high	steroid	concentrations	are	
required	to	produce	this	effect	and	there	is	debate	as	to	whether	such	
concentrations	are	achieved	under	physiological	or	pathophysiological	
conditions	(Smith	et	al.,	2014).	Indeed,	levels	detected	both	in	rat	and	human	
brains	have	not	been	above	the	high	nanomolar	range	(Schumacher	et	al.,	
2008).	Furthermore,	at	similar	concentrations	to	those	required	for	activity	at	
the	NMDA	receptor,	pregnenolone	sulphate	acts	to	inhibit	GABAA	receptor-
mediated	responses	(Majewska	et	al.	(1988),	see	also	Chapter	1,	Figure	1.9),	
an	action	that	may	contribute	to	the	cognitive	enhancing	properties	of	this	
steroid.	In	summary,	not	only	is	pregnenolone	sulphate	not	selective	for	the	
NMDA	receptor,	but	it	may	not	be	potent	enough	to	act	as	a	PAM	of	the	
NMDA	receptor	in	the	brain	under	physiological	or	pathophysiological	
conditions.	Therefore,	it	is	of	particular	interest	that	Organon	was	able	to	
identify	synthetic	compounds	that	are	both	potent	and	selective	NMDA	
receptor	PAMs.	
The	first	novel	steroid	tested	was	the	Organon	compound,	Org49209,	which	
was	effective	at	relatively	low	concentrations	(100	nM),	but	only	modestly	
increased	the	NMDA-evoked	response	of	the	CGNs	even	at	the	highest	
concentration	tested	(1	µM,	Figure	2.7);	i.e.,	it	is	a	potent	PAM	of	the	NMDA	
receptor	but	exhibits	relatively	limited	efficacy	at	the	concentrations	
measured.	As	pregnenolone	sulphate,	but	not	pregnenolone,	is	active	as	a	
PAM	of	the	NMDA	receptor,	it	was	of	interest	to	investigate	the	effect	of	
sulphation	of	Org49209	at	the	same	3-position	of	the	steroid	A	ring	i.e.	
Org49230.	In	the	CGN	assay	this	structural	modification	produced	a	large	
increase	in	NMDA	receptor	potency	of	the	steroid,	demonstrated	by	large	
increase	in	response	at	the	same	concentrations	as	Org49209	(Figure	2.8).	
Indeed,	inspection	of	the	concentration	response	relationship	for	these	two	
steroids	suggested	that	sulphation	may	have	also	increased	the	NMDA	
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receptor	potency	of	the	steroid	by	lowering	the	concentration	needed	to	
produce	a	minimum	response.	Should	time	permit	it	would	be	of	interest	to	
investigate	the	NMDA	receptor	actions	of	lower	concentrations	of	Org49230.	
These	data	are	in	agreement	with	an	electrophysiological	study	from	the	
Lambert	laboratory	comparing	the	effects	of	Org49209	and	Org49230	on	
NMDA-evoked	currents	mediated	by	recombinant	NMDA	receptors	expressed	
in	Xenopus	laevis	oocytes	(see	Table	1.1).	
Investigation	of	the	molecular	structure	of	Org49209	revealed	a	structural	
similarity	to	the	endogenous	cholesterol	metabolite,	cerebrosterol.	
Examination	of	this	effect	of	cerebrosterol	revealed	that	in	common	with	
Org49209,	this	naturally	occurring	steroid	is	a	potent	PAM	of	the	NMDA	
receptor	(Figure	2.9).	However,	although	active	at	relatively	low	
concentrations,	cerebrosterol	is	not	as	efficacious	at	these	concentrations	as	
Org49209,	or	Org	49230.	These	observations	raise	the	exciting	prospect	that	
the	activity	of	a	major	excitatory	ionotropic	glutamate	receptor	in	the	
mammalian	CNS	could	potentially	be	under	the	fine	control	of	a	locally	
produced	neurosteroid.	Furthermore,	given	that	excessive	activation	of	NMDA	
receptors	are	known	to	be	neurotoxic	and	potentially	pro-convulsant,	the	
limited	efficacy	of	cerebrosterol	might	be	desirable	for	an	endogenous	
modulator	i.e.	producing	a	subtle	change	in	receptor	function.	However,	
cerebrosterol	is	known	to	be	sulphated	in	the	mammalian	CNS	(Cook	et	al.,	
2009).	Therefore,	the	effect	of	cerebrosterol	sulphate	was	also	investigated	in	
CGNs.	In	common	with	cerebrosterol,	the	sulphated	cerebrosterol	was	a	
potent	PAM	of	the	NMDA	receptor,	but	produced	a	much	higher	response	at	
these	concentrations	(Figure	2.10).	This	observation	raises	the	exciting	
prospect	that	cerebrosterol	not	only	modulates	NMDA	receptor	activity,	but	
that	sulphation	of	this	steroid	provides	an	additional	method	for	fine-tuning	
the	enhancement	of	NMDA	receptor	activity.	
Finally,	the	possibilities	to	modify	the	basic	structure	of	Org49209	to	gain	an	
understanding	of	the	structure-activity	relationship	with	regard	to	the	NMDA	
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receptor	is	a	crucial	tool	both	for	understanding	the	mechanism	of	the	
endogenous	neurosteroids	(i.e.	pregnenolone	sulphate,	cerebrosterol,	
cerebrosterol	sulphate)	but	also	for	the	development	of	effective	and	viable	
drugs.	For	this	purpose,	we	began	investigating	the	role	of	the	hydroxyl	group	
on	the	24-position	of	the	steroid	ring.	We	discovered	that	this	group	is	critical	
for	the	enhancing	effect	of	cerebrosterol	sulphate	on	the	NMDA	receptor	
(Figure	2.12).	While	modifications	at	the	3-position,	such	as	sulphation,	are	
able	to	greatly	change	the	efficacy	of	the	steroid	on	NMDA	receptor	activity,	it	
seems	that	the	24-alcohol	is	crucial	for	any	steroid	activity.	
In	summary,	this	set	of	experiments	illustrates	the	effect	of	neuroactive	
steroid	in	cultured	CGNs	using	calcium	imaging	techniques.	The	synthetic	
steroid	Org49209,	and	the	endogenous	steroid	cerebrosterol	are	more	potent	
than	the	well-documented	PAM	of	the	NMDAR,	pregnenolone	sulphate.	The	
sulphated	steroids,	Org49230	and	cerebrosterol	sulphate,	retain	the	same	
potency	as	their	unconjugated	steroids,	however,	have	a	much	higher	efficacy	
at	equivalent	concentrations.	As	this	chapter	shows	Org49209	as	a	promising	
candidate	for	enhancing	NMDA	receptor	function,	the	remainder	of	the	thesis	
will	investigate	the	potential	of	this	steroid	to	ameliorate	cognitive	deficits	
associated	with	HD	in	animal	models.	
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Chapter	3	
	
HDHQ111+/-	Mice	Improve	in	Novel	
Place	Recognition	with	Practice	
	
	
Illustration	by	C.	Brazaitis	 	
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3.1	Introduction	
This	chapter	uses	the	HDHQ111+/-	mouse	model	of	HD,	which	has	previously	
been	shown	to	have	both	episodic	and	spatial	memory	impairments	(see	
section	1.3.6).	In	this	chapter	the	novel	place	recognition	(NPR)	task	is	used	as	
a	spontaneous	spatial	memory	task.	This	task	was	selected	as	HDHQ111+/-	mice	
have	previously	been	shown	to	be	impaired	in	this	task	(Chandler	(2014)	
Chapter	1,	Figure	1.4).	Furthermore,	the	task	is	also	known	to	be	hippocampal	
dependent	and	the	HDHQ111+/-	mouse	has	LTP	deficits	in	the	hippocampus	(see	
Chapter	1,	Figure	1.4A).	For	this	reason,	it	is	important	to	replicate	the	
HDHQ111+/-	mice	NPR	deficit	in	order	to	establish	if	it	is	a	reliable	assay	in	which	
putative	treatments	may	be	tested.	The	novel	object	recognition	(NOR)	task	
was	expected	to	be	unimpaired,	based	on	previous	observations	(see	Chapter	
1,	Figure	1.4C),	and	therefore,	this	would	be	used	as	a	control	task.	
It	has	been	established	that	NMDA	receptor	function	plays	a	key	role	in	NPR	
performance	(see	section	1.3.2);	therefore,	a	NMDA	receptor	modulator	
would	be	an	ideal	candidate	for	therapy.	Org49209,	specifically,	is	a	good	
candidate	as	it	is	able	to	reverse	the	LTP	deficit	of	a	3-pulse	theta	burst	to	the	
“normal”	levels	of	a	4-pulse	theta	burst	in	vitro	(see	Chapter	1,	Figure	1.10).	
3.1.3	Study	Aims	
This	chapter	explores	the	possibility	for	the	NMDA	receptor	PAM,	Org49209,	
to	improve	spatial	memory	impairments.	The	aims	of	this	study	are	two-fold:	
(1)	to	replicate	the	NPR	deficit;	(2)	to	reverse	the	deficit	with	Org49209.	
3.2	General	Methods	
3.2.1	HDHQ111	Mouse	Model	of	Huntington’s	Disease	
Homozygotes	(HDHQ111+/+)	were	purchased	from	Jackson	Laboratories	and	
crossed	with	wildtype	(WT)	C57/BL6	mice	to	produce	heterozygote	(HDHQ111+/-	
or	HET)	mice	in	an	inbred	colony.	To	identify	the	genotype	of	the	resulting	
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mixed	litters	of	HDHQ111+/-	and	WT	mice,	DNA	was	extracted	from	ear	clips	
(Machery	&	Nagel	and	Qiagen	Hotstar	Taq	Plus	polymerase	kit)	and	amplified	
(in	the	C1000	thermal	cycler,	Biorad,	Annealing	temp	56	°C).	The	resulting	DNA	
samples	were	run	on	agarose	gels.	The	WT	Huntington	gene	forms	a	band	at	
424	base	pairs,	while	the	knock-in	Huntington	gene	forms	a	band	at	694	base	
pairs.	Heterozygotes	are	identified	with	the	formation	of	both	bands	while	the	
WT	will	only	form	one	band	at	424	base	pairs	(Figure	3.1).	The	gel	was	
visualised	and	image	captured	using	the	Uvipro	Silver	gel	documentation	
system	by	Uvitec.	
	
Figure	3.1:	Genotyping	the	HDHQ111+/-	mouse.	Agarose	gel	image	showing	the	ladder	on	the	
far	left	(lane	1),	a	WT	band	(lanes	2&3),	and	a	HDHQ111+/-	(HET)	band	(lanes	4&5).	The	
heterozygote	is	distinguished	by	the	additional	band	in	lane	4	at	694	base	pairs,	which	is	
absent	in	the	WT	lane	2	which	only	has	a	line	at	424	base	pairs.	
	
3.2.2	Subjects	
15	HDHQ111+/-	(male	and	female)	mice	were	used	for	all	object	recognition	
tasks.	Mice	were	3-4	months	of	age	at	the	start	of	testing.	Mice	were	kept	in	
standard	housing	conditions	on	a	12	hour	light/dark	cycle	from	7	AM	to	7	PM.	
Food	and	water	was	available	ad	libitum.	
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3.2.3	Apparatus	
Experiments	were	conducted	in	a	rectangular	arena	(25x36x22	cm)	with	
plastic	wood-effect	floor	and	white	walls	(Figure	3.2).	Cues	were	hung	in	the	
top	north-west	and	north-east	corners	of	the	box	to	act	as	spatial	cues.	Velcro	
strips	were	used	to	secure	an	object	to	one	of	the	four	corners	of	the	arena.	
Between	every	trial,	the	box	and	objects	were	wiped	with	lemon	scented	
antibacterial	wipes	(Tesco)	to	reduce	cues	from	odours.	Objects	used	for	NOR	
were	selected	from	an	extensive	object	pair	database	from	the	Langston	
laboratory,	which	minimised	object	bias	based	on	previous	data.	A	holding	box	
was	used	during	testing	when	the	mouse	was	not	in	the	arena.	The	holding	
box	was	a	large	white	opaque	plastic	box,	roughly	the	same	size	as	the	arena,	
with	a	perforated	lid,	and	plenty	of	sawdust	to	provide	a	comfortable	
environment	for	the	mouse.	Mouse	exploration	was	viewed	on	a	screen	(LG)	
connected	to	an	overhead	video	camera	(Sony	HandyCam)	mounted	on	the	
wall	above	the	arena.	The	video	camera	also	recorded	the	input,	which	
enabled	re-scoring	at	a	later	date	if	needed.	
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Figure	3.2:	The	object	recognition	arena.	Two	objects	are	shown	in	the	northern	corners	of	
the	arena.	Velcro	strips	can	be	seen	in	the	south	corners	of	the	arena,	these	were	used	to	
adhere	the	objects	to	the	floor.	Hanging	cues	can	be	seen	in	top	corners	of	the	north	wall,	
which	act	as	spatial	markers.	
	
3.2.4	Experimental	Procedures	
During	the	object	recognition	experiments,	mice	were	timed	at	how	long	they	
spent	exploring	the	objects	in	the	arena	at	each	phase	of	the	task.	Exploration	
was	recorded	manually	with	two	key	press-activated	timers-	one	for	each	
object.	Exploration	was	defined	as	sniffing	at,	chewing,	scratching,	climbing	
on,	or	looking	at	the	object	from	a	close	(approx.	1	cm)	distance.	If	the	mouse	
was	on	top	of	the	object,	but	otherwise	not	interacting	with	it,	this	was	not	
counted	as	exploration.	All	testing	was	carried	out	during	the	light	phase	
starting	at	about	9	AM.	
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3.2.4.1	Handling	and	Habituation	
Prior	to	testing	mice	were	handled	for	five	days	in	the	experimental	room	to	
get	them	used	to	the	transport	from	the	holding	room	to	the	experimental	
room,	and	to	habituate	them	to	the	experimenter.	They	were	then	habituated	
to	the	testing	apparatus	and	experimental	procedure	over	two	days.	On	day	
one,	mice	were	placed	in	the	arena	together	with	cage	mates	for	10	minutes	
in	the	morning.	In	the	afternoon,	individual	mice	were	placed	briefly	in	the	
holding	box	and	then	the	testing	arena	for	three	minutes.	On	day	two,	mice	
were	again	placed	in	the	holding	box,	and	then	into	the	arena	with	two	
random	objects	(that	are	not	used	for	testing)	in	the	NE	and	NW	corners	of	the	
box.	Exploration	was	recorded	and	used	to	ensure	mice	were	exploring	objects	
sufficiently.	
3.2.4.2	Novel	Object	and	Novel	Place	Recognition	Protocol	
In	this	study,	both	novel	object	and	novel	place	recognition	experiments	were	
used.	Both	tasks	consist	of	a	3-minute	sample	phase	and	a	3-minute	test	
phase,	with	a	1-minute	break	in	between.	The	mouse	was	placed	in	the	
holding	box	briefly	before	the	sample	phase	to	prepare	it	for	testing,	and	
during	the	1-minute	break	in	between	sample	and	test	phases.	For	NOR	
(Figure	3.3,	bottom),	two	identical	objects	were	placed	in	the	north	side	(far	
end	of	experimenter),	the	mouse	was	placed	into	the	arena	on	the	opposite	
side	(south),	facing	the	wall,	and	exploration	times	were	scored.	After	3	
minutes,	the	mouse	was	removed	from	the	arena	and	placed	back	into	the	
holding	box	while	the	box	was	cleaned	and	objects	set	up	for	the	test	phase.	
During	the	test	phase,	one	of	the	objects	was	replaced	with	a	novel	object.	
The	familiar	object	was	a	third	copy	of	the	two	objects	used	during	the	sample	
phase	to	minimise	the	use	of	odour	cues.	The	mouse	was	placed	back	in	the	
arena	for	another	3	minutes	and	exploration	was	scored.	NPR	(Figure	3.3,	top)	
used	the	identical	procedure,	except	that	the	same	two	objects	were	used	in	
the	sample	and	test	phase,	but	one	was	moved	from	the	corner	of	the	north	
wall	to	the	corner	of	the	south	wall	in	the	test	phase.	Again,	the	test	phase	
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objects	were	identical	copies	to	those	used	in	the	sample	phase.	The	mouse	
entry	point	was	adjusted	to	lie	equidistant	between	the	two	objects.	The	novel	
object	and	novel	place	was	counterbalanced	to	minimise	effects	of	object	or	
location	preference.	
	
Figure	3.3:	A	diagram	of	the	experimental	procedure	for	novel	place	recognition	(NPR,	top)	
and	novel	object	recognition	(NOR,	bottom).	For	NPR	two	identical	objects	(circles)	were	
presented,	and	after	a	1-minute	break,	the	same	two	objects	were	presented	again	but	one	
was	moved	to	the	other	side	of	the	arena.	For	NOR	two	identical	objects	(circles)	were	
presented,	and	after	1	minute,	a	new	object	was	presented	in	place	of	one	of	the	old	ones	
(circle	and	triangle).	Crosses	mark	the	mouse	entry	points.	
3.2.5	Data	Analysis	
Data	was	recorded	by	hand	during	testing.	This	was	entered	into	a	Microsoft	
Excel	spreadsheet.	The	discrimination	index	(DI)	was	calculated	using	the	
following	formula:	
	
	
This	formula	produces	a	value	between	-1	and	1.	A	positive	score	indicates	
preference	for	the	novel	object,	while	a	negative	score	indicates	preference	
for	the	familiar	object.	A	score	of	zero	indicates	no	preference.	
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Exploration	times	below	10	seconds	during	the	test	phase	were	excluded	from	
analysis.	If	mice	did	not	explore	at	all	during	the	sample	phase,	their	scores	
were	also	excluded.	Bar	graphs	were	produced	in	GraphPad	Prism	5.	Scatter	
Plots	were	produced	in	Microsoft	Excel.	Statistics	were	performed	with	IBM	
SPSS	Statistics	21.	Effect	sizes	were	calculated	with	partial	eta	squared	or	
Cohen’s	d.	Power	analysis	was	conducted	with	G*Power	(Faul	et	al.,	2009,	Faul	
et	al.,	2007).	
3.3	Experiment	1:	NPR	Replication	Study	
This	experiment	aimed	to	replicate	the	impaired	NPR	DI	previously	reported	in	
the	HDHQ111+/-	mouse	(Chandler	(2014)	Chapter	1,	Figure	1.4).	
3.3.1	Experimental	Procedure	
To	increase	power	and	to	enable	full-counterbalancing,	this	study	was	
designed	as	repeated-measures.	The	intention	was	to	use	the	(non-impaired)	
1-minute	NOR	test	as	a	comparison	for	the	(impaired)	NPR	test	in	a	
subsequent	drug	study.	Therefore,	both	the	NPR	and	the	control-NOR	tests	
were	performed,	one	immediately	after	the	other,	on	four	consecutive	days.	
The	possibility	of	task-order	effects	was	controlled	for	by	counterbalancing:	on	
days	1	and	3	the	NPR	task	immediately	preceded	the	NOR	task,	while	on	days	
2	and	4	the	NOR	task	preceded	the	NPR	task.	The	side	of	the	novel	place	or	
object	was	counterbalanced	across	each	day.	DI	data	were	analysed	using	a	
two-way	analysis	of	variance	(ANOVA).	Significant	ANOVA	results	were	
analysed	further	with	post-hoc	pairwise	comparisons	using	a	Bonferroni	
correction.	Exploration	data	was	analysed	with	a	paired	t-test.	
3.3.2	Results	
The	HDHQ111+/-	mice	showed	a	reduced	preference	for	the	novel	place	
compared	to	the	novel	object	(main	effect	of	task,	F(1,56)=16.7,	p<0.001,	partial	
eta	squared	=	0.23,	Figure	3.4A)	by	having	a	lower	DI	in	the	1-minute	NPR	task	
compared	to	the	1-minute	NOR	task.	The	task	order	also	had	an	effect	on	DI	
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score,	where	the	first	task	of	the	day	had	a	significantly	lower	score	than	the	
second	(main	effect	of	order:	F(1,	56)=6.3,	p<0.01,	partial	eta	squared	=	0.10,	
Figure	3.4B).	However,	there	was	no	interaction	effect	(F(1,56)<1.0,	p>0.05,	
partial	eta	squared	=	0.01),	thereby	showing	that	the	NPR	score	is	consistently	
lower	independent	of	order,	and	likewise,	the	first	task	score	is	consistently	
lower	independent	of	task.	One	DI	value	was	excluded	from	analysis	due	to	
low	exploration.	
Additionally,	the	HDHQ111+/-	mouse	did	not	show	a	preference	for	the	novel	
object	in	a	24-hour	NOR	task,	where	mice	were	given	24	hours	in	between	the	
sample	and	test	phases	(data	not	illustrated;	one-sample	t-test,	t=1.1,	df=14,	
p>0.05,	Cohen’s	d	=	0.28).	
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Figure	3.4:	HDHQ111+/-	mice	had	a	lower	DI	for	the	first	task	of	the	day	compared	to	the	
second,	and	the	NPR	task	compared	to	the	NOR	task.	On	days	1	and	3	the	NPR	task	preceded	
the	NOR	task,	while	on	days	2	and	4	the	NOR	task	preceded	the	NPR	task.	(A)	The	NPR	score	
was	lower	compared	to	the	NOR	DI	(p<0.001)	(B)	and	the	DI	of	the	first	task	of	the	day	was	
lower	than	the	second	(p<0.01).	Error	bars	show	SEM.	 	
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Total	exploration	times	were	lower	for	the	NPR	task	than	the	NOR	task	in	both	
the	sample	(paired	t-test;	t=	4.7,	df=	59,	p<0.001,	Cohen’s	d	=	-0.61)	and	test	
(paired	t-test;	t=	6.4,	df=	59,	p<0.001,	Cohen’s	d	=	-0.81)	phases.	However,	
sample	phase	exploration	times	do	not	correlate	with	DI	scores	in	the	test	
phase	(Figure	3.5).	
	
Figure	3.5:	Sample	phase	exploration	does	not	correlate	with	DI	score.	(A)	The	DI	score	
plotted	against	the	seconds	of	object	exploration	in	the	sample	phase	of	the	NPR	task.	(B)	The	
DI	score	plotted	against	the	seconds	of	object	exploration	in	the	sample	phase	of	the	NOR	
task.	
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3.4	Experiment	2:	Org49209	Study	
As	the	NPR	impairment	of	the	HDHQ111+/-	at	first	inspection,	before	full	
analysis,	appeared	to	be	replicated,	Org49209	was	administered	to	test	if	it	
could	increase	the	NPR	DI	score.	
3.4.1	Experimental	Procedure	
Mice	were	tested	for	five	days	on	both	the	NOR	and	NPR	task.	As	both	the	task	
and	testing	order	had	a	significant	effect	on	the	DI	(see	results	3.3.2),	NPR	was	
always	tested	before	NOR	as	this	resulted	in	the	lowest	DI.	On	days	1,	3,	and	5	
mice	were	tested	without	injections.	Day	1	was	used	as	a	baseline	day.	On	
days	2	and	4,	eight	mice	received	10mg/kg	Org49209	(intraperitoneal,	i.p.);	
with	injection	volume	not	exceeding	10ml/kg),	and	seven	received	vehicle	
(20%	hydroxypropyl	beta-cyclodextrin,	HPBCD,	in	sterile	phosphate	buffered	
saline,	PBS)	30	minutes	before	testing.	The	experimenter	was	blind	to	the	drug	
conditions.	Days	3	and	5	were	used	to	assess	if	performance	returned	to	
baseline	after	drug	administration	on	the	previous	day.	Data	were	analysed	
using	a	2-way	ANOVA.	
3.4.2	Results	
As	the	HDHQ111+/-	mice	appeared	to	show	no	preference	in	the	1-minute	NPR	
task,	we	tested	them	with	Org49209	to	see	if	this	restored	the	preference.	
Five	scores	were	excluded	from	analysis	due	to	low	exploration.	Figure	3.6	
shows	that	Org49209	changed	neither	novel	place	nor	novel	object	preference	
DI	scores	compared	to	vehicle	injections	(2-way	ANOVA,	main	effect	drug:	
F(1,56)=	1.40,	p>0.05,	partial	eta	squared=	0.03;	task	and	drug	interaction:	
F(1,56)=	2.85,	df=	1,	P>0.05,	partial	eta	squared=	0.049).	A	sample	size	of	155	
would	be	needed	to	see	a	significant	interaction	effect.	
To	rule	out	the	effects	of	injection	stress	causing	increased	variability	and	thus	
masking	main	effects,	we	tested	the	mice	following	PBS	injections	(DI	NPR=	
0.26	±	0.06;	NOR=	0.30	±	0.08)	compared	to	no	injections	(DI	NPR=	0.10	±	
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0.03;	NOR=	0.33	±	0.08).	There	was	no	significant	difference	of	DI	between	
injection	conditions	(2-way	ANOVA,	main	effect	of	injection:	F(1,56)=1.30,	p>	
0.05,	partial	eta	squared=	0.022).	As	expected	there	was	a	significantly	lower	
score	in	the	NPR	than	NOR	task	(main	effect	of	task:	F(1,56)=6.37,	p<	0.05,	
partial	eta	squared=	0.10),	but	the	task	score	did	not	change	with	injection	
condition	(interaction:	F(1,56)=1.9,	p>	0.05,	partial	eta	squared=	0.03).	Three	
scores	were	excluded	from	this	analysis	due	to	low	exploration.	
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Figure	3.6:	Org49209	did	not	improve	NPR	DI	scores	of	HDHQ111+/-	mouse	(5	months	old).	
Mice	were	tested	in	the	NPR	task	(A)	followed	by	the	NOR	task	(B)	over	5	days.	On	day	one	all	
mice	(n=15)	were	tested	in	control	conditions	of	no	injections.	This	was	followed	by	a	drug	day	
where	8	mice	received	10	mg/kg	Org49209	and	7	mice	received	the	vehicle	(20%	HPBCD	in	
PBS).	This	was	followed	by	a	day	of	no	injections,	and	on	day	4	the	mice	received	the	same	
drug	or	vehicle	treatments,	followed	again	by	a	day	of	no	injections.	The	bar	graphs	show	the	
average	score	for	each	treatment.	Error	bars	show	SEM.	 	
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Mice	explored	less	during	the	sample	phase	when	in	the	Org49209	treatment	
compared	to	the	control	day	(ANOVA	main	effect	of	condition:	F(3,142)=	3.9,	
p<0.05,	Bonferroni	pairwise	comparison	p<0.05,	partial	eta	squared	=	0.08).	As	
in	experiment	1,	they	also	explored	less	during	the	NPR	task	than	the	NOR	task	
(main	effect	of	task:	F(1,142)=	32.8,	p<0.001,	partial	eta	squared	=	0.19).	A	
significant	interaction	(F(3,142)=	7.0,	p<0.001,	partial	eta	squared	=	0.13)	
indicates	that	exploration	is	affected	by	both	task	and	condition.	Again,	higher	
sample	phase	exploration	does	not	predict	higher	DI	scored	during	the	test	
phase	(Figure	3.7).	
	
Figure	3.7:	Sample	phase	exploration	during	the	Org49209	study	does	not	correlate	with	DI	
scores.	(A)	The	DI	score	plotted	against	the	seconds	of	object	exploration	in	the	sample	phase	
of	the	NPR	task.	(B)	The	DI	score	plotted	against	the	seconds	of	object	exploration	in	the	
sample	phase	of	the	NOR	task.	 	
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3.5	Experiment	3:	Task	Order	and	Practice	Effect	Study	
After	analysis	of	experiments	1	and	2,	we	hypothesised	that	providing	mice	
sequentially	with	two	tests	would	give	them	additional	practice,	causing	an	
improvement	of	the	DI	score	on	the	second	test.	To	assess	why	task	order	has	
an	effect	of	the	DI,	the	NPR	task	was	repeated	with	three	sample	phases	
instead	of	one.	
3.5.1	Experimental	procedure	
This	experiment	was	conducted	over	7	days.	For	two	days	the	NPR	task	was	
conducted	with	two	additional	sample	phases,	for	a	total	of	three	sample	
phases	before	the	test	phase.	To	compare,	the	NPR	post-NOR	task	was	
conducted	for	two	days.	The	standard	NPR	task	(section	3.2.4.2)	was	
conducted	once	at	the	start	of	testing,	once	in	between	the	two	testing	
conditions	above,	and	once	at	the	end,	to	serve	as	baseline	days	for	the	
altered	testing	conditions	to	see	a	return	to	baseline	NPR	scores.	During	this	
experiment,	a	new	set	of	objects	was	given	to	each	mouse	and	these	rotated	
throughout	the	experiment.	Therefore,	all	mice	saw	the	same	objects	over	the	
course	of	the	experiment;	however,	different	objects	were	used	each	day	
across	the	mice.	This	eliminated	the	potential	for	preferential	exploration	of	
any	particular	object(s)	to	influence	the	results.	Repeated	measures	ANOVA	
was	used	for	the	analysis	of	the	practice	effect	study.	The	practice	effect	was	
further	analysed	by	presenting	all	the	instances	in	which	the	NPR	task	was	
conducted	either	in	isolation	or	as	the	first	test	of	the	day.	A	repeated	
measures	ANOVA	was	used	to	assess	if	performance	increased	across	days.	
Significant	ANOVA	results	were	analysed	further	with	post-hoc	pairwise	
comparisons	using	Bonferroni	corrections.	
3.5.2	Results	
To	explore	why	the	second	task	produced	a	higher	DI	score	than	the	first,	we	
tested	the	hypothesis	that	the	NOR	task	preceding	the	NPR	task	effectively	
provided	two	additional	sample	phases,	allowing	for	more	encoding	time	
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before	the	final	NPR	test	phase.	Indeed,	the	testing	conditions	produced	
significantly	different	DI	scores	(repeated	measures	ANOVA:	effect	of	task	type	
F(2,50)=	10.70,	p<0.001,	partial	eta	squared	=0.30),	where	both	additional	
sample	phases,	and	the	NOR-preceding-NPR	task	increased	NPR	task	
performance	(Figure	3.8B,	pairwise	post-hoc	comparisons	with	Bonferroni	
corrections,	p<0.05).	Four	scores	were	excluded	from	analysis	due	to	low	
exploration.	
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Figure	3.8:	Additional	sample	phases	improve	NPR	task	performance	in	the	HDHQ111+/-	
mouse.	Mice	(n=15)	were	tested	over	7	days.	(A)	On	day	1	the	standard	NPR	task	was	
conducted	in	isolation.	On	the	following	two	days	the	NPR	task	was	conducted	with	three	
sample	phases	instead	of	one.	The	standard	NPR	was	conducted	again,	before	two	days	of	the	
NPR	post	NOR	task.	On	the	final	day	the	standard	NPR	task	was	tested	once	more.	(B)	The	
averaged	DI	scores	based	on	task	type,	where	the	score	for	the	standard	NPR	task	was	
significantly	reduced	compared	to	the	3	sample	(p<0.05)	and	NPR	post	NOR	task	(p<0.05).	 	
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Finally,	it	was	discovered	that	with	repeated	testing,	the	HDHQ111+/-	mouse	
increased	its	DI	score	in	the	NPR	task	(repeated	measure	ANOVA,	F(10,140)=2.86,	
p<0.05,	partial	eta	squared	=	0.17,	Figure	3.9).	When	all	the	data	was	
compared	during	which	the	NPR	task	was	the	only	or	first	task	of	the	day,	
performance	during	the	9-11th	days	were	significantly	better	than	on	the	first	
day	of	testing	(pairwise	comparisons	with	Bonferroni	corrections,	p<0.05).	
	
	
Figure	3.9:	Repeated	testing	of	the	NPR	task	enhanced	task	performance	in	the	HDHQ111+/-	
mouse.	All	testing	days	in	which	the	NPR	task	was	conducted	in	isolation	or	as	the	first	task	of	
the	day	are	plotted	in	chronological	order	(days	are	not	consecutive).	Days	9,	10,	and	11	are	
significantly	different	to	the	score	on	the	first	day	of	testing	(p<0.05).	 	
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3.6	Discussion	
Experiment	1	(Figure	3.4)	appeared	to	confirm	a	deficit	in	NPR,	but	not	NOR,	in	
HD	mice	and,	as	such,	was	consistent	with	the	previous	findings	of	Chandler	
(2014)	(see	Chapter	1,	Figure	1.4)	that	there	is	no	place	preference	in	the	1-
minute	NPR	test,	but	1-minute	NOR	is	normal	and	only	at	24-hours	is	there	no	
NOR	effect	(as	seen	by	Mitchell	(2012),	see	section	1.3.6).	However,	this	
experiment	has	also	demonstrated	that	the	behavioural	deficits	may	not	have	
a	simple	explanation.	As	the	observed	effect	was	that	which	was	expected	
(i.e.,	no	DI	in	the	NPR	task),	the	assumption	was	that	this	was	the	same	
impairment.	However,	a	wild-type	control	group	was	not	available	due	to	
breeding,	and	therefore	was	not	tested	and	the	only	control	was	‘task’.	
Clearly,	only	a	wild-type	control	group	would	have	enabled	the	strong	
conclusion	to	be	drawn	regarding	the	presence	or	otherwise	of	an	NPR	deficit	
in	these	mice.	
As	a	difference	in	exploration	at	the	sample	phase	could	have	resulted	in	an	
explanation	for	a	difference	in	DI	scores	during	the	test	phase,	this	was	also	
investigated.	Although	mice	did	explore	more	during	the	NOR	sample	phases	
than	the	NPR	sample	phases,	the	higher	exploration	times	did	not	predict	
higher	DI	scores	(Figure	3.6).	Therefore,	it	seems	that	as	long	as	mice	explored	
the	objects,	they	were	able	to	encode	them,	independent	of	how	long	they	
actively	spent	exploring.	Nevertheless,	the	difference	in	sample	phase	
exploration	at	the	NPR	and	NOR	test	could	have	been	avoided	by	using	the	
same	objects	for	both	tests,	in	a	counterbalanced	fashion,	instead	of	using	
separate	objects	for	the	NPR	and	NOR	tests.	
It	is	possible	to	conclude	from	this	set	of	experiments	that	exposure	to	the	
testing	arena	and	stimuli	has	an	effect	on	performance.	This	was	manifest	as	
the	task-order	effect	in	Experiments	1	and	2	and	confirmed	by	the	
manipulation	in	Experiment	3.	In	addition	to	the	task-order,	or	practice	effect,	
the	NPR	task	overall	resulted	in	a	lower	DI	score	than	the	NOR	task.		
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The	assumption	was	that	the	deficit	in	NPR	task	performance	might	be	
ameliorated	by	the	NMDA	receptor	PAM	and	putative	cognitive	enhancer,	
Org49209,	prior	to	testing.	However,	there	was	no	effect	on	the	DI	scores	
compared	to	vehicle	in	either	task	(Figure	3.5).	The	possibility	of	injection	
stress	influencing	the	results	was	ruled	out	by	showing	that	PBS	injections	did	
not	change	DI	scores.	However,	injection	stress	may	effect	exploration	times,	
as	there	was	a	significant	effect	of	treatment	condition	for	sample	phase	
exploration	times	(section	3.4.2).	As	higher	exploration	times	do	not	predict	
higher	DI	scores	see	(Figure	3.7),	this	difference	in	exploration	should	not	
affect	the	DI	scores.	
Experiment	3	investigated	the	reason	why	task	order	might	influence	the	DI	
scores.	It	was	hypothesised	that	mice	have	a	higher	DI	score	in	the	second	test	
than	the	first,	because	in	the	case	of	the	NOR-preceding-NPR	task,	the	NOR	
task	could	provide	“extra”	sample	phases.	The	NOR	task	could	act	as	these	
“extra”	sample	phases	because	the	locations	of	the	objects	throughout	the	
NOR	task	are	the	same	as	the	locations	in	the	sample	phase	of	the	NPR	task.	
This	reasoning	could	not	work	for	increasing	the	NOR	DI	score,	as	the	object	
identity	changes	between	the	NPR	and	NOR	tasks;	therefore,	the	NPR	cannot	
provide	“extra”	sample	phases	for	the	NOR	task.	Figure	3.8	shows	that	
additional	NPR	sample	phases	(where	the	same	objects	and	locations	are	
presented	3	times	before	the	test	phase)	increase	the	DI	score,	just	as	the	
NOR	task	which	immediately	preceded	the	NPR	task	might	increase	the	DI	
score.	A	possible	explanation	for	the	increased	NOR	score	after	exposure	to	
the	NPR	task	is	that	the	NPR	task	allows	for	a	higher	familiarity	with	the	testing	
arena.	It	is	well	documented	that	familiarity	with	the	environment	enhances	
exploration	of	the	novel	object,	which	is	also	why	mice	are	habituated	to	the	
testing	arena	prior	to	testing	(Besheer	and	Bevins,	2000).	
Finally,	additional	analysis	shows	that	the	NPR	task	DI	score	increases	with	
practice	over	days.	This	analysis	took	all	the	DI	scores	from	the	NPR	tasks	that	
were	performed	as	the	only	or	first	task	of	the	day.	Figure	3.9	shows	that,	by	
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day	9,	the	DI	is	significantly	higher	compared	to	the	first	day	when	there	was	
no	evidence	of	discrimination	of	novelty.	
Collectively,	these	data	show	that	not	only	does	repeated	exposure	to	testing	
increase	the	NPR	task	DI	score	within	a	day,	but	there	is	a	cumulative	effect	of	
testing	over	days,	where	the	DI	score	of	the	NPR	task	increases	even	when	
tested	first	in	the	day.	There	are	two	possible	explanations	for	this	increase	in	
scores:	first,	it	could	be	the	mice	improve	memory	for	the	familiar	place	with	
practice;	second,	the	salience	of	the	novel	place	could	have	increased	with	
repeated	testing.	
If	the	NPR	score	increases	with	repeated	testing,	this	could	be	a	reflection	of	
improved	spatial	memory	with	practice.	Just	as	increased	sample	phases	
increased	the	DI	score	during	the	test	phase	within	one	test,	repeated	
exposure	to	the	objects	in	the	testing	arena	could	increase	the	encoding	time	
of	those	object	locations.	However,	as	no	specific	behaviour	is	reinforced	(due	
to	the	spontaneous	nature	of	the	task),	it	cannot	be	that	the	mice	learn	the	
task,	per	se,	with	practice.	Nevertheless,	repeated	exposure	to	the	objects	in	
the	same	locations	could	allow	for	more	experience	and	familiarity	with	the	
object	locations.	
It	is	possible	that	the	spatial	memory	could	be	improved	through	repeated	
testing	due	to	the	environmental	enrichment	provided	by	the	testing	
experience	itself.	Environmental	enrichment	increased	the	spatial	memory	of	
R6/1	mice	in	the	Barnes	maze	(Nithianantharajah	et	al.,	2008).	These	authors	
also	attempted	to	test	the	effects	of	environmental	enrichment	in	the	NPR	
task,	however,	WT	performance	was	confounded	and	therefore	no	
conclusions	could	be	made	to	R6/1	mouse	performance.	
Future	experiments	would	not	only	benefit	from	a	WT	control	group,	but	it	
would	also	be	worthwhile	investigating	sub-chronic	administration	of	
Org49209.	Past	studies	have	shown	that	sub-chronic	administration	of	
pregnenolone	ameliorates	NOR	deficits	in	dopamine	transporter	knockout	
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mice,	which	display	a	schizophrenic	–	like	phenotype	(Wong	et	al.,	2012).	
Additionally,	sub-chronic	administration	of	the	NDMA	receptor	co-agonist	D-
cycloserine	was	able	to	improve	memory	deficits,	including	impaired	NOR,	in	a	
1-methyl-	4-phenyl-1,2,3,6-tetrahydropyridine	(MPTP)-induced	PD	rat	model	
(Ho	et	al.,	2011).	If	a	genotype	difference	is	found	in	the	rate	of	learning	in	the	
NPR	task,	sub-chronic	steroid	administration	could	be	compared	across	
administration,	between	HETs	and	WTs. 
	
The	novel	place	recognition	task	is	established	as	a	test	of	spatial	memory.	
However,	as	this	is	a	spontaneous	task,	there	is	no	reinforced	motivation	to	
explore	the	object	in	the	new	location;	the	task	relies	on	the	mouse	naturally	
wanting	to	explore	the	new	location.	This	makes	the	task	very	susceptible	to	
stress	effects	and	environmental	or	procedural	changes.	Therefore,	a	DI	score	
that	does	not	show	a	preference	for	the	novel	location	does	not	automatically	
mean	that	the	mouse	has	no	memory	for	the	old	object	location:	it	could	just	
be	that	the	same	object	in	a	different	location	is	not	salient	or	interesting	
enough	to	warrant	exploring.	In	contrast	to	the	NOR	task,	where	a	completely	
new	object	may	be	much	more	interesting	than	the	same	object	in	a	different	
location,	resulting	in	a	preferred	exploration	of	the	novel	object	but	not	the	
novel	location,	as	seen	in	this	study.	It	could	be	useful	to	be	able	to	measure	
exploration	both	at	the	object	in	the	novel	location,	as	well	as	the	location	
where	the	object	was	previously-	as	both	of	these	locations	are	theoretically	
novel	(i.e.,	an	object	is	somewhere	it	has	not	been	before,	and	an	object	is	no	
longer	somewhere	it	was	previously).	However,	we	cannot	measure	
exploration	of	empty	space,	although	the	use	of	tracking	software	may	be	able	
to	give	an	idea	of	time	spent	in	the	vicinity	of	the	old	object	location.	To	help	
with	these	questions,	having	a	control	group	of	WT	animals	to	compare	to	the	
HDHQ111+/-	animals	would	be	very	useful.	The	next	chapter	will	look	at	a	spatial	
memory	task	which	uses	reinforcement	to	attempt	a	different	approach	to	
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test	the	spatial	abilities	of	the	HDHQ111+/-	mouse,	and	also	has	a	WT	control	
group.	 	
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Chapter	4	
	
HDHQ111+/-	mice	are	Unimpaired	in	
Spatial	and	Reversal	Learning	in	
the	Morris	Water	Maze	
	
	
“I	see	that	you	have	a	little	swimming	mouse”	-David	Sedaris	
	
	
Illustration	by	C.	Brazaitis	 	
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4.1	Introduction	
The	Morris	water	maze	(hereafter	referred	to	as	water	maze)	was	developed	
by	Richard	Morris	at	the	University	of	St	Andrews	(Morris,	1984).	It	is	a	classic	
apparatus	for	measuring	spatial	learning	in	the	context	of	motivated	escape	
and	therefore	differs	from	other	discrimination	or	spatial	learning	tasks	based	
on	appetitive	reinforcement	or	spontaneous	behaviours	such	as	exploration.	
The	above	paper	describes	a	variety	of	spatial	tasks	that	can	be	used	in	the	
water	maze,	as	well	as	a	method	for	testing	visual	discrimination	learning.	This	
chapter	consists	of	two	studies,	both	utilising	the	water	maze:	spatial	memory	
and	spatial	re-location,	and	two-choice	cue	discrimination	and	reversal	
learning.	
4.1.1	Spatial	Learning	
The	primary	reason	for	choosing	the	water	maze	task	to	test	for	spatial	
learning	is	to	provide	a	motivational	drive	to	complete	the	task	without	the	
need	for	dietary	restrictions,	as	the	HDHQ111+/-	has	an	altered	metabolism	
(Carroll	et	al.,	2015).	Chapter	2	showed	my	first	attempt	to	measure	spatial	
memory	in	the	HDHQ111+/-	mice	using	the	NPR	task.	Although	the	mice	initially	
showed	no	preference	for	the	novel	place,	repeated	testing	revealed	that	they	
had	spatial	memory.	Therefore,	we	decided	that	a	task	was	needed	which	did	
not	rely	on	the	unconditioned	responses	of	the	mice.	The	water	maze	was	
chosen	as	the	mice	would	be	motivated	to	locate	the	platform.	This	would	also	
ensure	that	performance	was	due	to	memory	rather	than	other	factors	such	
as	attention	or	salience.	However,	the	possible	confound	to	a	motivational	
task	is	a	difference	in	motivation	to	perform	the	tasl.	Indeed,	HD	patients	
often	have	decreased	motivation	(van	Duijn	et	al.,	2014),	and	the	HDHQ111+/-	
mouse	has	previously	shown	lower	motivation	in	the	progressive	ratio	task	
(Yhnell	et	al.,	2016b).	
Both	HD	patients	and	rodent	models	have	deficits	in	spatial	memory	(Brandt	
et	al.	(2005),	Lione	et	al.	(1999),	and	sections	1.3.5	and	1.3.6).	We	propose	
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Org49209	would	have	the	same	beneficial	effects	on	spatial	memory	
impairments	found	in	the	water	maze	as	in	NPR	task	(see	Chapter	2):	briefly,	
enhancing	NMDA	receptor	function	could	lead	to	enhanced	hippocampal	LTP	
which	may	improve	spatial	memory.	
4.1.2	Reversal	Learning	
Reversal	learning	is	a	test	of	behavioural	flexibility	(see	section	1.4.4),	where	
both	HD	patients	and	rodent	models	show	impairments	(Lawrence	et	al.	
(1999),	Farrar	et	al.	(2014),	and	section	1.4.6).	Org49209	has	previously	
ameliorated	reversal	learning	deficits	of	aged	rats	(Chase	(2013),	see	Chapter	
1,	Figure	1.11);	therefore,	if	a	reversal	deficit	were	also	found	in	this	study	
with	HDHQ111+/-	mice,	we	would	predict	it	to	have	a	similar	effect.	
4.1.3	Study	Aims	
To	assess	the	spatial	memory	function	and	reversal	abilities	of	the	HDHQ111+/-	
mouse	in	the	water	maze,	with	the	aim	to	use	Org49209	in	future	studies	to	
reverse	any	deficits	that	may	arise.	
4.2	Methods	
4.2.1	Subjects	
The	mouse	model	used	is	described	in	detail	in	section	3.2.1.	All	water	maze	
experiments	were	conducted	with	16	experimentally	naïve	male	and	female	
mice	consisting	of	8	HDHQ111+/-	(HET)	and	8	littermate	control	wild	types	(WT),	
3-4	months	of	age	at	the	start	of	testing.	Mice	were	kept	in	standard	housing	
conditions	on	a	12	hour	light/dark	cycle	from	7	AM	to	7	PM.	Food	and	water	
was	available	ad	libitum.	Discrimination	learning	started	when	the	mice	were	
6	months	old	and	they	had	reached	8.5	months	by	the	end	of	testing.	Mice	
were	weighed	weekly	during	testing.	Two	WT	mice	failed	to	learn	the	initial	
discrimination	and	so	were	excluded	from	the	remainder	of	testing.	
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4.2.2	Apparatus	
The	water	maze	was	2	meters	in	diameter	and	had	a	raising	platform	(CNS	
Technologies,	Edinburgh).	The	platform	can	be	held	down	with	
electromagnets	that	are	remotely	switched	off	to	release	the	platform	back	to	
just	under	the	water’s	surface.	When	filled,	the	water	was	at	21	±	1	°C	and	the	
surface	is	0.5	cm	above	the	platform.	A	CCTV	camera	was	mounted	on	the	
ceiling	above	the	centre	of	the	pool	and	the	image	was	sent	to	both	the	
computer	recording	the	data	and	a	separate	monitor.	The	CCTV	set	up	
recorded	a	back-up	copy	of	the	testing.	
For	the	spatial	learning	experiments	extra-maze	cues	were	hung	around	the	
water	maze;	these	included	brightly	coloured	and	patterned	curtains,	
decorative	hanging	objects,	as	well	as	normal	essential	laboratory	furniture	
such	as	lamps,	shelves,	etc.	Around	these	cues	two	sets	of	white	curtains	were	
drawn	to	separate	the	maze	from	the	rest	of	the	room,	and	the	experimenter.	
This	was	to	ensure	the	experimenter	did	not	act	as	a	spatial	cue.	
For	the	discrimination	and	reversal	learning	experiments,	the	extra-maze	cues	
were	removed,	and	white	curtains	were	drawn	directly	around	the	maze	to	
minimize	visual	extra-maze	cues;	however,	spatial	cues	due	to	smells	and	
sounds	could	not	be	eliminated.	Therefore,	although	spatial	learning	was	
discouraged	during	the	visual	discrimination	task,	it	was	still	possible	for	mice	
to	have	a	representation	of	their	location	in	space	due	to	sounds	from	the	
computer	and	smells	from	their	cage	mates.	A	barrier	was	introduced	to	the	
water	maze,	which	extended	from	the	outer	edge	into	the	middle	of	the	pool.	
On	either	side	of	the	barrier,	two	cues	were	hung	directly	over	the	pool	by	
transparent	nylon	string	attached	to	the	ceiling	with	Velcro	strips	or	curtain	
hangers:	one	centrally,	above	the	platform	location,	in	the	target	quadrant;	
and	the	other	in	the	equivalent	location	in	the	neighbouring	quadrant.	
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4.2.3	Data	Collection	
Data	was	collected	using	ANYmaze	(Version	4.99m).	Within	the	software,	
regions	of	interest	(or	“zones”)	were	marked	both	for	the	spatial	learning	task	
(Figure	4.1)	and	the	reversal	learning	task	(Figures	4.2	and	4.3).	ANYmaze	
tracked	the	mouse	in	the	maze,	and	recorded	the	time	and	path	the	mouse	
took	during	each	trial.	Data	was	collected	in	Microsoft	Excel	and	pivot	tables	
were	used	to	organise	the	data.	
4.2.4	Spatial	and	Spatial	Relocation	Learning	
Mice	were	handled	for	one	week	prior	to	testing.	During	this	time,	they	were	
transported	to	the	water	maze	room	daily	and	handled	for	two	minutes	each.	
Each	testing	day	consisted	of	6	trials.	The	mice	were	run	in	two	cohorts	of	8,	
with	equal	numbers	of	genotype	and	sex	in	each	cohort.	Cohort	A	was	run	
first,	followed	by	cohort	B.	Each	trial	was	started	by	selecting	one	of	the	4	
potential	start	locations,	spaced	equally	around	the	maze,	pseudo-randomly	
(using	random.org).	The	mouse	was	gently	lowered	into	the	water,	keeping	its	
head	above	the	water	and	positioned	facing	the	side	of	the	pool,	away	from	
the	centre.	Each	mouse	had	an	inter	trial	interval	of	10	minutes,	during	which	
it	was	placed	under	a	heat	lamp	to	stay	warm	and	get	dry.	Each	mouse	was	
housed	in	a	separate	labelled	cage,	lined	with	absorbent	tissue	for	the	
duration	of	testing.	
Each	trial	had	a	maximum	duration	of	90	seconds,	after	which	the	mouse	was	
guided	to	the	platform.	The	mouse	was	left	on	the	platform	for	30	seconds	to	
allow	for	additional	spatial	encoding	of	the	environment.	The	mouse	was	only	
removed	when	on	the	platform,	to	train	it	to	remain	on	the	platform	for	the	
duration	of	the	waiting	time,	and	to	make	sure	that	locating	the	platform	was	
associated	with	the	only	means	of	escape.	
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Figure	4.1:	The	set-up	of	the	water	maze	for	spatial	learning.	The	pool	was	split	into	zones.	
These	consisted	of	the	thigmotaxis,	four	quadrants,	the	platform	zone	and	a	zone	immediately	
around	the	platform.	
The	spatial	learning	experiment	consisted	of	3	stages:	
4.2.4.1	Visual	Platform	
On	the	first	day	of	testing,	the	hidden	platform	was	made	visible	with	a	black	
and	white	striped	cue	card	placed	directly	on	top	of	the	platform.	White	
curtains	were	drawn	directly	around	the	water	maze	to	eliminate	extra-maze	
cues	as	described	above	for	the	discrimination	learning	task.	Visual	platform	
training	served	two	purposes:	firstly,	so	that	the	mice	would	become	
habituated	to	the	pool	and	training	procedure;	secondly,	so	that	the	visual	
ability	of	the	mice	was	tested.	Differences	in	duration	or	distance	to	find	the	
visual	platform	could	be	due	to	impaired	vision,	and	differences	in	duration	
could	be	due	to	different	swimming	speeds.	The	visual	platform	stage	was	
used	to	check	for	visual	ability,	where	genotype	difference	would	make	the	
water	maze	an	inappropriate	task	for	examining	learning	and	memory	in	this	
mouse	model.	
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4.2.4.2	Spatial	Learning	
During	spatial	learning	mice	were	required	to	use	extra-maze	cues	to	locate	
the	platform.	The	platform	was	in	a	different	quadrant	location	for	each	
cohort	and	different	to	the	visual	platform	location.	Mice	were	tested	until	
their	duration	and	distance	had	reached	a	plateau,	and	the	swim	paths	to	the	
platform	were	direct.	
4.2.4.3	Spatial	Relocation	
Once	the	mice	had	learned	the	location	of	the	platform,	the	platform	was	
moved	to	the	opposite	quadrant	location.	Testing	was	stopped	once	
performance	reached	the	same	level	as	for	the	initial	spatial	learning.	Spatial	
re-location	learning	is	a	test	of	behavioural	flexibility,	and	the	ability	to	learn	a	
new	spatial	location.		
4.2.4.4	Probe	Trials	
Probe	trials	(or	transfer	tests),	in	which	the	hidden	platform	is	removed	
entirely	from	the	pool,	are	a	further	test	of	the	spatial	memory	and	confirm	
that	the	mouse	is	not	using	a	non-spatial	search	strategy.	If	the	mouse	has	
learned	the	spatial	location	of	the	platform,	it	is	expected	to	spend	more	time	
in	the	proximity	of	the	(now	absent)	platform	location.	Probe	trials	were	
conducted	on	the	last	day	of	spatial	learning	and	the	last	day	of	spatial	re-
location	learning,	one	hour	after	the	last	trial	was	completed.	During	the	trial,	
the	platform	was	held	down	by	electromagnets	for	60	seconds,	after	which	
the	magnets	were	switched	off,	raising	the	platform.	The	mouse	was	then	
allowed	to	locate	the	platform	and	remain	on	it	for	the	usual	30	seconds.	This	
ensured	that	no	extinction	occurred	during	the	probe	trial	which	could	impact	
future	learning.	
4.2.4.5	Data	Analysis	
ANYmaze	recorded	the	distance	and	duration	taken	for	each	mouse	to	reach	
the	platform	on	each	trial.	During	probe	trials	ANYmaze	provided	data	on	the	
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distance	and	duration	spent	in	the	quadrants.	Below	is	a	summary	of	the	
zones	and	measurements	used	by	ANYmaze.	
Zones	Used	
Thigmotaxis-	is	the	area	around	the	edge	of	the	water	maze.	Mice	
spending	time	in	this	area	are	trying	to	find	an	escape	from	the	edge	of	
the	pool.	
Quadrant-	The	pool	is	split	into	4	equal	quadrants:	NE,	NW,	SE,	SW.	
The	platform	is	located	in	the	centre	of	one	quadrant.		
Platform-	denotes	the	exact	location	of	the	platform	within	each	
quadrant.	
Platform	proximity-	a	zone	drawn	just	around	the	platform,	to	measure	
the	instances	when	the	mouse	is	close	to	the	platform.	
Factors	Measured	
Distance	to	find	platform	(in	meters)-	the	length	of	the	swim	path	from	
the	entry	point	to	the	platform	location.	
Duration	to	find	platform	(in	seconds)-	the	time	from	entry	to	arriving	
at	the	platform	location.	
Speed	(in	meters	per	second)-	Distance	/	Duration	gives	the	speed	of	
the	mice	for	each	trial.	
Length	of	swim	path	and	duration	spent	in	quadrant-	used	in	analysis	
of	the	probe	trials	to	measure	the	distance	of	swim	path	and	time	
spent	in	the	relevant	quadrants.	
ANYmaze	also	records	the	actual	path	taken	by	the	mouse,	which	can	be	used	
to	compare	swim	paths	and	assess	if	the	mouse	is	using	a	direct	route	to	find	
the	platform.	These	traces	were	used	to	show	representative	swim	paths	at	
different	stages	of	the	water	maze	tasks.	
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The	distance	to	reach	the	platform	was	assessed	across	trials	for	each	
genotype	with	a	repeated	measures	ANOVA.	Probe	trials	were	analysed	by	
averaging	the	time	spent	in	the	target	quadrant	for	each	genotype.	A	2-way	
ANOVA	with	pairwise	comparisons	using	Bonferroni	corrections	was	used	to	
see	if	mice	spent	more	time	in	the	target	quadrant	compared	to	other	
quadrants.	Effect	sizes	were	calculated	with	partial	eta	squared	or	Cohen’s	d.	
Power	analysis	was	conducted	with	G*Power	(Faul	et	al.,	2009,	Faul	et	al.,	
2007).	
4.2.5	Visual	Cue	Reversal	Learning	
Two-choice	discrimination	stimulus-response	(S-R)	reversal	learning	is	often	
used	as	a	measure	of	behavioural	flexibility.	Spatial	re-location	learning	is	
sometimes	referred	to	as	reversal	learning,	although	it	is	not	a	S-R	reversal.	
For	a	S-R	reversal	task	in	the	water-maze,	the	mouse	learns	which	of	two	
stimuli	indicates	the	platform	location	(discrimination	learning).	The	correct	
choice	is	reinforced	by	the	platform	providing	a	means	of	escape	from	the	
maze.	Once	the	discrimination	has	been	learned	the	previously	reinforced	
stimulus	is	no	longer	reinforced,	instead	the	unreinforced	stimulus	becomes	
the	new	predictor	of	successful	escape.	
Trial	number	was	increased	from	6	to	8	trials	per	animal	per	day.	The	platform	
location	was	pseudo-randomly	determined	(using	random.org)	on	every	trial.	
Only	the	north	and	south	entry	points	were	used	for	this	experiment.	Entry	
points	were	alternated	daily,	and	both	entry	points	were	used	between	the	
two	cohorts	each	day.	
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Figure	4.2:	The	set-up	of	the	water	maze	for	reversal	learning.	White	curtains	were	drawn	
directly	around	the	maze.	A	barrier	was	placed	in	half	of	the	pool	to	separate	the	quadrants	
which	contain	different	cues.	Only	one	of	the	cues	predict	the	platform	location.	The	pool	was	
split	into	the	same	zones	as	in	Figure	4.1	of	spatial	learning,	with	the	addition	of	the	cue	
proximity	zone,	which	is	a	larger	circle	around	the	platform	locations	in	each	quadrant.	These	
zones	are	used	as	a	threshold	for	the	mouse	making	a	choice	between	the	two	cues.	
	
4.2.5.1	Cue	Training	
In	the	first	stage	of	the	task	the	mice	were	trained	to	associate	the	platform	
location	with	a	cue	hanging	directly	above	the	platform.	The	cue	was	a	large	
5L	blue	bottle.	Each	trial	used	only	one	cue	to	ensure	the	mice	were	using	the	
cue	as	a	predictor	for	platform	location	rather	than	spatial	or	egocentric	
memory.	A	threshold	of	80%	first	choice	accuracy	for	the	genotype	group	as	a	
whole	was	used	as	a	criterion	for	learning	each	stage	of	the	task.	
4.2.5.2	Discrimination	Learning	
Once	the	cue	training	was	complete,	two	new	cues	(owl	lunch	box,	dustpan	
and	brush	set)	were	introduced	to	the	water	maze	at	the	same	time.	Only	one	
cue	predicted	the	platform	location.	The	owl	lunch	box	predicted	platform	
location	for	cohort	A,	while	the	dustpan	and	brush	predicted	platform	location	
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for	cohort	B.	On	the	last	day	of	discrimination	learning,	a	probe	trial	was	
conducted	before	the	usual	8	trials	to	test	for	memory	of	the	correct	cue	24	
hours	after	the	last	trial.	The	cues	were	set	up	as	for	discrimination	learning;	
however,	the	platform	was	held	down	for	60	seconds,	as	in	the	probe	trial	
during	spatial	learning	(described	in	section	4.2.4.4).	More	time	spent	at	the	
correct	cue	compared	to	the	incorrect	cue	indicates	a	learned	discrimination.	
This	stage	of	the	task	was	attempted	first	without	the	presence	of	a	barrier	(as	
described	in	Bannerman	et	al.	(2012));	however,	after	two	weeks	of	testing	
the	mice	were	not	showing	any	learning.	Therefore,	the	barrier	was	
introduced	to	increase	the	cost	of	making	a	wrong	choice.	This	was	sufficient	
to	motivate	the	mice	to	learn	the	discrimination.	
4.2.5.3	Reversal	Learning	
Once	discrimination	learning	was	complete,	the	stimulus-outcome	
contingency	was	reversed.	The	cue	previously	predicting	the	platform	location	
no	longer	did	so,	and	the	other	cue	became	the	new	predictor	of	the	platform	
location.	
4.2.5.4	Data	Analysis	
The	distance	and	time	were	measured	as	in	the	spatial	learning	tasks	above.	
To	measure	discrimination	and	reversal	learning,	first	choice	accuracy	was	
used.		
Below	is	a	full	description	of	the	zones	used	and	dependent	variables	
measured:		
Zones	Used	
The	same	zones	were	used	as	in	the	spatial	learning	task,	as	well	as:	
Cue	proximity-	A	wider	circle	around	the	platform	used	as	a	threshold	
to	calculate	first	choice	(see	Figure	4.2).	If	the	mouse	crosses	into	this	
zone,	it	is	recorded	as	having	made	a	choice	between	the	two	cues.	
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Quadrant	entry	zones	(Figure	4.3)-	Used	as	a	measure	of	indecision.	
During	this	task	ANYmaze	was	prone	to	track	the	cues	instead	of	the	
mouse,	which	would	inflate	the	number	of	quadrant	entries;	therefore,	
the	side	of	the	quadrant	zone	that	is	used	on	mouse	entry	is	given	an	
additional	zone,	to	ensure	any	crossings	are	due	to	mouse	behaviour	
rather	than	an	error	of	the	software	to	track	the	mouse.	
	
Figure	4.3:	Zone	locations	for	quadrant	entry	areas.	These	zones	were	used	to	measure	
indecision	of	choosing	between	the	two	cues.	
Factors	Measured	
The	same	factors	were	measured	as	in	the	spatial	learning	task,	as	well	
as:	
Distance	to	first	entry	of	Cue	proximity	zone-	The	distance	travelled	to	
enter	a	cue	proximity	zone	for	the	first	time.	
Distance	to	first	entry	of	quadrant-	The	distance	travelled	to	enter	a	
quadrant	for	the	first	time.		
Number	of	quadrant	entries-	Number	of	times	the	mouse	crossed	the	
zones	shown	in	Figure	4.3.	
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First	choice	accuracy	was	calculated	by	comparing	the	distance	to	reach	the	
cue	proximity	zone	of	each	of	the	cues	using	a	program	written	in	Perl	(written	
by	Gordon	McCormick,	see	Appendix	1	for	program	code).	The	shorter	
distance	was	scored	as	the	cue	first	approached	(first	choice).	If	the	first	choice	
was	at	the	correct	cue,	the	trial	was	scored	as	1;	if	the	first	choice	was	at	the	
incorrect	cue,	the	trial	was	scored	as	0.	
The	processed	data	were	analysed	in	Microsoft	Excel	using	pivot	tables.	The	
average	was	taken	for	each	genotype	for	each	trial.	The	average	across	each	
day	(8	trials)	was	then	taken	to	make	the	final	graph	in	Microsoft	Excel.	A	
repeated	measures	ANOVA	was	used	to	compare	the	percent	first	choice	
accuracy	across	28	days	for	each	genotype.	Individual	data	for	each	mouse	
were	used	to	exclude	outliers	and	was	also	averaged	across	each	day.	Mice	
were	excluded	if	they	did	not	learn	the	initial	discrimination	after	28	days.	
There	individual	data	were	also	used	for	regression	analysis.	A	trend	line	was	
fitted	for	each	mouse	and	the	slopes	were	compared	between	genotypes	with	
a	t-test.	
Probe	trial	data	was	collected	manually	as	the	ANYmaze	software	occasionally	
had	trouble	tracking	the	mouse	due	to	tracking	the	cues	instead	of	the	mouse.	
Therefore,	correct	and	incorrect	quadrant	entries	and	cue	proximity	zone	
entries	were	counted	manually	during	testing.	A	2-way	ANOVA	was	used	to	
see	if	mice	differed	in	frequency	of	quadrant	or	cue	proximity	zone	entries.	
The	initial	reversal	stage	was	analysed	by	calculating	the	number	of	days	taken	
to	reach	chance	performance	for	each	mouse.	Chance	level	is	the	correct	first	
choice	made	in	4/8	trials.	The	days	to	reach	chance	level	were	compared	
between	genotypes	using	a	t-test.	The	whole	reversal	stage	was	analysed	with	
a	repeated	measures	ANOVA	to	compare	the	percent	first	choice	accuracy	
across	27	days	for	each	genotype.	Regression	lines	were	also	fit	for	the	
individual	mice	during	the	reversal	stage	and	slopes	were	compared	with	a	t-
test	between	genotypes.	Effect	sizes	were	calculated	with	partial	eta	squared	
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or	Cohen’s	d.	Power	analysis	was	conducted	with	G*Power	(Faul	et	al.,	2009,	
Faul	et	al.,	2007).	
4.3	Results	
4.3.1	Spatial	Learning	and	Spatial	Relocation	Learning	
The	first	water	maze	experiment	conducted	was	spatial	learning	and	spatial	
relocation	learning.	Both	WT	(n=8)	and	HDHQ111+/-	(n=8)	littermates	were	
required	to	search	for	a	hidden	platform	using	extra	maze	cues.	First	the	mice	
were	habituated	in	the	visual	platform	task,	followed	by	the	spatial	learning	
task,	and	finished	with	spatial	relocation	learning.	
4.3.1.1	Visual	Platform	
During	the	visual	platform	task	mice	are	required	to	locate	the	platform	based	
on	a	visual	cue	placed	directly	on	top	of	the	platform.	This	test	served	to	
habituate	the	mice	to	the	pool	and	testing	procedure	and	ensured	that	all	
subjects	had	sufficient	visual	and	motor	ability.	All	subjects	located	the	
platform	within	one	day,	consisting	of	6	trials	(ANOVA,	main	effect	of	trial:	
F(5,65)=13.7,	p<0.001,	partial	eta	squared=	0.51),	with	no	difference	between	
genotypes	(no	main	effect	of	genotype:	F(1,13)<1,	df=1,	partial	eta	squared=	
0.04,	and	no	interaction	effect:	F(5,65)<1,	partial	eta	squared=	0.08,	Figure	4.4).	 	
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Figure	4.4:	HDHQ111+/-	(HET)	and	littermate	controls	(WT)	learned	the	visual	platform	task	
equally	quickly.	The	platform	was	hidden	just	under	the	water	surface	with	a	black	and	white	
striped	card	sitting	on	top	to	mark	the	platform	location.	Both	genotypes	learned	the	platform	
location	equally	quickly	in	one	day,	consisting	of	6	trials.	Fit	line	parameters:	HET:	y	=	10.664x-
1.009,	R²	=	0.86586;	WT:	y	=	9.3467x-1.064,	R²	=	0.75779.	Error	bars	show	SEM.	
	
4.3.1.2	Spatial	Learning	
The	spatial	learning	task	assesses	the	mouse’s	ability	to	locate	a	hidden	
platform	with	the	use	of	visual	extra	maze	cues.	This	is	a	test	of	spatial	
learning,	as	the	mouse	must	orient	itself	in	space,	before	swimming	to	the	
correct	platform	location.	First,	it	is	crucial	to	confirm	that	the	HDHQ111+/-		
mouse	is	able	to	swim	equally	well	as	its	littermate	controls.	This	is	achieved	
by	measuring	the	swim	speed,	which	does	not	differ	between	the	genotypes	
(repeated	measures	ANOVA:	main	effect	genotype:	F(1,14)<1,	partial	eta	
squared=	0.04).	The	mice	do	get	slightly	slower	during	spatial	learning	(main	
effect	of	trial:	F(35,490)=7.2,	p<0.001,	partial	eta	squared=	0.34,	Figure	4.5).	
Figure	4.6A	shows	each	group’s	mean	distance	(length	of	swim	path)	for	each	
of	the	6	trials	over	the	6	days	of	spatial	learning.	It	is	evident	that	the	mean	
distance	swum	decreases	even	within	the	first	day	(ANOVA,	main	effect	of	
trial:	F(35,490)=11.1,	p<0.001,	partial	eta	squared=	0.44).	Furthermore,	there	is	
no	difference	between	groups	in	the	slope	of	the	decrease:	both	WT	and	
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HDHQ111+/-	mice	learned	the	platform	location	equally	well	over	6	days	of	
testing	(no	main	effect	of	genotype:	F(1,14)<1,	partial	eta	squared=	0.03,	no	
interaction	effect:	F(35,490)<1,	partial	eta	squared=	0.05).	The	tracings	of	a	
typical	swim	path	(Figure	4.6B)	indicate	that	the	swim	paths	are	increasingly	
direct	to	the	platform.	Tracings	from	the	probe	trial	(Figure	4.6B)	show	that	
the	mice	have	a	memory	for	the	platform	location;	even	when	the	platform	
was	absent,	they	remained	in	the	vicinity	of	the	former	platform	location.	WT	
and	HDHQ111+/-	did	not	differ	in	the	spatial	learning	probe	trial	(ANOVA	main	
effect	of	genotype:	F(1,56)<1,	partial	eta	squared=	0.00),	where	mice	spent	
significantly	more	time	in	the	target	quadrant	(main	effect	of	quadrant:	
F(3,56)=26.7,	p<0.001,	partial	eta	squared=	0.59;	Figure	4.6C).	
	
	
Figure	4.5:	HDHQ111+/-	(HET)	and	littermate	controls	(WT)	do	not	differ	in	swim	speeds.	Both	
genotypes	become	slightly	slower	across	spatial	learning	days	(p<0.001).	Fit	line	parameters:	
HET:	y	=	0.2464x-0.168,	R²	=	0.4226;	WT:	y	=	0.2249x-0.11,	R²	=	0.24445.	Error	bars	show	SEM.	
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Figure	4.6:	HDHQ111+/-	mice	were	unimpaired	in	the	spatial	water	maze	task	at	3	months.	
Following	the	visual	platform	task,	mice	were	tested	in	the	spatial	learning	task,	where	the	
platform	was	under	the	water’s	surface	and	not	visible.	On	each	trial	the	mouse	was	released	
from	a	different	entry	site	at	random,	but	the	platform	location	always	remained	constant.	(A)	
Over	6	days	of	testing,	with	6	trials	per	day,	the	HDHQ111+/-	(HET)	mouse	and	littermate	
controls	(WT)	learned	to	locate	the	platform	equally	quickly.	Fit	line	parameters:	HET:	
y=12.611x-1.056,	R²	=	0.73064;	WT:	y	=	11.398x-0.941,	R²	=	0.59342.	(B)	Representative	path	
traces	for	each	genotype	during	days	1,	3,	and	6	of	spatial	learning	and	the	spatial	probe	trial.	
(C)	One	hour	after	the	last	spatial	learning	trial	on	day	5	the	platform	was	submerged	so	that	
the	mouse	could	not	reach	it.	In	this	probe	trial,	both	genotypes	spent	more	time	in	the	target	
quadrant	(Target)	than	all	other	quadrants	(Opposite,	Left	Adjacent,	Right	Adjacent)	
(p<0.001).	Error	bars	show	SEM.		 	
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4.3.1.3	Spatial	Relocation	
The	spatial	relocation	task	is	intended	to	measure	behavioural	flexibility	and	
the	ability	to	learn	a	new	platform	location.	After	the	mice	have	learned	the	
location	of	the	platform	during	spatial	learning	(section	4.3.1.2),	the	platform	
was	moved	to	the	opposite	quadrant.	Both	genotypes	learned	the	new	
platform	location	equally	quickly	(Repeated	ANOVA	main	effect	of	genotype:	
F(1,14)<1,	partial	eta	squared=	0.01;	Figure	4.7A).	A	sample	size	of	710	would	be	
needed	to	see	a	significant	genotype	effect.	The	mice	rapidly	learn	the	new	
platform	location	over	3	days,	shown	by	a	decrease	in	distance	swum	to	reach	
the	platform	(main	effect	of	trial:	F(17,238)=	11.7,	p<0.001,	partial	eta	squared=	
0.45).	The	traces	show	that	although	the	mice	explore	the	old-location	
thoroughly,	they	then	swim	in	all	4	quadrants	until	they	find	the	new	platform	
location.	By	the	third	day,	they	swim	directly	to	the	new	location	(Figure	4.7B).	
The	probe	trial	shows	that	the	mice	have	a	memory	for	the	new	platform	
location	as	they	preferentially	remain	in	the	vicinity	of	the	current	target	
platform	location,	rather	than	the	acquisition	location	learned	during	the	
spatial	learning	task	(Figure	4.7C).	There	is	no	genotype	difference	in	the	time	
spent	in	each	quadrant	(ANOVA	no	main	effect	of	genotype:	F(1,56)=	2.3,	p>	
0.05,	partial	eta	squared=	0.04).	The	mice	spent	more	time	in	the	target	
quadrant	than	in	all	other	quadrants	(main	effect	of	quadrant,	F(3,56)=33.2,	
p<0.001,	partial	eta	squared=	0.64,	where	Bonferroni	corrected	pairwise	
comparisons	show	the	target	quadrant	is	different	to	all	other	quadrants,	
p<0.001).	The	increased	path	length	to	reach	the	platform	at	the	beginning	of	
the	relocation	task	was	due	to	increased	time	spent	in	the	former	correct	
platform	location	(Figure	4.8).	This	is	in	accordance	with	the	spatial	learning	
probe	trial	data	(Figure	4.6C).	After	the	first	trial	the	mice	quickly	learned	the	
new	platform	location,	and	after	the	first	day	they	had	already	almost	reached	
asymptotic	path	length	to	the	platform.	Accordingly,	the	time	spent	in	the	
former	correct	platform	location	quickly	dropped	after	the	first	trial	(Figure	
4.8,	repeated	measures	ANOVA:	main	effect	of	quadrant:	F(3,45)=21.1,	p<0.001,	
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partial	eta	squared=	0.58;	main	effect	of	trial:	F(5,75)=23.5,	p<0.001,	partial	eta	
squared=	0.61;	and	a	significant	trial	by	quadrant	interaction	(F(15,225)=6.7,	
P<0.001,	partial	eta	squared=	0.31),	where	Bonferroni	corrected	pairwise	
comparisons	show	the	acquisition	quadrant	is	significantly	different	to	all	
other	quadrants	(p<0.001)).	 	
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Figure	4.7:	HDHQ111+/-	mice	were	unimpaired	in	water	maze	spatial	relocation	task.	After	
mice	had	established	the	location	of	the	hidden	platform	during	the	initial	spatial	learning	
phase,	the	platform	was	moved	to	the	opposite	quadrant.	(A)	Over	3	days	of	testing,	with	6	
trials	per	day,	the	HDHQ111+/-	(HET)	mouse	and	littermate	controls	(WT)	learned	to	locate	the	
new	platform	location	equally	quickly.	Fit	line	parameters:	HET:	y	=	8.1475x-0.925,	R²	=	0.58589;	
WT:	y	=	10.122x-1.204,	R²	=	0.57308.	(B)	Representative	path	traces	for	each	genotype	during	
days	1	and	3	of	spatial	relocation	learning	and	the	spatial	relocation	probe	trial.	(C)	One	hour	
after	the	last	spatial	learning	trial	on	day	5	the	platform	was	submerged	so	that	the	mouse	
could	not	reach	it.	In	this	probe	trial,	both	genotypes	spent	more	time	in	the	target	quadrant	
than	all	other	quadrants	(P<0.001).	The	x-axis	labels	the	quadrant:	Target,	Acquisition,	and	
Left	and	Right	Adjacent	(to	the	target).	Error	bars	show	SEM.	 	
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Figure	4.8:	Analysis	of	the	distance	travelled	in	the	acquisition	quadrant	compared	to	the	
average	of	all	other	quadrants	across	6	trials	during	the	first	day	of	spatial	relocation	
learning.	During	the	first	trial	both	HDHQ111+/-	(HET)	and	littermate	controls	(WT)	spent	more	
time	in	the	acquisition	quadrant	than	in	all	other	quadrants,	but	this	time	quickly	dropped	
with	the	learning	of	the	new	platform	location.	Mice	spent	more	time	in	the	acquisition	
quadrant	during	trial	1	compared	to	other	quadrants	(p<0.001).	Fit	line	parameters:	
Acquisition	Het:	y	=	8.2691x-1.074,	R²	=	0.89464;	Acquisition	WT:	y	=	7.7894x-0.899,	R²	=	0.77027;	
Other	HET:	y	=	2.4178x-0.575,	R²	=	0.47628;	Other	WT:	y	=	2.0508x-0.49,	R²	=	0.77875.	Error	bars	
show	SEM.	
	
4.3.2	Visual	Cue	Reversal	Learning	
To	assess	the	executive	functions	of	the	HDHQ111+/-	mouse	the	water	maze	was	
used	to	perform	a	two-choice	visual	discrimination	learning	task	followed	by	a	
reversal.	
4.3.2.1	Cue	Training	and	Discrimination	Learning	
Mice	were	trained,	over	five	days,	to	locate	the	platform	using	a	single	cue	
hanging	directly	above	the	platform	location.	Both	genotypes	learned	the	cue	
association	equally	quickly	(repeated	measures	ANOVA,	no	main	effect	of	
genotype:	F(1,12)<1,	partial	eta	squared=	0.00,	main	effect	of	day:	F(4,48)=13.2,	
p<0.001,	partial	eta	squared=	0.53,	no	interaction	effect:	F(4,48)<1,	partial	eta	
squared=	0.03;	Figure	4.9A).	
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Following	cue	training,	two	new	cues	were	hung	next	to	each	other	and	the	
mice	had	to	discriminate	between	the	cues	and	learn	which	one	indicated	the	
platform	location.	Over	28	days	both	genotypes	reached	the	discrimination	
criterion	of	80%	first	choice	accuracy	(repeated	measures	ANOVA,	main	effect	
of	day:	F(27,324)=14.0,	p<0.001,	partial	eta	squared=	0.54;	no	main	effect	of	
genotype:	F(1,12)=1.5,p>0.05,	partial	eta	squared=	0.11;	no	interaction	effect:	
F(27,324)<1,	partial	eta	squared=	0.06;	Figure	4.9A).	A	probe	trial	was	conducted	
on	the	last	day	of	discrimination	learning.	The	number	of	quadrant	entries,	as	
well	as	the	number	of	entries	into	the	cue	proximity	zones,	were	compared	for	
the	incorrect	and	correct	cues	for	each	genotype.	There	was	no	genotype	
difference	during	the	probe	trial	both	in	quadrant	entries	(ANOVA	main	effect	
of	genotype:	F(1,24)=3.9,	p>0.05,	partial	eta	squared=	0.14)	and	in	cue	proximity	
zone	entries	(ANOVA	main	effect	of	genotype:	F(1,24)<1,	partial	eta	squared=	
0.00).	All	mice	entered	into	the	correct	cue	proximity	zone	more	frequently	
than	the	incorrect	cue	zone,	but	this	was	not	the	case	for	quadrant	entries	
(main	effect	of	cue	zone:	F(1,24)=27.0,	p<0.001,	partial	eta	squared=	0.53;	main	
effect	of	quadrant:	F(1,24)=3.4,	p>0.05,	partial	eta	squared=	0.13;	Figure	4.9C).	
Regression	lines	were	fitted	for	individual	mice	for	discrimination	learning;	the	
average	slopes	for	each	genotype	were	not	different	(t=	0.7,	df=	12,	p>	0.05,	
Cohen’s	d=	0.19;	Figure	4.10).	
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Figure	4.9:	The	HDHQ111+/-	(HET)	mouse	learns	to	discriminate	between	two	objects	in	the	
water	maze	equally	quickly	as	the	littermate	controls	(WT).	(A)	8	HETs	and	6	WTs	learned	to	
locate	the	platform	during	cue	training	within	five	days,	where	only	one	cue	was	used	to	
associate	the	platform	location	with	a	cue.	On	the	sixth	day	two	different	cues	were	used;	
however,	only	one	predicted	the	platform	location.	Both	genotypes	learned	this	
discrimination	equally	quickly	within	28	days.	The	red	line	shows	50%	first	choice	accuracy	
(the	average	percent	per	day	to	choose	the	correct	cue	first).	50%	represents	chance	level.	
The	green	line	shows	the	learning	criterion	of	80%	first	choice	accuracy.	(B)	Representative	
track	plots	from	each	genotype	during	the	probe	trial.	(C)	Probe	trial	24	hours	after	
discrimination	learning	on	day	28.	The	left	hand	graph	shows	the	quadrant	entries	for	both	
the	correct	and	incorrect	quadrants	for	HETs	and	WT;	the	right	hand	graph	shows	the	same	
data	for	the	cue	proximity	zones.	Both	genotypes	had	significantly	less	entries	to	the	incorrect	
cue	zone	than	the	correct	one	(p<0.001).	Error	bars	show	SEM.	 	
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Figure	4.10:	Individual	data	shown	with	a	regression	line	for	each	mouse	during	the	
discrimination	learning	stage.	The	average	of	the	slopes	of	the	HDHQ111+/-	group	(HET)	was	not	
different	to	the	littermate	control	group	(WT)	(p>0.05).	(A)	The	regression	lines	of	the	8	
individual	HET	mice	and	(B)	the	regression	lines	of	the	6	WT	mice.	Each	colour	represents	one	
mouse.	 	
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4.3.2.2	Reversal	Learning	
The	cue	association	was	reversed	once	discrimination	learning	was	complete.	
The	mice	initially	persisted	at	the	formerly	correct	cue	for	about	four	days,	at	
which	point	they	reached	chance	performance	(Figure	4.11A).	They	slowly	
learned	the	new	association	(ANOVA	effect	of	day,	F(26,312)=12.2,	p<0.001,	
partial	eta	squared=	0.50);	however,	testing	was	stopped	at	just	under	80%	
first	choice	accuracy	after	27	days	of	testing	(Figure	4.11A).	It	was	expected	
that	the	mice	would	learn	the	reversal	faster	than	the	initial	discrimination,	
and	when	this	did	not	occur,	due	to	time	and	cost	restraints,	testing	was	
stopped.	There	was	no	difference	between	genotypes	(main	effect	genotype,	
F(1,12)<1,	partial	eta	squared=	0.00).	As	can	be	seen	from	the	individual	data	
(Figure	4.12),	there	was	also	no	difference	in	the	rate	of	learning	between	
HDHQ111+/-	and	WT	mice	(t=	1.3,	df=	12,	p>0.05,	Cohen’s	d=	0.36).	A	sample	size	
of	246	would	be	needed	to	show	a	significant	difference	in	rate	of	learning.	
The	first	four	days	of	reversal	looked	as	though	there	might	be	a	small	trend	
where	HDHQ111+/-	mice	took	slightly	longer	to	reach	chance	performance,	but	
Figure	4.11C	shows	there	is	no	difference	in	the	days	to	reach	chance	between	
the	genotypes	(t=	0.95,	df=	12,	p>0.05,	Cohen’s	d=	0.26).	Figure	4.11B	shows	
that	the	mice	of	both	genotypes	were	repeatedly	visiting	the	formerly	correct	
cue	during	the	first	day	of	reversal	learning,	as	expected.	
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Figure	4.11:	The	HDHQ111+/-	(HET)	mouse	is	equally	fast	at	reversal	learning	as	the	littermate	
controls	(WT).	(A)	Reversal	learning	was	conducted	for	27	days.	The	reversal	stage	consisted	
of	reversing	the	cue	and	platform	association	previously	established	at	the	discrimination	
stage.	The	red	line	shows	50%	first	choice	accuracy	(the	average	percent	per	day	to	choose	
the	correct	cue	first).	50%	represents	chance	level.	The	green	line	shows	the	learning	criterion	
of	80%	first	choice	accuracy.	(B)	Representative	track	plots	from	each	genotype	during	the	
first	day	of	reversal	learning.	(C)	The	average	days	for	each	genotype	to	reach	chance	
performance.	Error	bars	show	SEM.	 	
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Figure	4.12:	The	Individual	data	shown	with	a	regression	line	for	each	mouse	during	the	
reversal	learning	stage.	The	average	of	the	slopes	of	the	HDHQ111+/-	group	(HET)	was	not	
different	to	the	littermate	control	group	(WT)	(p>0.05).	(A)	The	regression	lines	of	the	8	
individual	HET	mice	and	(B)	the	regression	lines	of	the	6	WT	mice.	Each	colour	represents	one	
mouse.	
	
A	range	of	strategies	were	investigated	that	the	mice	could	have	tried	to	use	
to	locate	the	platform	during	the	reversal	stage	of	the	task,	other	than	cue	
identity.	A	few	mice	were	biased	towards	either	the	left	or	right	side	of	the	
barrier	(Figure	4.13A)	but	there	is	no	pattern	indicating	the	use	of	a	win-stay	
strategy	by	visiting	the	location	correct	on	the	former	trial	(Figure	4.13B).	To	
assess	if	there	was	a	difference	in	the	decision	making	between	the	genotypes	
the	number	of	entries	into	the	correct	or	incorrect	platform	were	compared	
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during	reversal	learning.	Figure	4.14	shows	a	rapid	drop	in	the	number	of	
entries	made	to	the	incorrect	quadrant	(repeated	measures	ANOVA,	main	
effect	of	day:	F(26,312)=37.5,	P<0.001,	partial	eta	squared=	0.76).	There	is	no	
genotype	difference	in	the	number	of	entries	made	to	either	the	correct	
(repeated	measures	ANOVA,	main	effect	of	genotype:	F(1,12)<1,	partial	eta	
squared=	0.00)	or	incorrect	(main	effect	of	genotype:	F(1,12)<1,	partial	eta	
squared=	0.00)	quadrants.	
	
Figure	4.13:	Alternative	strategies	used	by	both	HDHQ111+/-	(HET)	and	control	(WT)	to	attempt	
locating	the	platform	during	the	reversal	stage.	The	average	percent	over	8	trials	for	each	
day	is	plotted	for	the	individual	subject.	(A)	Side	preference:	the	percent	that	left	was	chosen	
first	at	any	given	trial.	Points	near	100%	or	0%	indicate	preference	for	one	side.	(B)	Win-stay	
analysis:	the	percent	that	the	chosen	side	was	the	previously	correct	side.	
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Figure	4.14:	HDHQ111+/-	(HET)	and	control	(WT)	mice	show	no	difference	in	indecision	in	cue	
choice.	This	was	measured	by	the	number	of	entries	into	the	quadrant	with	the	correct	and	
incorrect	cues	during	reversal	learning.	Fit	line	parameters:	Correct	HET:	y	=	2.3867x-0.053,	R²	=	
0.38126;	Correct	WT:	y	=	2.538x-0.079,	R²	=	0.47722;	Incorrect	HET:	y	=	6.089x-0.555,	R²	=	
0.89373;	Incorrect	WT:	y	=	5.0659x-0.49,	R²	=	0.831.	Error	bars	show	SEM.	
	
4.4	Discussion	
This	chapter	utilised	the	water	maze	to	assess	spatial	memory	and	reversal	
learning	in	the	HDHQ111+/-	mouse.	As	a	pre-requisite,	all	mice	had	to	pass	the	
visual	platform	stage,	where	the	platform	is	clearly	marked	with	a	black	and	
white	striped	marker.	All	mice	could	locate	the	platform	using	direct	swim	
paths	after	one	day	of	training	(Figure	4.4);	showing	that	mice	have	no	visual	
impairments.	
The	spatial	learning	task	showed	that	both	genotypes	could	find	the	hidden	
platform	equally	quickly	using	only	the	extra-maze	cues	to	locate	the	platform	
location	in	space	(Figure	4.6).	As	there	was	no	genotype	difference	in	swim	
	138	
speed,	it	can	be	assumed	that	there	are	no	motor	impairments	which	could	
interfere	with	measurements	of	cognition	(Figure	4.5).	Spatial	re-location	
learning	measures	the	ability	for	the	mice	to	learn	a	new	platform	location	
when	the	previous	learned	location	is	no	longer	rewarded.	This	is	a	measure	of	
behavioural	flexibility,	as	the	mice	must	learn	to	inhibit	swimming	to	the	old	
platform	location	to	search	for	the	new	one.	Both	genotypes	also	learned	the	
spatial	re-location	equally	quickly,	indicating	that	the	HDHQ111+/-	mouse	is	not	
impaired	in	spatial	learning	in	the	water	maze	(Figure	4.7).	This	contrasts	with	
the	HDH(CAG)150	and	R6/2	mouse	which	showed	increased	distance	to	find	both	
the	initial	platform	location,	and	the	platform	during	spatial	re-location	
(Brooks	et	al.,	2012b,	Lione	et	al.,	1999,	Murphy	et	al.,	2000).	
Moving	from	hippocampal	to	frontal	cortex	mediated	tasks,	we	next	tested	
the	2-choice	discrimination	reversal	learning	in	the	HDHQ111+/-	mouse.	Both	
genotypes	learned	the	simple	2-choice	discrimination	equally	quickly	within	28	
days	(Figure	4.9).	Learning	of	the	initial	discrimination	took	many	more	trials	
than	recorded	in	literature	to	reach	the	same	criterion;	Bannerman	et	al.	
(2012)	showed	that	WT	C57BL6	mice	were	able	to	learn	between	two	cues	in	
the	water	maze	within	144	trials,	compared	to	the	mice	in	this	study,	which	
took	224.	Differences	here	could	be	due	to	the	experimental	set	up,	where	
Bannerman’s	group	used	cues	sitting	on	poles	above	the	water’s	surface,	
rather	than	hanging	cues.	The	poles	and	close	vicinity	of	Bannerman’s	cues	to	
the	platform	may	be	able	to	create	a	stronger	association	between	the	
platform	and	cue,	than	a	cue	hanging	above	the	platform.	Upon	reversal	of	the	
stimuli,	there	was	no	genotype	difference	in	the	days	to	reach	chance	level	
performance	(or	the	unlearning	of	the	previously	learned	S-R	contingency)	
indicating	that	the	HDHQ111+/-	mice	did	not	persevere	at	the	old	stimulus	
(Figure	4.11).	This	is	unlike	the	literature	which	shows	reversal	learning	
impairments	in	both	BACHD	mice	and	HD	patients	(Lawrence	et	al.,	1999,	
Farrar	et	al.,	2014).	Both	genotypes	also	learned	the	new	discrimination	at	the	
same	rate	(Figure	4.12).	
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Differences	in	our	HDHQ111+/-	model	to	other	HD	mouse	models	mentioned	
above,	and	to	patient	data,	indicate	that	at	this	age	and	using	the	water	maze	
protocol,	HDHQ111+/-	mice	do	not	show	the	typical	spatial	or	behavioural	
flexibility	impairments	common	in	HD.		
There	has	been	some	criticism	for	using	the	water	maze	in	mice,	including	
increased	levels	of	stress	due	to	swimming.	It	is	possible	for	stress	to	alter	
behaviour	(Harrison	et	al.,	2009),	perhaps	making	the	task	less	sensitive	to	
finding	a	genotype	difference.	As	mice	originate	from	arid	habitats,	swimming	
is	a	behaviour	that	they	can	engage	in	when	necessary,	but	they	do	not	enjoy	
it.	This	is	in	contrast	to	rats,	which	are	much	more	comfortable	with	water,	
and	will	even	dive	under	the	surface,	which	mice	do	not.	Harrison	et	al.	(2009)	
have	measured	plasma	corticosterone	levels	in	C57/BL6J	mice	(the	same	strain	
as	the	HDHQ111+/-	background)	after	testing	in	the	water	maze.	Corticosterone	
is	released	in	response	to	stressful	stimuli.	They	observed	a	negative	
correlation	in	task	performance	with	increasing	corticosterone	levels.	In	
comparison,	rats	show	a	robust	increase	in	corticosterone	on	the	first	day	of	
testing,	which	attenuates	with	testing	progression	over	5	days	(Aguilar-Valles	
et	al.,	2005).	This	indicates	that	the	experimental	procedure	is	stressful	
enough	to	produce	motivation	to	escape,	but	is	not	as	stressful	in	general	as	
for	mice.	As	stress	can	influence	learning	and	memory,	it	was	important	to	
make	sure	that	our	HDHQ111+/-	mice	do	not	show	an	anxious	phenotype	before	
testing	in	the	water	maze.	Past	work	from	the	Lambert/Langston	laboratory	
reported	that	although	homozygous	mice	showed	an	increase	freezing	
response	in	the	activity	box,	heterozygous	mice	did	not	differ	from	WT	
(Mitchell,	2012).	
In	summary,	this	chapter	shows	that	the	HDHQ111+/-	mice	are	not	impaired	in	
spatial	learning	or	reversal	learning	when	tested	in	the	water	maze.	However,	
other	measures	of	behavioural	flexibility	which	are	impaired	in	HD,	like	
attentional	set-shifting	(see	section	1.4.1),	may	still	be	good	candidates	for	
treatment	with	Org49209.	 	
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Chapter	5	
	
Inhibition	of	the	mPFC	Impairs	
Attentional	Set-Shifting:	Can	This	
be	Ameliorated	by	Org49209?	
	
	
	
Illustration	by	C.	Brazaitis	
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5.1	Introduction	
Due	to	the	hypothesised	cognitive	enhancing	potential	of	Org49209	through	
its	modulation	of	the	NMDA	receptor	(see	section	1.6.5),	this	chapter	sets	out	
to	explore	this	potential	in	further	aspects	of	executive	control	through	an	
archetypal	test	of	behavioural	flexibility-	the	attentional	set-shifting	task	(see	
section	1.4.1).		
NMDA	receptors	play	a	major	role	in	set-shifting	(see	section	1.4.2)	and	HD	
patients	have	impaired	set-shifting	ability,	likely	due	to	disruption	to	the	
frontal	cortex	and/or	corticostriatal	loops	(see	section	1.4.3).	To	date,	there	
have	been	no	convincing	reports	of	set-shifting	impairments	in	rat	or	mice	HD	
models.	Therefore,	the	approach	taken	here	was	to	test	a	group	of	rats,	in	
which	impaired	set-shifting	ability	had	been	demonstrated,	to	test	the	
hypothesis	that	Org49209	could	ameliorate	the	deficit.	The	set-shifting	
impairment	had	been	induced	by	inactivation	of	the	medial	prefrontal	cortex	
(mPFC)	and	confirmed	behaviourally	by	A.	Whyte.	The	same	rats	were	then	
tested	with	Org49209	and	vehicle.	This	chapter	does	not	aim	to	validate	mPFC	
inactivation	as	a	model	for	HD,	but	rather,	aims	to	investigate	an	alternative	
method	for	Org49209	application	in	ameliorating	cognitive	deficits	(which	may	
have	a	future	application	to	HD).	
5.1.1	DREADDs	
The	mPFC	was	inactivated	using	DREADDs	(Designer	Receptors	Exclusively	
Activated	by	Designer	Drugs),	which	are	G-protein	coupled	receptors	(GPCRs)	
that	have	been	mutated	to	no	longer	be	targets	for	their	endogenous	ligands,	
and	instead,	are	activated	solely	by	a	synthetic	ligand.	This	ligand	is	otherwise	
completely	inert.	Strader	et	al.	(1991)	mutated	the	first	receptor	to	be	
exclusively	activated	by	a	synthetic	ligand;	the	first	use	of	this	technology	to	
attempt	to	control	cell	signalling	was	published	by	Coward	et	al.	(1998).	The	
DREADDs	used	in	this	experiment	were	developed	by	Armbruster	et	al.	(2007)	
using	muscarinic	acetylcholine	receptors	(mAChRs).	The	authors	developed	
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these	DREADDs	specifically	to	reduce	the	prevalence	of	synthetic	ligand	
binding	to	native	receptors,	which	previously	limited	their	application	in	vivo.	
DREADDs	are	available	for	the	three	major	GPCR	pathways;	Gs,	Gi,	and	Gq.	
DREADDs	have	a	large	variety	of	uses,	such	as	in	developmental	studies	of	
tissue	growth	and	engineering,	or	in	excitable	cells	of	the	heart,	where	they	
can	be	used	to	control	heart	rate	(Conklin	et	al.,	2008).	For	this	thesis,	the	
most	exciting	application	is	the	ability	to	change	behaviour	by	targeting	
specific	cell	types	in	key	brain	areas.	Just	as	Gs	and	Gi	pathway	stimulation	can	
increase	and	decrease	heart	rate,	Gq	and	Gi	can	excite	or	silence	neuronal	
cells,	respectively.	A	viral	vector	allows	for	the	expression	of	the	designer	
receptors	in	the	target	cells.	Specific	cell	types	are	targeted	through	the	use	of	
promotor	regions	that	are	used	in	those	cell	types.	This	experiment	uses	
DREADDs	which	target	glutamatergic	cortical	pyramidal	cells	using	the	CamKII	
promotor.	The	DREADD	is	the	inhibitory	hM4Di	receptor	which	is	a	Gi-GPCR.	
This	GPCR	causes	temporary	neuronal	silencing	via	a	sustained	membrane	
hyperpolarisation	through	decreased	cyclic	AMP	(cAMP)	signalling	and	
increased	activation	of	inward	rectifying	potassium	channels	(Armbruster	et	
al.,	2007,	Rogan	and	Roth,	2011).	Various	viruses	can	be	used	to	administer	
the	DREADD;	here,	adeno-associated	virus	5	(AAV5)	was	used	due	to	its	
relative	low	anatomical	spread,	to	keep	expression	localised	around	the	
injection	sites.	The	synthetic	ligand	used	for	activation	of	the	DREADDs	is	
clozapine-N-oxide	(CNO).	
5.1.2	Study	Aims	
Using	the	inhibitory	hM4Di	DREADDs	in	the	mPFC	of	rats,	A.	Whyte	has	shown	
that	CNO	caused	an	increase	in	TTC	in	the	ED	stage	of	the	task	compared	to	
control	(Figure	5.1).	This	study	builds	on	A.	Whyte’s	findings,	using	the	same	
experimental	cohort	and	experimental	design,	to	assess	the	effect	of	
Org49209	on	set-shifting	behaviour	at	the	ED	stage.	
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Figure	5.1:	Results	from	the	ID/ED	task	(SD,	simple	discrimination;	CD,	compound	
discrimination,	REV1,	reversal	of	CD;	ID,	intradimensional	acquisition;	REV2,	reversal	of	ID;	ED,	
extradimensional	acquisition;	REV3,	reversal	of	ED).	Rats	(N=12)	were	tested	in	a	within-
subjects	design	where	they	received	both	CNO	or	vehicle.	CNO	activation	of	the	mPFC	
DREADDs	resulted	in	a	set-shifting	deficit	(greater	trials	to	criterion	at	the	ED	stage,	p<0.05).	
Data	collected	by	A.	Whyte.	
5.2	Methods	
5.2.1	Subjects	
The	same	twelve	male	Lister	Hooded	rats	(Charles	River,	UK),	infected	with	
inhibitory	DREADDs,	that	had	previously	been	tested	by	A.	Whyte,	were	used	
in	this	study.	Rats	were	pair-housed	throughout	the	study	in	standard	housing	
conditions.	Prior	to	this	study,	the	rats	had	been	tested	in	the	standard	7-stage	
ASST	or	a	variation	of	the	standard	task	9	times.	Surgery	and	previous	testing	
was	performed	by	D.	Tait	and	A.	Whyte,	respectively.	Surgery	used	the	Paxinos	
and	Watson	(1998)	co-ordinate	system	(	1:	Anterior/Posterior	+	3.9,	
Medial/Lateral	±	0.5,	Dorsal/Ventral	-3.1;	2:	Anterior/Posterior	+	2.9,	
Medial/Lateral	±	0.5,	Dorsal/Ventral	-3.1)	to	administer	bilateral	
microinjections	on	1	μl	AAV5-CamKII-hM4Di.	At	the	time	of	testing	rats	were	
approximately	7-9	months	old,	weighing	448-518	g.	
* 
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5.2.2	Apparatus	
Box:	The	testing	was	conducted	in	an	in-house	modified	plastic	housing-cage	
(69.5	x	40.5	x	18.5	cm)	with	two	separate	compartments	taking	up	one	third	of	
the	box	(Figure	5.2).	The	compartments	were	separated	from	the	rest	of	the	
testing	box	using	a	removable	Plexiglas	panel.	A	further,	smaller,	panel	was	
used	to	be	able	to	close	one	compartment	at	a	time.	The	bowls	were	placed	in	
two	different	compartments	in	the	testing	box.	The	holding	area	of	the	box	
contained	sawdust	and	a	bowl	of	water.	
Bowls:	The	digging	bowls	were	ceramic	pet	food	bowls	(8	cm	diameter,	4	cm	
deep,	Mason	Cash,	Liverpool,	UK).	
Media	and	odours:	Spices	and	herbs	were	bought	from	local	stores,	usually	
Tesco	own	brand,	or	Schwarz	brand.	The	fine	shavings	were	produced	in-
house	from	coarse	shavings	(Golden	Flakes,	DBM),	using	a	food	processor	until	
they	are	fine	enough	using	visual	inspection.	Additionally,	sand	(Children’s	Play	
Sand	from	Argos),	grit	(Cage	Proud	Mixed	Bird	Grit),	coarse	tea	(Darjeeling,	
Waitrose	own	brand),	and	the	fine	tea	(local	store	bought)	were	used	as	
media.	Odour	was	added	to	the	digging	media	until	a	difference	in	smell	was	
clearly	discernable.	All	media	and	odours	used	are	listed	in	Table	5.1.	
Reward:	One	third	of	a	Honey	loop	(Kellogg’s)	was	used	as	a	reward	per	trial.	
Data	was	recorded	on	a	laptop	in	software	developed	by	A.	Whyte.	
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Table	5.1:	The	media	and	odours	used	in	the	7-stage	ASST.	
Medium	 M1	 M2	 M3	 M4	 M5	 M6	
	
Coarse	
tea	
Fine	
tea	
Gravel	 Sand	
Coarse	
wood	
shavings	
Fine	
wood	
shavings	
Odour	 O1	 O2	 O3	 O4	 O5	 O6	
	 Paprika	 Sage	 Cinnamon	 Ginger	 Turmeric	 Cloves	
	
	
	
	
Figure	5.2:	The	ASST	testing	box.	One	third	of	the	box	was	divided	with	a	removable	Plexiglas	
panel.	This	section	was	again	split	in	two	sections,	in	which	each	bowl	was	placed.	The	rat	
must	choose	to	dig	in	one	of	the	two	bowls	for	a	food	reward.	Image	taken	by	A.	Chase.		 	
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5.2.3	Behaviour	
The	effect	of	Org49209	was	tested	in	the	standard	7-stage	ASST,	as	previous	
results	have	shown	that	rats	with	active	DREADDs	were	impaired	at	the	ED	
stage	(see	Figure	5.1).	
5.2.3.1	7-Stage	ASST	with	CNO	and	Org49209	
Due	to	previous	testing,	rats	were	already	on	mild	food	control	prior	to	this	
study,	which	was	maintained	at	15-20	g	per	day.	Water	was	available	ad	
libitum.	As	rats	were	already	trained	to	the	task	(digging	for	reward,	exposure	
to	testing	stimuli,	and	habituation	to	apparatus)	due	to	prior	testing,	it	was	
not	necessary	to	repeat	it	for	this	experiment.	A.	Whyte	tested	half	of	the	rats,	
at	the	same	time	and	the	same	room,	using	the	same	experimental	criteria.	
Org49209	was	freshly	prepared	each	day,	where	the	suspension	was	sonicated	
for	30	minutes	prior	to	use.	CNO	was	suspended	in	a	‘jelly’	mix	(60ml,	
Robinsons	concentrate;	6	g,	Dr.	Oetker	Gelatine	Sachet;	stirred	for	15	
minutes).	30	minutes	before	testing,	rats	received	either	10mg/kg	Org49209	
or	vehicle	(10%	HPBCD	in	saline)	i.p.	injection,	followed	immediately	by	a	jelly	
containing	10mg/kg	CNO.	To	ensure	CNO	activated	the	DREADDs	for	the	
duration	of	the	task,	a	concentration	of	10	mg/kg	was	used,	which	falls	in	the	
high	end	of	the	effective	range	(Roth,	2016).	A.	Whyte	previously	compared	
the	behavioural	effects	in	the	7-stage	task	of	CNO	administration,	showing	no	
significant	differences	between	i.p.	injections	and	oral	administration.	Others	
have	also	found	oral	administration	of	CNO	to	be	successful	(Jain	et	al.,	2013).	
Org49209	was	still	shown	to	be	present	in	mouse	plasma	3	hours	after	i.p.	
administration	(Paul	et	al.,	2013),	which	should	allow	sufficient	time	for	task	
completion.	
Each	trial	was	initiated	by	raising	the	Perspex	panel	which	allowed	the	rats	to	
access	the	compartments	containing	the	food	bowls.	A	dig	was	recorded	if	
more	than	two	paws	are	seen	and/or	if	the	nose	is	buried	deep	enough	that	
the	food	reward	could	be	reached.	A	correct	or	incorrect	choice	is	recorded,	as	
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well	as	whether	the	rat	had	investigated	both	bowls	before	making	a	choice.	A	
choice	which	is	made	correctly	after	investigating	both	bowls	makes	a	stronger	
argument	for	a	learned	discrimination,	as	the	incorrect	bowl	was	rejected.	This	
means	that	a	rat	is	less	likely	to	have	passed	the	stage	by	choosing	the	correct	
bowl	by	chance.	The	first	four	trials	of	each	stage	were	exploratory	trials,	
where	the	rat	is	allowed	to	retrieve	the	food	reward	from	the	correct	bowl	
even	if	an	incorrect	choice	was	made.	If	an	incorrect	choice	was	made	after	
the	first	four	trials,	the	barrier	was	lowered	to	the	chamber	containing	the	
correct	bowl	to	prevent	the	rat	from	correcting	the	error.	Rats	had	to	reach	
the	criterion	of	6	six	consecutive	correct	responses,	which	is	above	chance	
performance	(if	each	response	has	probability	of	0.5,	p=0.0156).	The	stimuli	
were	always	presented	in	pairs,	where	M1/M2	was	presented	with	O1/O2,	
M3/M4	was	presented	with	O3/O4	and	M5/M6	was	presented	with	O5/O6.	
The	stimuli	used	were	counterbalanced	with	regard	to	a	set-shift	from	odour	
to	medium,	and	from	the	odd	to	even	stimuli.	The	order	the	stimulus	pairs	
were	presented	in	was	also	counterbalanced.	
The	task	consisted	of	7	stages:	
Simple	(SD):	Either	odour	in	cage	bedding,	or	medium	with	no	added	odour.	
Compound	(CD):	Both	odour	and	medium	are	present,	but	only	one	dimension	
is	relevant.	
Reversal	(REV1):	Reversal	of	the	CD.	Previously	rewarded	stimulus	is	now	
unrewarded,	previously	unrewarded	stimuli	is	now	rewarded.	
Intradimensional	acquisition	(ID):	Both	medium	and	odour	are	changed,	but	
the	relevant	dimension	stays	the	same.	
Reversal	(REV2):	Reversal	of	the	ID.	Previously	rewarded	stimulus	is	now	
unrewarded,	previously	unrewarded	stimuli	is	now	rewarded.	
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Extradimensional	shift	acquisition	(ED):	Both	odour	and	medium	are	changed,	
and	relevant	dimension	is	switched.	
Reversal	(REV3):	Reversal	of	the	ED.	Previously	rewarded	stimulus	is	now	
unrewarded,	previously	unrewarded	stimulus	is	now	rewarded.	
5.2.3.2	Data	Analysis	
Data	were	collected	in	a	csv	file	from	the	software,	and	analysed	in	Microsoft	
Excel.	The	number	of	trials	to	criterion	for	each	stage	were	averaged	for	
vehicle	and	drug	groups.	The	data	were	plotted	in	a	histogram	using	GraphPad	
Prism	5	with	SEM.	A	two-way	ANOVA	was	used	to	assess	the	effect	of	
Org49209,	and	to	compare	the	CNO	data	with	previously	collected	control	
data	(from	A.	Whyte,	shown	in	Figure	5.1).	
5.2.4	Histology	
Once	behavioural	testing	was	complete,	rats	were	deeply	anaesthetised	with	
pentobarbital	(0.8ml,	i.p.;	Pharmasol,	Ltd,	UK)	and	perfused	intracardially	with	
4%	paraformaldehyde	in	0.1	M	phosphate	buffer	(PB).	The	whole	brain	was	
dissected	out	and	stored	in	a	20%	sucrose	solution	for	24	hours	at	4°C.	The	
cerebellum	and	brainstem	were	removed,	washed	with	distilled	water,	dried,	
placed	in	a	well	of	a	24-well	plate,	covered	in	egg	yolk	and	placed	in	a	
formaldehyde	bath	for	72	hours.	Brains	were	then	sectioned	at	50	µm	on	a	
freezing	stage	microtome	(Jung	Histoslide	2000,	Reichert-Jung,	Cambridge	
Instruments	GmbH).	The	sections	were	stored	in	glycerol	solution	at	-20o	C	
until	use.	D.	Tait	and	A.	Whyte	assisted	with	perfusions.	
The	DREADD	contains	a	fluorescent	reporter,	mCherry,	which	can	be	used	to	
verify	receptor	expression	and	location.	Every	4th	section	of	the	frontal	cortex	
was	used	for	mCherry	immunoreactivity	detection.	The	whole	
immunohistochemistry	protocol	described	here	was	performed	at	room	
temperature.	Sections	were	placed	in	9-hole	netwells	and	petri	dishes	and	
washed	four	times	(5	minutes	each)	in	PBS	(158	M	NaCl	in	0.2	M	PB)	on	a	
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shaker.	Next	the	netwells	were	incubated	in	a	blocking	solution	(1:5	normal	
goat	serum,	1:100	10%	Triton,	in	PBS)	on	the	shaker	for	one	hour.	Sections	
were	again	washed	as	above,	and	the	placed	in	histology	pots	with	5	ml	of	the	
primary	antibody	(rabbit	anti-mCherry	1:2000,	Abcam)	in	antibody	diluting	
solution	(ADS;	1:100	normal	goat	serum,	1:100	10%	triton,	in	PBS)	overnight.	
Sections	were	again	washed	(as	above),	and	incubated	in	5	ml	biotinylated	
secondary	antibody	(goat	anti-rabbit,	1:500,	Vectorlabs,	in	ADS)	for	one	hour.	
After	a	fourth	wash,	the	sections	were	incubated	in	5	ml	of	biotinylation	
solution	(Vectastain	ABC	KIT,	Vectorlabs)	and	after	an	hour,	were	washed	for	a	
fifth	time.	Finally,	sections	were	stained	with	3,3’-Diaminobenzidine	(DAB;	one	
tablet	per	20	ml,	Sigma,	in	distilled	H20)	until	landmark	anatomical	structures	
were	visible,	followed	by	a	final	wash.	Sections	were	stored	at	4oC	until	they	
were	mounted	on	glass	slides	and	cover-slipped	with	DPX	mountant.	A.	Whyte	
assisted	with	immunohistochemistry.	
Frontal	cortex	sections	from	three	brains	were	used	for	fluorescent	mCherry	
detection	in	order	to	compare	mCherry	expression	in	the	cell	bodies	and	
axons.	The	procedure	was	identical	to	the	above	DAB	immunoreactivity	
protocol,	except	that	after	the	primary	antibody,	the	sections	were	washed	
five	times	for	5	minutes,	incubated	in	the	secondary	antibody	(goat	anti-rabbit	
IgG	H&L,	Alexa	Flour	594,	Abcam)	for	one	hour,	and	covered	in	aluminium	foil.	
Sections	were	then	washed	three	times	for	5	minutes	in	PBS	and	mounted	on	
slides	with	Vectashield	anti-fade	mounting	medium	containing	4',6-diamidino-
2-phenylindole	(DAPI)	(Vectorlabs).	Finally,	slides	were	cover-slipped	and	
sealed	with	nail	polish.	
Sections	were	imaged	on	a	Zeiss	Axio	Imager	M2	using	Zen	software.	
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5.3	Results	
5.3.1	Histology	
DAB	staining	showed	DREADDs	were	present	in	all	brains.	
Immunofluorescence	showed	a	precise	and	punctate	spread	of	the	DREADDs	
in	the	mPFC	(Figure	5.3).	It	was	also	interesting	to	note	that	co-localisation	of	
DAPI,	a	nuclear	stain,	and	mCherry	was	seen	in	mPFC	regions	(Figure	5.3A);	
however,	in	projection	areas	of	the	mPFC	mCherry	was	also	present,	but	was	
not	co-localised	with	the	cell	bodies,	indicating	DREADDs	were	transported	
along	axons	to	mPFC	projection	sites,	as	shown	in	the	striatum	in	Figure	5.3B.	
The	histology	showed	no	indications	of	disruptions	caused	by	using	the	AAV	as	
a	vector.	
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Figure	5.3:	DREADDs	were	tagged	with	mCherry	to	visualise	viral	spread.	(A)	mCherry	(red)	
can	be	seen	in	the	mPFC	region.	The	cut	out	shows	co-localisation	of	mCherry	with	DAPI	(blue)	
to	show	DREADD	expression	at	the	cell	bodies.	(B)	mCherry	seen	in	the	striatum,	but	not	co-
localised	with	DAPI.	Schematics	from	Paxinos	and	Watson	(1998).	 	
Bregma	3.20	mm 
Bregma	1.70	mm 
A 
B 
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5.3.2	Standard	7-Stage	ASST	with	Org49209	
Org49209	had	no	effect	on	the	trials	to	criterion	in	the	standard	7-stage	ASST	
(main	effect	of	Drug,	F(1,70)<1.0,	p>0.05,	partial	eta	squared=0.01;	interaction,	
F(6,70)<1.0,	p>0.05,	partial	eta	squared=	0.07;	Figure	5.4A).	The	different	stages	
were	not	equal,	as	expected	(main	effect	of	stage	F(6,70)=5.04,	p<0.001,	partial	
eta	squared=	0.30);	however,	there	also	did	not	appear	to	be	an	ID/ED	
difference	(planned	contrast,	p>0.05).	
The	graph	seemed	to	indicate	that	the	previously	seen	impairment	at	the	ED	
stage	after	CNO	was	not	present.	To	confirm	this,	the	CNO	+	vehicle	was	
compared	directly	with	the	previously	acquired	control	data.	CNO-treated	rats	
required	more	TTC	than	the	controls	overall	(main	effect	of	Group:	
F(1,112)=11.33,	p<0.01,	partial	eta	squared=	0.09);	however	this	did	not	vary	by	
stage	(group	by	stage	interaction:	F(6,112)=	1.39,	p<0.05,	partial	eta	squared=	
0.07),	confirming	that	there	was	no	selective	impairment	at	the	ED	stage	(see	
Figure	5.4B).	Again,	as	expected,	different	stages	were	not	equal	(main	effect	
of	stage:	F(6,112)=14.04,	p<0.001,	partial	eta	squared=	0.43),	but	there	was	an	
ID/ED	difference	(planned	contrasts,	p<0.01).	
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Figure	5.4:	Org49209	does	not	have	an	effect	on	the	7-stage	ASST	for	rats	with	CNO-
activated	mPFC	DREADDs.	(A)	All	rats	were	given	10mg/kg	CNO	via	a	jelly	half	an	hour	before	
testing.	At	the	same	time,	they	also	received	Org49209	(n=6)	or	vehicle	(10%	HPBCD,	n=6)	via	
i.p.	injection.	There	was	no	difference	in	TTC	between	Org49209	and	vehicle	treated	rats	
(p>0.05).	(B)	Vehicle	treated	rats	(with	CNO)	were	compared	to	previous	data	of	control	jelly	
(i.e.	no	CNO).	There	was	no	difference	between	the	CNO	and	no	CNO	conditions	(p>0.05).	 	
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The	graphs	suggest	that	CNO	may	actually	increase	TTC	at	the	second	reversal	
stage;	however,	on	closer	examination	of	those	data	it	was	noted	that	these	
increased	values	are	due	to	two	very	high	values	(rat	4	&	6)	and	not	
representative	of	the	rat’s	performance	as	a	whole	(Table	5.2).	
	
Table	5.2:	TTC	for	each	rat	during	reversal	2.	CNO	is	present,	with	either	control	or	Org49209	
injections.	
Rat	 Condition	 TTC	Rev	2	
1	 Control	 12	
2	 Control	 20	
3	 Control	 14	
4	 Control	 50	
5	 Control	 31	
6	 Control	 57	
7	 Org49209	 10	
8	 Org49209	 12	
9	 Org49209	 9	
10	 Org49209	 21	
11	 Org49209	 23	
12	 Org49209	 44	
	
		
5.4	Discussion	
To	assess	the	expression	of	DREADDs,	mCherry	immunofluorescence	and	the	
nuclear	stain	DAPI	stain	were	used	to	show	co-localisation	of	the	DREADDs	
with	the	cell	bodies.	This	co-localisation	can	be	seen	in	the	mPFC	region	
(Figure	5.3A),	while	mCherry	in	the	absence	of	DAPI	co-localisation	in	non-
targeted	brain	areas	show	the	projections	from	the	target	area	(i.e.	striatum,	
Figure	5.3B).	This	can	be	due	to	the	axonal	transport	of	the	DREADD	receptors,	
which	has	been	shown	to	occur	after	around	4-9	weeks	post-infection	(Smith	
et	al.,	2016).	
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At	first	the	successful	use	of	Org49209	to	reverse	ED	deficits	caused	by	
activated	inhibitory-DREADDs	was	questioned	due	to	the	mechanism	of	action	
of	the	DREADDs.	If	glutamatergic	neurons	are	being	silenced	due	to	increased	
activation	of	inward	rectifying	potassium	channels,	would	a	PAM	of	the	NMDA	
receptor	be	able	to	overcome	the	consequences	of	this?	It	is	likely	that	due	to	
the	strong	hyperpolarisation,	Org49209	will	have	no	direct	effect	on	the	
DREADD	activated	cells,	as	the	NMDA	receptor	requires	membrane	
depolarisation	for	activation.	However,	Org49209	may	be	able	to	have	an	
effect	for	two	reasons.	Firstly,	DREADDs	are	not	able	to	infect	all	target	
neurons;	Mahler	et	al.	(2014)	showed	a	60%	suppression	of	activity	in	ventral	
pallidum,	with	79%	of	cells	affected.	This	would	suggest	that	there	is	room	for	
improvement	with	Org49209	of	the	remaining	neurons.	Smith	et	al.	(2016)	
also	suggest	that	incomplete	activity	suppression/activation	from	DREADDs	
may	be	a	more	realistic	manipulation	as	the	changes	are	made	by	the	neuron’s	
own	downstream	signalling-	the	same	mechanisms	that	are	used	if	
endogenous	receptors	were	activated	by	their	natural	ligands.	Secondly,	the	
DREADD	is	expressed	in	a	specifically	targeted	brain	area,	whereas	Org49209	
is	given	systemically.	This	allows	for	Org49209	to	enhance	NMDA	receptor	
function	in	possible	downstream	regions	where	DREADD	activation	has	no	
direct	influence.	On	the	other	hand,	even	though	NMDA	receptors	mediate	
excitatory	post	synaptic	potentials	(EPSPs),	NMDA	receptor	antagonists	have	
been	shown	to	cause	cortical	excitation	in	humans	and	rodents	in	vivo	(Lahti	
et	al.,	1995,	Jackson	et	al.,	2004,	Suzuki	et	al.,	2002).	Homayoun	and	
Moghaddam	(2007)	intriguingly	found	that	NMDA	receptor	hypofunction	
could	increase	pyramidal	neuronal	firing.	They	propose	that	this	mechanism	is	
through	the	disinhibition	of	the	pyramidal	neurons	by	the	decreased	activity	of	
GABA-ergic	interneurons.	Therefore,	it	is	possible	that	increased	NMDA	
receptor	function	actually	increases	the	inhibitory	control	of	GABA-ergic	
neurons	on	pyramidal	cells,	which	would	result	in	further	silencing	of	the	
pyramidal	neurons.	
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One	of	the	issues	in	this	study	is	that	CNO	did	not	result	in	the	impairments	at	
the	ED	stage	of	the	task	that	had	been	seen	in	the	same	rats	in	previous	tests.	
Therefore,	we	cannot	confidently	say	whether	Org49209	can	or	cannot	
recover	DREADD	induced	set-shifting	impairments.	There	may	be	a	number	of	
reasons	for	this	lack	of	CNO	effect,	which	are	explored	below.	
A	possible	disadvantage	of	using	DREADDs	is	that	it	cannot	be	excluded	that	
insertion	of	additional	synthetic	receptors	on	the	neuronal	membranes	would	
not	interfere	with	the	remaining	receptors	on	the	cell,	or	cause	signalling	
changes.	Indeed,	early	DREADDs,	or	Receptors	Activates	Solely	by	Synthetic	
Ligands	(RASSLs)	did	show	constitutive	activity	(activation	in	the	absence	of	
the	synthetic	ligand)	(Conklin	et	al.,	2008);	however,	Roth	(2016)	claim	that	
this	has	not	yet	been	observed	with	the	known	and	now	widely	used	
DREADDs.	As	DREADDs	can	have	a	more	widespread	effect	than	simply	
increasing	or	decreasing	the	activity	of	the	target	neurons,	Smith	et	al.	(2016)	
also	suggest	that	the	physiological	impact	of	the	DREADDs	should	be	
measured	in	the	brain,	either	through	electrical	recordings,	imaging	or	by	
staining	for	immunohistochemical	markers	of	activity	(e.g.	cFos).	Although	we	
investigated	cFos	expression	in	these	rats,	results	did	not	show	a	difference	in	
CNO	vs.	vehicle	treated	rats	in	the	mPFC.	However,	in	A.	Whyte’s	behavioural	
experiments,	there	was	a	very	clear	effect	of	CNO	on	set-shifting	behaviour.	
Although	cFos	has	been	used	successfully	to	show	physiological	changes	of	
hM4Di	DREADDs	before	(Michaelides	et	al.,	2013),	it	would	be	interesting	if	
the	other	methods	suggested	by	Smith	et	al.	would	reveal	any	physiological	
differences	consistent	with	the	behavioural	change.	Ideally,	we	would	have	
stained	for	mCherry	and	cFos	in	the	same	slices,	to	assess	if	the	neurons	
expressing	DREADDs	show	reduced	activity/cFos	expression.	
Other	possible	explanations	for	the	lack	of	a	CNO	effect	at	the	ED	stage	could	
be:	a	practice	effect	due	to	previously	performed	tasks,	or	the	repeated	
administration	of	CNO.	As	rats	were	tested	nine	times	previously	in	either	the	
7-stage	task,	or	a	related	task,	it	is	possible	that	they	could	have	improved	
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performance	over	time.	Similar	effects	due	to	repeated	testing	have	been	
seen	before,	improving	either	TTC	at	all	stages	(Xia,	2014)	or	the	reversal	
stages	(Chase,	2013).	However,	Tait	et	al.	(2014)	also	describe	that	that	they	
have	very	good	experience	with	re-testing	the	7-stage	task	up	to	9	times.	
Regarding	repeated	CNO	administration,	it	has	been	shown	that	GPCRs	are	
sensitive	to	desensitisation	and	subsequent	internalisation	(DeWire	et	al.,	
2007).	It	is	possible	that	repeated	DREADD	activation	through	CNO	
administration	during	the	repeated	testing	could	cause	this	desensitisation.	
Roth	(2016)	argues,	however,	that	this	tends	to	not	be	an	issue	unless	
DREADD	expression	is	very	low.	If	expression	is	sufficiently	high,	the	maximum	
CNO	response	can	be	achieved	without	full	receptor	occupancy;	and	more	
importantly,	if	some	receptors	are	internalised	or	inactive,	this	will	not	change	
the	maximal	response	(Roth,	2016).	An	example	of	successful	repeated	CNO	
administration	twice	daily	over	4	days	showed	a	robust	behavioural	effect	
throughout	(Roman	et	al.,	2016).	As	immunohistochemistry	showed	a	robust	
expression	of	DREADDs,	it	is	likely	that	repeated	CNO	administration	was	not	
the	cause	of	a	reduced	behavioural	phenotype.	
A.	Whyte’s	discovery	of	the	DREADD	induced	set-shifting	deficit	nevertheless	
shows	a	promising	model	for	testing	therapeutics	for	behavioural	flexibility.	To	
assess	the	effect	of	Org49209	in	this	model	in	the	future,	an	increased	sample	
size	would	be	advisable,	as	6	animals	per	group	were	not	enough	to	allow	for	
abnormally	high	scores	from	a	couple	of	rats.	Further,	if	running	a	fully	
controlled	study,	rather	than	a	pilot,	four	experimental	groups	would	have	
been	used:	CNO	±	Org49209	and	no-CNO/vehicle	±	Org49209.	The	pilot	used	
previous	data	that	demonstrated	the	behavioural	effect	of	CNO;	therefore,	
this	pilot	study	assumed	this	behavioural	effect	would	continue	to	be	present	
and	the	effect	of	Org49209	was	assessed	compared	to	the	vehicle	injection.	
The	no-CNO/vehicle	±	Org49209	condition	would	be	needed	in	a	full	study	to	
support	previous	data	for	the	CNO	behavioural	deficit,	as	well	as	assessing	if	
Org49209	has	any	effect	on	normally	behaving	rats.	The	animals	would	be	
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experimentally	naïve,	and	DREADD	activation	would	be	confirmed	through	
physiological	measurements	such	as	electrophysiological	slice	recordings.	
Indeed,	it	would	be	interesting	to	assess	Org49209	application	in	neurons	of	
DREADD	activated	slices,	to	answer	some	of	the	questions	about	the	suitability	
of	Org49209	as	a	treatment	for	DREADD	induced	behaviour.	 	
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Chapter	6	
	
General	Discussion	
	
	
“What	we	know	is	a	drop,	what	we	don't	know	is	an	ocean.”	―	Isaac	Newton	
	
	
	
Illustration	by	C.	Brazaitis	 	
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In	this	thesis,	I	have	reported	the	results	of	a	series	of	studies	investigating	the	
action	of	the	synthetic	steroid	Org49209	and	the	endogenous	neurosteroid,	
cerebrosterol,	on	the	NMDA	receptor.	The	studies	presented	in	this	thesis	can	
be	split	into	two	categories:	in	vitro	and	in	vivo	experiments.	We	first	set	out	
to	validate	the	mechanism	of	action	of	the	steroids	on	the	NMDA	receptor	in	
vitro,	before	attempting	to	assess	the	relevance	of	Org49209	in	vivo.	Chapter	2	
used	calcium	imaging	in	primary	cell	cultures	derived	from	mice	to	elucidate	
the	action	of	these	steroids	directly	on	the	receptor.	Moving	from	the	
molecular	to	the	functional	and	cognitive	level,	the	following	2	chapters	used	
behavioural	tasks	in	mice	with	a	genetic	mutation	modelling	HD:	the	‘novel	
place	recognition’	test	of	spatial	memory,	and	a	water	maze	test	of	spatial	
learning	and	a	form	of	spatial-reversal	(new	place)	learning	and	cue-reversal	
learning.	The	limitation	when	using	the	HD	mouse	model	was	the	restriction	to	
non-appetitive	(escape)	positive	reinforcement,	rather	than	using	an	
appetitive	(food	reward)	positive	reinforcement.	Therefore,	in	the	final	
experimental	chapter,	food-restricted	rats	were	used	in	the	attentional	set-
shifting	task.	This	task	includes	reversal	learning	but	also	measures	the	
formation	and	shifting	of	attentional	set,	which	are	impaired	in	HD	patients	
and	therefore,	might	reasonably	be	expected	to	be	amenable	to	‘treatment’	
with	the	steroid	compound.	The	range	of	techniques	and	model	systems	was	
intentionally	selected	to	be	broad	to	maximise	the	possibility	that	the	
functional	effects	of	Org49209	would	be	apparent.	As,	ultimately,	the	study	of	
Org49209	administration	in	rodent	models	of	disease	could	give	an	insight	
both	into	treatment	opportunities	and	disease	aetiology,	this	approach	is	an	
important	step	in	drug	discovery	and	the	study	of	neurological	disorders.		
Thus,	the	overall	goal,	and	the	potential	impact,	of	this	research	is	the	
identification	of	models	and	assays	sensitive	to	deficits	in	an	animal	model	in	
which	putative	treatments	could	be	validated.	In	particular,	the	identification	
a	potent	and	selective	PAM	of	the	NMDA	receptor	–	a	modulator	that	has	no	
effect	alone,	but	enhances	the	effect	of	the	endogenous	NMDA	ligand	–	opens	
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the	possibility	for	treatments	targeting	the	cognitive	deficits	seen	in	many	
neurodegenerative	diseases	and	psychiatric	disorders,	not	just	HD.	The	
dysfunction	of	the	NMDA	receptor	could	very	likely	under-pin	the	cognitive	
deficits	of	all	these	disorders.	As	NMDA	receptors	also	play	a	role	in	
excitotoxic	cell	death	when	over-activated	(Hardingham	and	Bading,	2010),	
the	identification	of	a	PAM	is	crucial,	so	as	to	limit	activation	outwith	
physiological	activity.	This	may	help	avoid	excitotoxicity	associated	with	
neurodegenerative	disease	progression	(Parsons	and	Raymond,	2014).	
Although	it	is	still	possible	that	PAMs	could	lead	to	NMDA	receptor	over-
activation,	it	is	less	likely	to	cause	harm	than	NMDA	receptor	agonists.	
These	cognitive	deficits	are	life-changing	impairments;	loss	of	cognitive	
abilities	required	for	everyday	functioning,	such	as	time	management	and	
organisation	of	thoughts	and	activities,	compromises	independence	for	
patients	and	reduces	life-quality	(Ghosh	and	Tabrizi,	2015).	This	puts	strain	on	
the	wellbeing	of	the	patients	themselves,	as	well	as	society	and	relatives.	
Finding	a	treatment	for	the	early-onset	cognitive	symptoms,	as	well	as	those	
accompanying	later	motor	symptoms,	would	result	in	a	large	unburdening	of	
society.	
In	Vitro	Studies	
Chaper	2	showed	that	both	cerebrosterol	and	Org49209	potentiate	NMDA-
evoked	responses	in	cultured	neurons.	This	is	consistent	with	data	from	HEK	
cells	(Paul	et	al.,	2013)	and	oocytes	(Lambert	laboratory	unpublished	
observations,	Chapter	1,	Table	1.1)	expressing	NMDA	receptors;	both	studies	
reported	an	increased	NMDA-evoked	current	with	application	of	both	
cerebrosterol	and	Org49209.	While	previous	work	showed	enhancement	in	
hippocampal	cultures	(Paul	et	al.,	2013),	I	have	demonstrated	the	same	effect	
in	cultured	cerebellar	granule	neurons	using	calcium	imaging	techniques	(see	
Chapter	2,	Figures	2.7	and	2.9).	As	cerebrosterol	is	produced	by	neurons	
(Ramirez	et	al.,	2008),	and	the	present	results	have	shown	that	it	is	also	able	
to	modulate	neuronal	NMDA	receptors,	it	is	possible	that	cerebrosterol	has	
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effects	outwith	the	role	of	a	modulator	of	cholesterol	homeostasis	in	the	
brain.	Although	the	enhanced	efficacy	of	Org49230	compared	to	the	
unsulphated	Org49209	has	been	shown	in	oocytes	(unpublished	data	from	the	
Lambert	laboratory,	see	Chapter	1,	Table	1.1),	I	have	shown	here	that	this	is	
also	the	case	in	neurons	at	the	concentrations	used	(see	Chapter	2,	Figure	
2.8).	I	also	demonstrated	that	the	endogenous	cerebrosterol	sulphate	has	a	
similar	potentiating	effect	on	the	NMDA	receptor	as	Org49230	(see	Chapter	2,	
Figure	2.10).	Unlike	the	known	NMDA	receptor	PAM	pregnenolone	sulphate,	
which	only	enhances	NMDA	receptor	activity	when	given	in	concentrations	
that	far	exceed	endogenous	levels	(Schumacher	et	al.,	2008),	cerebrosterol	is	
present	in	the	brain	in	concentrations	well	above	those	which	enhance	NMDA	
receptor	activation	(Lutjohann	et	al.,	1996).	As	SULT	enzymes	are	able	to	
sulphate	cerebrosterol	in	the	brain	(Fuda	et	al.,	2007),	the	enhanced	effect	of	
cerebrosterol	sulphate	compared	to	cerebrosterol	raises	the	exciting	
possibility	that	the	strength	of	NMDA	receptor	enhancement	is	modulated	by	
the	sulphation	and	desulphation	of	cerebrosterol.	Linsenbardt	et	al.	(2014)	
have	already	investigated	the	potential	binding	site	of	Org49209,	suggesting	a	
location	within	the	cell	membrane	or	extracellularly.	Although	beyond	the	
scope	and	time	available	for	this	thesis,	in	future	studies,	it	would	be	valuable	
to	investigate	the	effect	of	sulphation	on	the	properties	of	the	binding	of	these	
neuroactive	steroids.	Patch-clamp	recordings	comparing	the	kinetics	of	
cerebrosterol	sulphate	to	cerebrosterol	would	give	insight	into	the	binding	
properties	of	the	neurosteroid.	Additionally,	competition	studies	and	removal	
of	steroid	with	cyclodextrin	application	would	show	whether	the	sulphate	
group	changes	affinity	for	the	binding	site.	
As	indicated	in	the	discussion	above,	the	reason	for	optimism	about	NMDA	
PAMs	is	that	they	can	operate	within	physiological	parameters,	and	cause	
facilitation	of	relevant	signalling,	unlike	agonists	that	could	be	neurotoxic	at	
high	doses.	It	has	been	suggested	that	NMDA	excitotoxicity	plays	a	major	role	
in	the	neurodegeneration	seen	in	HD	(Parsons	and	Raymond,	2014).	
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Therefore,	simply	enhancing	NMDA	receptor	function	with	the	aim	of	
treatment	of	cognitive	symptoms	is	fraught	with	danger.	The	toxicity	of	
cerebrosterol	alone	on	neurons	in	culture	has	been	demonstrated	(Yamanaka	
et	al.,	2011);	however,	whether	non-toxic	levels	of	cerebrosterol	in	the	
presence	of	non-toxic	levels	of	NMDA	would	become	toxic	has	not	been	
determined.	It	would	also	be	important	to	establish	whether	the	sulphated	
steroid	would	be	more	toxic	than	the	non-sulphated	steroid.	This	would	
provide	important	information	about	the	safety	of	what	could	be	long-term	
treatments,	as	well	as	an	insight	into	the	significance	of	sulphation	and	also	
the	role	of	cerebrosterol	in	disease	progression.	As	cerebrosterol	and	
Org49209	have	a	relatively	low	efficacy,	and	as	PAMs,	only	modulate	NMDA	
receptor	activity	when	the	receptor	is	activated	by	an	endogenous	ligand,	it	is	
possible	for	modulation	to	occur	without	a	high	risk	of	excitotoxicity	or	over-
stimulation.	It	is	also	possible	that	cerebrosterol	has	beneficial	effects	in	this	
finely	balanced	system	(Noguchi	et	al.,	2015,	Boussicault	et	al.,	2016).	The	
benefits	of	endogenous	cerebrosterol	could	be	investigated	using	the	24-
hydroxylase	inhibitor,	voriconazole,	to	stop	cerebrosterol	production	in	
cultures;	if	cerebrosterol	supports	cell	survival,	inhibiting	cerebrosterol	would	
result	in	an	increase	in	cell	death	that	could	be	reversible	with	cerebrosterol	
application.	
The	absence	of	endogenous	cerebrosterol	has	been	investigated	by	others	
with	the	use	of	a	transgenic	CYP46A1	knockout	mouse	(Kotti	et	al.,	2006).	This	
mouse	had	reduced	hippocampal	LTP	as	well	as	spatial	memory	impairments	
(Kotti	et	al.,	2006,	Kotti	et	al.,	2008).	Additionally,	data	from	the	Lambert	
laboratory	has	shown	a	LTP	deficit	in	the	HDHQ111+/-	mouse	(Mitchell,	2012).	As	
cerebrosterol	has	now	been	well	validated	as	a	PAM	of	the	NMDA	receptor,	
the	next	steps	for	in	vitro	work,	besides	investigating	the	above	mentioned	
binding	properties	and	toxicity,	would	be	to	further	assess	its	role	in	synaptic	
plasticity.	The	above	mentioned	models	could	be	used	to	test	this	by	applying	
cerebrosterol	to	the	hippocampal	slices	in	attempt	to	recover	the	LTP	deficits.	
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Org49209	has	already	been	shown	to	be	able	to	enhance	low	LTP	due	to	
lowered	stimulation	(Etherington	(2012),	unpublished	observations,	see	
Chapter	1,	Figure	1.10).	Alternatively,	hippocampal	slices	could	be	incubated	
with	voriconazole	(a	24-hydroxylase	inhibitor)	before	induction	of	LTP.	If	this	
resulted	in	reduced	LTP	due	to	a	reduction	in	cerebrosterol,	exogenous	
cerebrosterol	application	could	be	used	to	attempt	to	recover	this	effect.	The	
effect	of	sulphation	of	the	steroids	on	LTP	could	also	be	investigated,	as	a	
more	efficacious	PAM	may	be	able	to	potentiate	LTP	further,	or	at	lower	
concentrations.	
Long-term	depression	(LTD),	in	contrast	to	LTP,	is	the	weakening	of	synaptic	
strength	and	both	are	involved	in	the	healthy	functioning	of	synaptic	plasticity	
(Collingridge	et	al.,	2010).	LTD	is	usually	dependent	on	activation	of	either	
NMDA	receptors	(like	LTP)	or	metabotropic	glutamate	receptors	(Collingridge	
et	al.,	2010).	There	is	evidence	for	NMDA	receptor-mediated	LTD	being	
necessary	for	hippocampal-dependent	learning	and	memory	(Brigman	et	al.,	
2010)	as	well	as	for	forebrain-dependent	reversal	learning	and	behavioural	
flexibility	(Courtney	et	al.,	1990,	Ma	et	al.,	2015).	Additionally,	there	is	some	
evidence	that	disrupted	LTD	may	be	involved	in	HD;	both	the	R6/2	and	R6/1	
HD	mouse	model	showed	hippocampal	CA1	LTD	in	response	to	low	frequency	
stimulation,	while	WTs	did	not	(Murphy	et	al.,	2000,	Milnerwood	et	al.,	2006).	
Dallerac	et	al.	(2016)	provided	evidence	that	this	aberrant	LTD	induction	is	not	
due	to	dopamine	dysregulation,	leaving	a	possibility	that	abnormal	NMDA	
receptor	signalling	may	play	a	role.	To	further	explore	the	phenotype	of	the	
HDHQ111+/-	mouse,	hippocampal	and	cortical	LTD	could	be	explored	in	addition	
to	the	already	present	LTP	deficit.	Application	of	cerebrosterol	to	slices	of	
mice	with	aberrant	LTD	could	give	insight	to	the	role	of	cerebrosterol	in	
synaptic	plasticity	beyond	LTP.	
In	Vivo	Studies	
As	one	of	the	main	aims	of	the	development	of	a	NMDA	receptor	PAM	is	to	
treat	the	cognitive	deficits	associated	with	neurodegenerative	diseases,	
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including	HD,	the	effect	of	Org49209	needs	to	be	investigated	in	vivo.	To	this	
end,	a	variety	of	behavioural	tasks	were	selected	for	study.	The	particular	
tasks	in	murine	and	rat	model	systems	were	selected	on	the	basis	that	there	
was	prior	evidence	suggesting	there	were	relevant	cognitive	impairments.	
First,	the	HDHQ111+/-	mouse	was	used	as	it	was	previously	shown	to	have	
spatial	memory	impairments	(Mitchell,	2012,	Chandler,	2014).	The	
behavioural	results	reported	by	Chandler,	to	the	extent	to	which	the	
methodology	matched,	were	replicated	in	the	present	study.	However,	the	
purpose	of	this	study	was	to	replicate	and	extend;	this	resulted	in	a	rather	
dramatically	different	conclusion	being	drawn.	Specifically,	Chandler	
concluded	that	the	novel-object	recognition	of	the	HDHQ111+/-	mouse	was	
intact,	while	novel-place	recognition	was	impaired	(Chapter	1,	Figure	1.4).	
However,	although	this	seemed	to	be	the	case	when	NPR	was	the	first	test	of	
the	day,	when	NPR	followed	NOR	testing,	they	were	significantly	improved	in	
the	NPR	task	(see	Chapter	3,	Figure	3.4).	When	the	HDHQ111+/-	mice	were	then	
tested	repeatedly,	with	each	test,	the	DI	score	increased	until	the	HDHQ111+/-	
mice	eventually	showed	a	preference	for	the	novel	place	(see	Chapter	3,	
Figure	3.9).	This	would	indicate	that	the	HDHQ111+/-	mouse	does	not	have	a	
spatial	memory	impairment	as	previously	thought,	because	they	can	
demonstrate	memory	for	object	location.	As	the	present	design	did	not	
include	a	WT	control	group,	it	is	not	known	whether	the	apparently	lower	DIs	
in	NPR	compared	to	NOR	are	a	result	of	an	inherently	lower	exploration	
motivation	when	a	familiar	object	moves,	compared	to	a	novel	object	that	
appears.	Org49209	was	without	effect	in	this	study	(see	Chapter	3,	Figure	3.6);	
however,	in	the	absence	of	a	behavioural	impairment	and	without	a	WT	
control,	the	significance	of	this	is	not	known.	
A	key	property	of	NOR	/	NPR	tasks	is	that	they	are	spontaneous	
demonstrations	of	an	intrinsic	perception	of	novelty.	Exploration	is	a	
spontaneous	response	to	novelty	and	is	no	more	‘reinforced’	by	novelty	than	
shivering	is	by	cold	air.	For	this	reason,	it	is	possible	that	memory	impairments	
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will	only	become	apparent	in	tasks	where	there	is	learning	by	reinforcement.	
The	water	maze	was	selected	as	it	is	also	an	exploratory	task,	with	inherent	
motivation	(to	escape)	and	yet	the	learning	of	the	platform	location	is	
positively	reinforced	(i.e.,	the	behaviour	increases	with	reinforcement)	by	the	
removal	of	a	negative	stimulus	(i.e.,	drowning	threat).	This	study	showed	that	
HDHQ111+/-	mice	and	WTs	performed	equally	well	in	both	initial	learning	of	the	
platform	location	and	in	spatial	re-location	learning,	where	the	platform	was	
moved	to	the	opposite	quadrant	(see	Chapter	4,	Figures	4.6	and	4.7).	Again,	
this	indicated	that	the	HDHQ111+/-	mouse	does	not	have	a	spatial	memory	
impairment.	This	result	was	somewhat	surprising	as	deficits	have	been	
reported	in	another	HD	model;	the	R6/2	line	is	impaired	at	platform	
acquisition	and	the	probe	trial	compared	to	WT	controls	(Murphy	et	al.,	2000,	
Lione	et	al.,	1999).	
Although	the	NPR	task	and	water	maze	task	were	both	used	to	probe	spatial	
memory	in	the	HDHQ111+/-	mouse,	they	may	be	looking	at	different	levels	of	
hippocampal	cellular	function	as	Danielson	et	al.	(2016)	have	recently	argued.	
In	their	study,	goal	orientated	activity	was	more	associated	with	deep	layer	
pyramidal	neurons	of	the	CA1,	in	contrast	to	spontaneous	exploratory	
behaviour,	which	was	associated	with	superficial	pyramidal	neurons.	As	NPR	
and	water	maze	protocols	are	both	exploratory,	but	only	the	water	maze	is	
goal-orientated,	it	could	be	speculated	that	HDHQ111+/-	mice	could	be	
differently	impaired	due	to	different	populations	of	neurons	being	responsible	
for	different	types	of	learning	in	the	hippocampus.	In	addition,	Whishaw	and	
Tomie	(1996)	found	that,	in	contrast	to	rats,	mice	performed	less	well	in	
spatial	tasks	when	tested	in	the	water	maze	than	when	tested	on	dry	land.	
This	could	be	due	to	increased	stress,	which	has	been	known	to	affect	learning	
(Harrison	et	al.,	2009).	Therefore,	it	may	be	possible	that	different	results	
would	be	found	if	the	spatial	learning	task	used	food	rewards	and	was	land-
based.	
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Although	HD	patients	show	clear	executive	function	disturbances,	including	a	
reversal	learning	deficit	(Lawrence	et	al.,	1999),	this	had	not	been	extensively	
studied	in	HD	mouse	models.	The	R6/2	line	of	mice	do	show	spatial	memory	
deficits,	but	we	did	not	find	any	deficits	in	the	HDHQ111+/-	model.	It	is	possible	
that	using	spontaneous	exploratory	behaviour	to	test	spatial	memory	was	not	
testing	executive	functions,	and	this	was	why	the	HDHQ111+/-	mouse	did	not	
seem	to	be	impaired	and	yet,	an	impairment	might	be	revealed	in	an	explicit	
learning	task.	The	water	maze	was	used	again,	because	escape-reinforcement	
removes	the	need	to	control	food	or	water	intake,	and	the	mice	were	
presented	with	a	simple	visual	discrimination	task	followed	by	a	reversal	of	the	
stimulus-outcome	contingency.	As	in	the	spatial	learning	task,	HDHQ111+/-	mice	
were	no	different	to	WT	controls	in	either	the	rate	or	efficiency	of	initial	
discrimination	or	reversal	learning	(see	Chapter	4,	Figures	4.9	and	4.11).	As	
mentioned	above,	the	R6/2	mouse	had	a	reversal	learning	impairment	when	
required	to	discriminate	between	a	bright	and	dimmed	light	in	the	water	maze	
(Lione	et	al.,	1999).	It	was,	therefore,	surprising	that	the	HDHQ111+/-	mouse	did	
not	seem	to	have	a	reversal	learning	impairment.	The	HDHQ111+/-	mouse	may	
have	a	milder	phenotype	than	other	models	such	as	the	R6/2	line,	which	
shows	more	prominent	cognitive	dysfunctions	(Li	et	al.,	2005,	Lione	et	al.,	
1999,	Murphy	et	al.,	2000).	The	disadvantages	of	the	R6/2	line,	however,	are	
that	motor	impairments	are	present	at	a	very	early	age	and	the	total	life	span	
of	the	animals	is	short,	resulting	in	complications	of	measuring	cognitive	
function	using	behavioural	tasks	(Li	et	al.,	2005).	
The	mice	were	surprisingly	slow	to	learn	the	initial	discrimination	and	even	
slower	to	acquire	the	reversal;	performance	remained	poor	even	after	27	days	
of	reversal	learning	when	testing	was	terminated	due	to	a	lack	of	group	
difference.	It	is	likely,	given	the	above	report,	that	land-based	protocols,	such	
as	a	T-maze	or	the	7-stage	set-shifting	task,	would	be	learned	more	rapidly.	It	
is	also	possible	that,	with	a	more	rapidly	learned	discrimination,	that	subtle	
behavioural	impairments	might	be	apparent.	Results	from	studies	using	mice	
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have	suggested	that	they	are	less	reliable	in	their	performance	of	the	set-
shifting	task	and	may	require	additional	discriminations	to	form	attentional	set	
compared	to	rats	(Garner	et	al.,	2006).	For	this	reason,	rats	were	used	to	
explore	the	potential	value	of	the	attentional	set-shifting	task	for	testing	
cognitive	benefits	of	Org49209.	
A	cohort	of	rats	was	available	that	had	inhibitory	DREADDs	in	the	mPFC	
resulting	in	impaired	set-shifting.	HD	patients	also	have	impairments	in	set-
shifting,	thought	to	arise	from	corticostriatal	dysfunction	(Lawrence	et	al.,	
1996).	Therefore,	it	was	of	interest	to	ask	whether	the	cognitive	impairments	
arising	from	inactivation	of	the	mPFC	could	be	reversed	with	Org49209.	Set-
shifting	is	an	executive	function	and,	along	with	reversal	learning,	is	a	form	of	
behavioural	flexibility.	Unfortunately,	although	the	rats	had	been	tested	
previously	and	showed	normal	acquisition	of	attentional	set,	when	tested	in	
the	present	study,	the	rats	did	not	form	set	(see	Chapter	5,	Figure	5.4).	Not	
only	was	the	previously	observed	set-shifting	deficit	not	replicated	(in	the	
absence	of	attentional	set,	there	cannot	be	a	set-shifting	deficit),	there	was	
also	no	effect	of	Org49209	(which	is	not	surprising,	given	that	there	was	no	
deficit	to	be	ameliorated).	This	means	that	conclusions	could	not	be	drawn	
from	Org49209	administration,	although	no	differences	in	the	drug	condition	
were	observed	during	any	stage	of	the	standard	7-stage	set-shifting	task	(see	
Chapter	5,	Figure	5.4).	
Although	the	original	goal	of	the	behavioural	testing	was	to	establish	the	
effect	of	Org49209	administration	on	the	behaviours	of	animal	models	with	
impaired	cognition,	this	was	not	possible	to	explore	due	to	all	the	assays	
tested	here	not	showing	the	expected	cognitive	deficits.	More	aggressive	
models	of	HD	such	as	the	R6/2	model	which	has	good	published	evidence	of	
cognitive	deficits	(Lione	et	al.,	1999,	Murphy	et	al.,	2000)	could	be	more	
fruitful	to	the	investigation	of	cerebrosterol.	Indeed,	Boussicault	et	al.	(2016)	
have	already	suggested	that	cerebrosterol	dysfunction	contributes	to	HD	
pathology	using	the	R6/2	line;	however,	they	only	investigated	striatal	
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neurodegeneration	and	motor	abilities.	Investigating	the	effect	of	CYP46A1	
restoration	on	the	cognitive	impairments	of	the	CYP46A1	knockout,	and	the	
R6/2	model	may	give	insight	to	the	role	of	cerebrosterol	in	cognition	and	for	
the	potential	benefit	of	exogenous	Org49209	administration.	As	sulphation	of	
both	Org49209	and	cerebrosterol	results	in	a	PAM	of	the	NMDA	receptor	of	
much	higher	efficacy,	it	would	be	interesting	to	investigate	the	effect	of	
cerebrosterol	sulphate	on	behaviour	compared	to	cerebrosterol.	Although	
cerebrosterol	and	Org49209	easily	cross	the	BBB	(Paul	et	al.,	2013),	assessing	
the	function	of	steroid	sulphation	in	vivo	would	require	the	direct	
administration	to	the	brain	as	the	sulphated	steroid	cannot	cross	the	BBB.	
However,	due	to	the	presence	of	enzymes	in	the	brain	that	can	sulphate	and	
desulphate	cerebrosterol,	it	may	not	even	be	possible	to	use	direct	delivery	to	
the	brain	as	the	administered	cerebrosterol	sulphate	could	be	rapidly	
desulphated.	Finally,	rodent	models	other	than	those	attempting	to	model	HD,	
which	also	show	cognitive	impairments,	could	be	investigated	as	NMDA	
receptor	mediated	cognitive	impairments	are	implicated	in	a	wide	range	of	
disorders	(for	instance,	a	developmental	rat	PCP	model	of	schizophrenia	as	
described	by	Broberg	et	al.	(2013)).	
The	Bigger	Picture	and	Future	Directions	
This	thesis	focused	on	the	cognitive	impairments	associated	with	HD	disease;	
however,	other	disorders	where	NMDA	receptor	dysfunction	is	observed	may	
also	respond	well	to	PAM	treatments.	The	ketamine	model	of	schizophrenia	
(Frohlich	and	Van	Horn,	2014),	for	example,	is	gaining	support,	especially	with	
regard	to	understanding	the	cognitive	symptoms	of	the	disorder	(see	section	
1.2.1).	Currently	treatments	for	schizophrenia	focus	on	the	positive	psychotic	
symptoms,	but	not	the	negative	or	cognitive	symptoms	(Balu,	2016).	The	
ketamine	model	suggests	that	specifically	NMDA	receptor	hypofunction	could	
be	at	the	root	of	cognitive	impairments;	therefore,	positive	allosteric	
modulation	is	a	prime	candidate	for	a	treatment	avenue	for	schizophrenia.	
Specifically,	NMDA	receptor	hypofunction	of	the	cortical	GABAergic	
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interneurons,	which	consequentially	cause	disinhibition	of	the	cortical	
pyramidal	cells,	causes	general	increased	cortical	excitation	(Jadi	et	al.,	2016,	
Homayoun	and	Moghaddam,	2007).	Therefore,	using	the	ability	of	DREADDs	
to	silence	specific	neuronal	populations,	specifically	targeting	hyperactive	
cortical	pyramidal	cells	may	alleviate	the	symptoms	seen	in	models	of	
schizophrenia.	Alternatively,	NMDA	receptor	PAMs	such	as	Org49209	may	be	
able	to	increase	GABAergic	interneuron	firing	to	regulate	the	circuit	in	a	
similar	fashion.	As	Org49209	has	no	direct	effect	on	GABA	receptors,	this	
would	be	accomplished	through	the	increase	in	NMDA	receptor	mediated	
activity	in	GABAergic	interneurons,	which	cause	inhibition	of	glutamatergic	
(excitatory)	pyramidal	cells.	
Examples	of	other	diseases	which	may	benefit	from	NMDA	receptor	
modulation	are	AD	(see	section	1.7.1)	and	anti-NMDA	encephalitis.	Regarding	
the	former,	as	with	other	neurodegenerative	diseases	such	as	HD	or	
Parkinson’s	disease,	dysfunctional	cholesterol	metabolism	may	in	fact	imply	a	
direct	involvement	of	cerebrosterol	in	disease	aetiology	(Brown	et	al.,	2004,	
Popp	et	al.,	2012).	Investigation	of	the	role	of	cerebrosterol	in	behavioural	
models	would	give	greater	insight	to	cerebrosterol	activity,	beyond	the	use	as	
a	potential	biomarker	for	neurodegenerative	disease.	In	contrast,	anti-NMDA	
encephalitis	is	an	autoimmune	disease	which	causes	the	internalisation	of	
NMDA	receptors	resulting	in	psychotic,	motor,	and	cognitive	dysfunction	
(Miya	et	al.,	2014).	Consequently,	it	may	be	beneficial	to	enhance	the	activity	
of	the	remaining	NMDA	receptors	in	attempt	to	slow	and	alleviate	some	of	the	
cognitive	disorders	present	in	this	disease.	The	extent	of	possible	applications	
for	a	potent	and	selective	NMDA	receptor	PAM	show	how	exciting	and	
important	the	discovery	of	these	neuroactive	steroids	is.	
The	use	of	Org49209	as	a	treatment	for	cognitive	impairments	presents	some	
practical	challenges.	Although	Org49209	has	good	brain	permeability	when	
administered	i.p.	(Paul	et	al.,	2013),	the	oral	availability	remains	unstudied.	
Due	to	its	lipophilic	structure,	however,	it	is	likely	to	have	poor	oral	availability	
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(pers.	comm.	N.	Hamilton).	Therefore,	in	its	current	form,	Org49209	is	a	good	
tool	for	investigation	of	the	endogenous	role	of	cerebrosterol,	and	for	
elucidating	the	potential	for	exogenous	neuroactive	steroid	treatments,	but	
structural	modifications	to	improve	drug	viability	remain	to	be	investigated.	
Returning	to	the	endogenous	role	of	cerebrosterol,	if	cerebrosterol	is	needed	
for	normal	cognitive	function	is	the	healthy	brain,	the	ubiquitous	use	of	statins	
may	affect	this	interaction.	Korinek	et	al.	(2015)	found	that	cholesterol	
depletion	almost	abolished	the	NMDA	induced	current	responses	in	cultured	
rat	CGNs,	which	was	reversible	with	cholesterol	repletion.	The	authors	claim	
this	is	a	direct	effect	of	cholesterol	on	the	open	probability	of	the	NMDA	
receptor.	A	part	of	the	loss	of	response	could	also	be	due	to	decreased	
cerebrosterol	levels	due	to	cholesterol	depletion.	There	has	also	been	some	
evidence	that	statins	impaired	memory	from	case	studies	(Wagstaff	et	al.,	
2003),	and	randomised	control	trials	(Santanello	et	al.,	1997).	However,	more	
recent	randomised	control	trials,	systematic	reviews,	and	meta-analyses	have	
found	no	association	between	statin	use	and	memory	function	(Richardson	et	
al.,	2013,	Ott	et	al.,	2015,	Bitzur,	2016).	Finally,	Thelen	et	al.	(2006)	showed	
that	treatment	with	high	doses	of	statin	either	did	not	alter	or	slightly	
increased	the	cerebrosterol	to	cholesterol	ratio	in	plasma.	This	ratio	is	a	
marker	for	brain	homeostasis,	indicating	that	although	overall	plasma	
cholesterol	levels	decrease,	brain	cholesterol	remains	largely	unchanged.	It	
seems	that	there	is	not	sufficient	evidence	to	believe	statin	treatment	has	a	
negative	impact	on	cognition.	
Summary	and	Conclusions	
To	summarise,	the	extent	to	which	the	aims	set	in	the	introduction	(section	
1.8)	will	be	assessed.	The	calcium	imaging	experiments	clearly	demonstrated	
the	NMDA	receptor-enhancing	effects	of	cerebrosterol	and	Org49209	in	
neurons.	The	effect	of	the	sulphation	of	these	neuroactive	steroids	was	also	
shown,	where	an	increased	potentiation	was	seen	at	equivalent	
concentrations	of	unsulphated	steroid.	Thus,	it	can	be	concluded	that	
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sulphation	creates	a	more	potent	steroid;	however,	conclusions	about	efficacy	
could	not	be	made	as	an	asymptotic	maximum	response	to	the	unsulphated	
steroids	was	not	measured.	With	regard	to	recovering	behavioural	phenotypes	
of	the	HDHQ111+/-	mouse	with	Org	49209,	no	conclusions	could	be	made	as	the	
phenotype	seen	previously	in	the	lab	was	not	replicated.	Additional	
behavioural	tests	were	tried	to	find	a	deficit	both	in	spatial	learning	and	
discrimination	and	reversal	learning,	but	showed	that	the	HDHQ111+/-	mouse	
was	not	impaired	compared	to	WT	mice.	Finally,	the	effect	of	Org49209	on	the	
set-shifting	impairment	of	mPFC	inactivated	rats	could	also	not	be	assessed	as	
the	set-shifting	deficit	was	also	not	replicated.	Therefore,	the	basic	mechanism	
of	these	steroids	on	the	enhancing	effect	of	NMDA	receptor	activity	was	
supported	with	the	calcium	imaging	experiments,	and	more	experiments	are	
required	with	models	displaying	more	robust	cognitive	impairments	to	assess	
the	application	of	these	neuroactive	steroids	as	cognitive	enhancers.	
To	end	on	a	hopeful	note,	methodological	progress,	such	as	the	development	
of	DREADDs,	is	providing	useful	tools	that	will	allow	a	more	thorough	
investigation	toward	the	origins	and	treatments	of	cognitive	impairments.	
Until	successful	treatments	are	found,	however,	lifestyle	changes	may	be	able	
to	alleviate	some	of	the	pressure	of	neurodegenerative	and	neuropsychiatric	
disease.	For	example,	dietary	restriction	may	indeed	be	beneficial	to	
Huntington’s	disease	treatment,	as	shown	by	Duan	et	al.	(2003)	who	
demonstrated	delayed	disease	onset	and	motor	dysfunction,	prolonged	
lifespan,	reduced	brain	atrophy,	reduced	huntingtin	aggregation,	and	reduced	
caspase	activity	in	a	mouse	model	for	HD	on	dietary	restriction.	Additionally,	
environmental	enrichment	improved	motor	symptoms	and	peristriatal	
cerebral	volume	loss	in	the	R6/2	mouse	(Hockly	et	al.,	2002),	indicating	that	
environmental	changes	may	be	able	to	slow	disease	progress	and	improve	
quality	of	life	for	HD	patients.	
The	results	from	this	thesis,	together	with	the	literature	of	cerebrosterol	in	
disorders	such	as	HD,	and	the	wide	range	of	disorders	associated	with	NMDA	
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receptor	dysfunction	such	as	schizophrenia,	it	would	be	valuable	to	focus	
further	research	on	the	interaction	of	cerebrosterol	with	the	NMDA	receptor	
with	the	aim	to	ameliorate	the	cognitive	deficits	associated	with	these	
disorders.	Not	only	would	this	contribute	to	a	better	understanding	of	a	wide	
range	of	disorder	aetiologies,	but	also	provide	the	opportunity	for	drug	
development	(such	as	Org49209)	to	aid	in	the	treatment	of	the	detrimental	
cognitive	impairment	associated	with	these	disorders.	The	synthetic	Org49209	
may	prove	useful	not	only	in	the	possible	treatment	of	cognitive	deficits,	but	
can	be	used	to	elucidate	the	role	of	the	NMDA	receptor	in	cognitive	
mechanisms.	
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Appendix	1	
	
Code	for	Discrimination	Learning	
Analysis	
	
#!/usr/bin/perl	
	
use	strict;	#	This	line	just	makes	sure	that	errors	are	more	noticable	
use	Data::Dumper;	
	
my	$randomiser_file	=	shift;	#	This	takes	the	first	argument	to	the	program	as	
randomiser_file	
my	$randtype	=	`file	$randomiser_file`;	
	
my	$casmira_data_file	=	shift;	#	This	takes	the	second	argument	to	the	
program	as	casmira_data_file	
my	$datatype	=	`file	$casmira_data_file`;	
	
#$/	=	"\r";	
if($randtype	=~	/CRLF/)	{	
	 open(RFILE,'<:unix',$randomiser_file)	or	die("Can't	open	
$randomiser_file	$!\n");	#	this	opens	the	file	for	reading	
}	
else	{	
	 open(RFILE,'<:unix:crlf',$randomiser_file)	or	die("Can't	open	
$randomiser_file	$!\n");	#	this	opens	the	file	for	reading	
}	
#	define	a	hash	(dictionaries	in	python	speak)	
	
my	%random_data;	
	
while(my	$line	=	<RFILE>)	{	#	This	line	says	we	will	loop	through	the	file	one	
line	at	a	time	
	 chomp	$line;	#	remove	the	newline	at	the	end	of	the	line	
	 my	@line	=	split	/,/,$line;	#	This	takes	each	line	and	splits	it	into	an	
array	(list	in	python)	
	
	 my	$day	=	$line[0];	
	
	 if($day	=~	/\d+/)	{	#	This	says	-	if	the	first	entry	is	a	number	
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	 	 my	$a	=	10;	#	column	K		
	 	 my	$b	=	20;	#	column	U	
	 	 for(my	$i	=	1;$i	<=	8;$i++)	{	
	 	 	 	
	 	 	 my	$a_part	=	$a+$i;	
	 	 	 my	$b_part	=	$b+$i;	
	
	 	 	 $random_data{'A'}->{$day}->{$i}	=	$line[$a_part];	
	
	 	 	 $random_data{'B'}->{$day}->{$i}	=	$line[$b_part];	
	 	 }	
	 }	
}	
	
	
close(RFILE);	
	
#die	Dumper(%random_data);	
#	We	need	to	set	the	initial	state	variables	
my	$day	=	0;	
my	$cohort	=	'A';	
my	$init;	
my	$trial;	
	
my	%distance_rows;	
my	%latency_rows;	
my	%quad_distance_rows;	
my	%quad_latency_rows;	
	
my	%platform_distance;	
my	%platform_latency;	
my	%quad_platform_distance;	
my	%quad_platform_latency;	
	
	
my	%previous_platform;	
my	%previous_first_choice;	
my	$count_of_lines	=	0;	
	
my	%other_platform	=	(	
	 1	=>	4,	
	 2	=>	3,	
	 3	=>	2,	
	 4	=>	1,	
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);	
	
my	%quad2cue	=	(	
	 'NE'	=>	1,	
	 'SE'	=>	2,	
	 'SW'	=>	3,	
	 'NW'	=>	4,	
);	
	
print	"Test	Number,Cohort,Correct	Platform,Wrong	Platform,Platform	
distance	correct	platform,Platform	distance	wrong	platform,Same	As	Prev	
Correct	Platform,Same	as	Prev	First	Choice,Latency	Success,Success,Quad	
Latency	Success,Quad	Success\n";	
	
$/	=	"\r";	
open(DFILE,'<:unix:crlf',$casmira_data_file)	or	die("Can't	open	
$casmira_data_file	$!\n");	
while(my	$line	=	<DFILE>)	{	
	
	 $count_of_lines++;	
	 chomp	$line;	
	 my	@line	=	split	/,/,$line;	
	
	 my	$test	=	$line[0];	
	 my	$mouse	=	$line[1];	
	 my	$stage	=	$line[2];	 	
	
	 if($test	eq	'Test')	{	
	 	 foreach	my	$i	(0..100)	{	
	 	 	 if($line[$i]	=~	
/Cue\s(\d)\s:\s*distance\sto\sfirst\sentry/)	{	
	 	 	 	 $distance_rows{$1}	=	$i;	
	 	 	 }	
	 	 	 if($line[$i]	=~	/Cue\s(\d)\s:\s*latency\sto\sfirst\sentry/)	
{	
	 	 	 	 $latency_rows{$1}	=	$i;	
	 	 	 }	
	 	 	 if($line[$i]	=~	
/(\w\w)\sQuad\s:\s*latency\sto\sfirst\sentry/)	{	
	 	 	 	 $quad_latency_rows{$quad2cue{$1}}	=	$i;	
	 	 	 }	
	 	 	 if($line[$i]	=~	
/(\w\w)\sQuad\s:\s*distance\sto\sfirst\sentry/)	{	
	 	 	 	 $quad_distance_rows{$quad2cue{$1}}	=	$i;	
	 	 	 }	
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	 	 }	
	
	 	 warn	"Distance	Columns:	
$distance_rows{1},$distance_rows{2},$distance_rows{3},$distance_rows{4}\n
";	
	 	 warn	"Latency	Columns:	
$latency_rows{1},$latency_rows{2},$latency_rows{3},$latency_rows{4}\n";	
	 	 warn	"Quad	Distance	Columns:	
$quad_distance_rows{1},$quad_distance_rows{2},$quad_distance_rows{3},$q
uad_distance_rows{4}\n";	
	 	 warn	"Quad	Latency	Columns:	
$quad_latency_rows{1},$quad_latency_rows{2},$quad_latency_rows{3},$qua
d_latency_rows{4}\n";	
	
	 	 next;	
	 }	
	
	 $platform_distance{1}	=	$line[$distance_rows{1}];	
	 $platform_distance{2}	=	$line[$distance_rows{2}];	
	 $platform_distance{3}	=	$line[$distance_rows{3}];	
	 $platform_distance{4}	=	$line[$distance_rows{4}];	
	
	 $platform_latency{1}	=	$line[$latency_rows{1}];	
	 $platform_latency{2}	=	$line[$latency_rows{2}];	
	 $platform_latency{3}	=	$line[$latency_rows{3}];	
	 $platform_latency{4}	=	$line[$latency_rows{4}];	
	
	 $quad_platform_distance{1}	=	$line[$quad_distance_rows{1}];	
	 $quad_platform_distance{2}	=	$line[$quad_distance_rows{2}];	
	 $quad_platform_distance{3}	=	$line[$quad_distance_rows{3}];	
	 $quad_platform_distance{4}	=	$line[$quad_distance_rows{4}];	
	
	 $quad_platform_latency{1}	=	$line[$quad_latency_rows{1}];	
	 $quad_platform_latency{2}	=	$line[$quad_latency_rows{2}];	
	 $quad_platform_latency{3}	=	$line[$quad_latency_rows{3}];	
	 $quad_platform_latency{4}	=	$line[$quad_latency_rows{4}];	
	
	 if(	($trial	==	8)	and	($line[3]	==	1)	)	{	
	 	 if($cohort	eq	'A')	{	$cohort	=	'B';	}	else	{	$cohort	=	'A';	}	
	 }	
	 $trial	=	$line[3];	
	
	 if($stage	=~	/(\d+)$/)	{	
	 	 $day	=	$1;	
	 }	
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	 my	$correct_platform	=	$random_data{$cohort}->{$day}->{$trial};	
	 my	$wrong_platform	=	$other_platform{$correct_platform};	
	
	 my	$success	=	
did_it_win(\%platform_distance,$correct_platform,$wrong_platform);	
	 my	$latency_success	=	
did_it_win(\%platform_latency,$correct_platform,$wrong_platform);	
	 my	$quad_success	=	
did_it_win(\%quad_platform_distance,$correct_platform,$wrong_platform);	
	 my	$quad_latency_success	=	
did_it_win(\%quad_platform_latency,$correct_platform,$wrong_platform);	
	
	 my	$which_platform_did_mouse_go_to_first;	
	
	 if($success	eq	'1')	{	
	 	 $which_platform_did_mouse_go_to_first	=	$correct_platform;	
	 }	
	 else	{	
	 	 $which_platform_did_mouse_go_to_first	=	$wrong_platform;	
	 }	
	
	 my	$was_prev_platform	=	'0';	
	 my	$was_prev_first_choice	=	'0';	
	 if($which_platform_did_mouse_go_to_first	eq	
$previous_platform{$mouse})	{	
	 	 $was_prev_platform	=	'1';	
	 }	
	 if($which_platform_did_mouse_go_to_first	eq	
$previous_first_choice{$mouse})	{	
	 	 $was_prev_first_choice	=	'1';	
	 }	
	
	 print	
"$test,$cohort,$correct_platform,$wrong_platform,$platform_distance{$corr
ect_platform},$platform_distance{$wrong_platform},$was_prev_platform,$w
as_prev_first_choice,$latency_success,$success,$quad_latency_success,$qua
d_success\n";	
	
	
	 $previous_platform{$mouse}	=	$correct_platform;	
	 $previous_first_choice{$mouse}	=	
$which_platform_did_mouse_go_to_first;	
}	
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warn	"Analysed	lines:	$count_of_lines	(including	header)\n";	
	
	
sub	did_it_win	{	
	 my	$hashref	=	shift;	
	 my	$correct_platform	=	shift;	
	 my	$wrong_platform	=	shift;	
	
	 my	$success;	
	
	 if($hashref->{$correct_platform}	>	0)	{	
	 	 if($hashref->{$wrong_platform}	>	0)	{	
	 	 	 if($hashref->{$correct_platform}	<	$hashref-
>{$wrong_platform})	{	
	 	 	 	 $success	=	'1';	
	 	 	 }	
	 	 	 else	{	
	 	 	 	 $success	=	'0';	
	 	 	 }	
	 	 }	 	
	 	 else	{	
	 	 	 $success	=	'1';	
	 	 }	
	
	 }	 	
	
	 return	$success;	
	 	
	
}	
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